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7Introduction and outline
of the thesis
chapter  1

Gastroduodenal ulcers
Apart from aging, Helicobacter pylori (H. pylori) and non-steroidal anti-inﬂ ammatory 
drugs (NSAIDs) are the most important risk factors in the pathogenesis of peptic ulcers. 
Gastroduodenal ulcers are in most instances either induced by H. pylori infection or 
by chronic use of NSAIDs. Eradication of H. pylori is eff ective and advocated in non-
NSAID-treated patients with gastroduodenal ulcers. However, it is still not clear whether 
eradication of H. pylori can prevent NSAID induced gastroduodenal ulcers in patients 
chronically using NSAIDs.
NSAID-gastropathy
NSAIDs are widely prescribed for rheumatic diseases especially because of their anal-
gesic and anti-inﬂ ammatory eff ect. Worldwide NSAIDs are among the most frequently 
prescribed drugs. However, their use is limited by the frequent occurrence of upper 
gastroduodenal toxicity and, as later been documented, cardiovascular side eff ects. 
The so-called ‘NSAID gastropathy’ varies from subjective symptoms such as dyspepsia, 
heartburn, nausea and upper abdominal pain (up to 15-40%), superﬁ cial gastroduode-
nal mucosal damage such as gastritis and erosions, and, oft en asymptomatic, gastric 
and duodenal ulcers (5-20%) and their life-threatening complications such as hemor-
rhage, obstruction and perforation1. These severe complications occur in 1-2% of NSAID 
 users and they are associated with a mortality rate of 10-15%2, 3. Several factors such 
as age and a history of peptic ulcers can substantially increase this ris k4, 5. In view of 
this substantial morbidity and mortality of NSAID gastropathy, preventive strategies are 
recommended for all patients at high risk for NSAID gastropathy. The most important 
risk factors are high age, previous ulcer, high dose of NSAIDs, use of multiple NSAIDs, 
concomitant use of corticosteroids or anticoagulants, infection with H. pylori, or comor-
bidity, such as (severe) rheumatoid arthrit is5, 6.
Prevention, treatment and costs of ulcers
Several strategies have been tested to prevent NSAID-induced gastropathy. These stra-
tegies include medical co-therapy with misoprostol, a prostaglandin analogue as NSAID 
gastropathy is related to the inhibition of prostaglandin synthesis in the gastroduodenal 
mucosa and is proven to be eff ective for the prevention of NSAID associated gastroduo-
denal mucosal dam age7. A second strategy comprise the concomitant use of high dose 
histamine-2 receptor antagonists (H2As) and proton pump inhibitors (PP Is)8-10. These 
co-therapies should be used as long as the NSAIDs are used, and in rheumatologic 
practice this could for years.
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The enzyme cyclo-oxygenase (COX) is responsible for the prostaglandin synthesis. In 
1993 two iso-enzymes were discovered: COX-1 believed to be responsible for NSAID-
gastropathy, and COX-2 held responsible for the anti-inﬂ ammatory eff ects. The replace-
ment of traditional NSAIDs (which block both COX-1 and COX-2) by COX-2 selective 
 antagonists, also called COX-2 inhibitors (COXIBs), was proven to be as eff ective as the 
traditional NSAIDs but caused less gastroduodenal tox icity11-14. Another strategy in pre-
venting NSAID gastropathy could be H. pylori eradication therapy.
H. pylori
In 1983, Warren and Marshall were the ﬁ rst to successfully culture H. pylori from gastric 
biopsy samples. By self–ingestion they conﬁ rmed that this bacterium caused gastro-
duodenal disorders. Today, H. pylori is known to have an important pathogenic role in 
the development of chronic gastritis, peptic ulcer disease, gastric carcinoma, and gas-
tric mucosa-associated lymphoid tissue (MALT) lymp homa.15-17. For that reason, it has 
been declared by the WHO as a class I carcinogen.
H. pylori is one of the world’s most common infections18. There are substantial dif-
ferences in its prevalence both within and between countries. In industrialized countries 
the overall prevalence of H. pylori generally varies between 30-40% and increases with 
age. This is related to an age-cohort eff ect with decreasing infection rates in subsequent 
generations due to improved hygiene, housing conditions and possibly antibio tic use19, 20.
It is estimated that 20% of H. pylori positive subjects develop peptic ulcer disease 
during their lifetime, and those with an ulcer have a more than 50% risk for recurrent 
ulcer disease in the years thereaft er. It is generally accepted that eradication of H. pylori 
accelerates healing of ulcers and decreases ulcer recurrence rates in patients with pep-
tic ulcers and H. pylori i nfection21, unless they have a second risk factor for ulceration, 
in particular use of NSAIDs.
H. pylori infection has also a prominent role in the cancer cascade passing the stag-
es of chronic gastritis, atrophic gastritis, intestinal metaplasia and dysplasia. Although 
atrophic gastritis and intestinal metaplasia are quite common in H. pylori positive sub-
jects, only 1-2% of them will eventually develop gastric carcinoma a result of lifelong 
i nfection22, 23.
H.pylori in NSAID users
As a consequence of the widespread use of NSAIDs and the prevalence of H. pylori 
infection (particularly in elderly people), these risk factors oft en coexist in the same pa-
tients. However, there is no consensus about the interaction of H. pylori and NSAIDs and 
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whether there is a beneﬁ t of eradication of H. pylori. In a meta-analysis of 16  endoscopic 
studies of 1625 NSAID users, uncomplicated peptic ulcer disease was twice as com-
mon in patients positive than in those negative for H. pylori24. Eradication of H. pylori 
substantially decreases the rate of recurrence of peptic ulcers in patients not taking 
NSAIDs25.
Studies on the interaction between NSAIDs and H. pylori on the development of gas-
troduodenal mucosal damage are controversial. A synergistic action between H. pylori 
and NSAIDs associated ulcers was shown in so me studies24, 26, whereas in other studies 
no interaction could be d emonstrated27-29. Several studies, particularly from Hong-Kong, 
suggested that screening for and eradication of H. pylori at the start of NSAID therapy 
signiﬁ cantly reduces the incidence of ul cer disease30-33. Nevertheless, the test and treat 
strategy of H. pylori-positive NSAID starters is hardly implemented in the international 
and national guidelines, nor in clini cal practice34-37. This can be explained by the practi-
cal diffi  culties of this strategy, which requires postponing NSAID treatment in patients 
with pain, bother them with invasive or non-invasive H. pylori tests, and if positive treat 
them with eradication therapy. Another issue is whether eradication of H. pylori is useful 
in patients already on long-term NSAIDs, to reduce the occurrence of gastrodu odenal 
ulcers38. H. pylori causes continuous gastric inﬂ ammation in nearly all infected persons. 
This chronic inﬂ ammation persists throughout life and may lead to mucosal gland loss 
or atrophic gastritis, which may precede the development of intestinal metaplasia, dys-
pl asia and cancer39. While many studies have shown that eradication of H. pylori causes 
resolution of active and chronic gastritis in non-NSAID-users, the eff ect of H. pylori 
eradication on gastric histology in patients on long-term NSAIDs is unclear because of 
a paucity of data. One of the most eff ective and safest strategies to prevent ulcers is co-
therapy with proton pump inhibitors8, 9, 36, 37. However, profound acid suppressive therapy 
with PPIs or high dose H2As changes the extent of H. pylori gastritis into a corpus-
predominant gastritis, which may accelerate the development of gastric gland loss lead-
ing to atrophic gastritis and, potentiall y, gastric cancer40. The International Maastricht 
guideline therefore advises to consider H. pylori eradication in l ong-term PPI users21, 35. 
This is of relevance for a considerable proportion of patients on long-term NSAIDs who 
are co-treated with acid suppressive therapy for many years. It is however unknown 
what the eff ect is of H. pylori eradication under these long-standing conditions.
Diagnosis and treatment of H.pylori
Currently, non-invasive diagnostic tests and the widespread shortage in endoscopic 
capacity make that many patients with H. pylori are managed without upper gastro-
intestinal endoscopy. The American College of Gastroenterology41 recommends that 
when an endoscopy is not performed, a serological test is the least expensive means of 
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evaluating for evidence of H. pylori infection. The main disadvantage of serology is that 
antibodies can still be detected for a considerable period aft er eradication of H. pylori. 
Other non-invasive tests include urea breath test (which is based on large urease pro-
duction of H. pylori and measured by labeled CO2 in a breath sample) and fecal antigen 
testing (based on H. pylori speciﬁ c antigens in stool samples). When endoscopy is indi-
cated, invasive techniques can be used such as culture, microscopic demonstration of 
the organism, or urease testing on a biopsy specimen. Even if endoscopy is performed, 
biopsies are oft en not routinely sent for culture because of the high cost, culture of 
H. pylori could be diffi  cult and labor-intensive.
Treatment
Indications for treatment (eradication) of H. pylori are still evolving. Consensus exists for 
eradication of H. pylori in patients with peptic ulcer disease, gastric MALT lymphoma. In 
case of non-ulcer dyspepsia, eradication is more controversial, as the eff ect is limited. 
Treatment of subjects, who are at high risk for gastric carcinoma, e.g. those with positive 
family history of gastric carcinoma or those with early mucosal changes, is probably jus-
tiﬁ ed. The current European guidelines imply that a positive H. pylori test is an indication 
for er adication treatment21.
Apart from patient compliance, resistance of H. pylori to antibiotics can decrease the 
success of H. pylori eradication therapy. Regimens of choice for empirical eradication of 
H. pylori should be guided by local antibiotic resistance rates. Metronidazole, clarith-
romycin amoxicillin and tetracycline are the most widely used drugs for treatment of 
H. pylori infection. None of the above mentioned antibiotics is eff ective enough to elimi-
nate H. pylori when given as monotherapy. Successful eradication of H. pylori requires 
a combination of drugs, regularly consisting of 2 antibiotics in combination with an 
acid suppressing drug. However, treatment failure is common and most importantly 
due to bacterial resistance and insuffi  cient patient compliance (possible as a result of 
gastro-inte stinal side eff ects)42. In The Netherlands, the overall prevalence of resistance 
to clarithromycin and metronidazole was lower than in some surrounding countries 
due to restrictive us of antimicrobials. Therefore, since the early nineties the advised 
treatment in The Netherlands consists of a PPI-triple therapy for 7 days without prior 
s usceptibility testing25, 43, 44. An increase of resistance rates to antimicrobial agents is 
however expected because of an increasing number of patients treated and an increas-
ing consumption of antibiotics, in particular macrolides, in recent years.
Since NSAIDs are widely used, implementation of any of these prevention strategies 
would have important economic consequences, when proven eff ective. Bleeding ulcers 
are nowadays most frequently treated by endoscopic intervention such as injection of 
adrenaline. To prevent early recurrences this is oft en followed by clipping of the blood 
ch apter 1
13
vessel or bipolar electrocoagulation. Perforated ulcers are treated operatively by suture 
repair or with ﬁ brin glue either by laparotomy or laparoscopically. These interventions 
are followed by the use of proton pump inhibition and in case of H. pylori infection, 
eradication of this bacterium. Almost all serious ulcer complications acquire hospital-
ization for several days. Treatment of ulcer complications is relatively standard, but little 
is known about their costs in The Netherlands.
Outline and aims of this thesis
The general aim of this thesis is to explore the eff ect of H. pylori and eradication therapy 
in a population of patients with rheumatic diseases who chronically use NSAIDs.
The thesis contains investigations in several areas:
 − the eff ect of eradication of H. pylori on both clinical eff ects and histological changes on 
the stomach mucosa in patients with a rheumatic disease and long term NSAID use,
 − costs of ulcer complications,
 − prevalence of H. pylori
 − diagnosis of H. pylori by several techniques.
For that reason we designed in 1997 (before the  introduction of COXIBs11 and publi-
cation of the national guideline on NSAID related gastroduodenal damage34), a large, 
multicenter, randomized, placebo-controlled trial in order to answer questions about 
whether eradication of H. pylori is useful during long-term NSAID-use.
Since studies suggested a decreasing seroprevalence of H. pylori in the Western 
world, we investigated the prevalence of antibodies to H. pylori in patients with rheu-
matic diseases, treated with NSAIDs, in The Netherlands. Many patients were tested on 
H. pylori antibodies, as is described in [Chapter 2]. In this chapter, the prevalence of 
H. pylori was investigated as well as the eff ect of age in the studied population.
Because of the planned cost-eff ectiveness analysis parallel to the randomized con-
trolled trial as is described in [Chapter 4], and since of the low incidence of bleeding and 
perforations, it was not possible to reliably calculate the cost of treatment of these com-
plications within this trial, we conducted a retrospective study to estimate the direct 
hospital costs of treatment of upper gastroduodenal bleeding and perforation from the 
payer perspective. In [Chapter 3] we estimated the direct hospital costs of treatment of 
bleeding and perforated ulcers in our university hospital.
The debate on the eff ect of H. pylori eradication in long term NSAID users gave rise to 
[Chapter 4 and 5]. In [Chapter 4], the clinical eff ects (symptoms, gastoduodenal dam-
age and quality of life) of H. pylori eradication therapy was investigated in a multicenter, 
randomized, placebo-controlled trial in a large group of long-term NSAID users. In the 
next chapter the changes in histologic stains of the biopsy samples were investigated in 
long term NSAID users aft er H. pylori eradication or placebo.
introduction and outline of the thesis
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[Chapter 6] presents a post hoc analysis of this randomized controlled trial, which in-
vestigates whether long-term COX-2 selective NSAID use is associated with lower inci-
dence of endoscopic ulcers than use of long-term non-selective NSAIDs.
 [Chapter 7] describes the post hoc analysis aft er we measured the sensitivity and 
speciﬁ city of H. pylori IgG-antibody titer changes, hematoxylin and eosin stains, immu-
nohistochemical stains and culture results in NSAID using patients, following H. pylori 
eradication therapy or placebo.
In [Chapter 8] the effi  cacy of this test-and-treat strategy is described and also the 
role of resistance of H. pylori to antibiotics in a group of rheumatology patients on long-
term NSAIDs.
Finally, a summary of the results, the conclusions, and a general discussion of this 
thesis are presented in [Chapter 9].
ch apter 1
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chapter  2

Abstract
The separate contribution of NSAIDs and H. pylori in the pathogenesis of peptic ulcer 
disease has not been fully elucidated. The aim of this study was to investigate the sero-
prevalence of H. pylori in patients with rheumatic diseases and chronic NSAID treat-
ment. Patients with a rheumatic disease, age 40-80 years and regular use of NSAIDs 
(at least 3 times a week) were included (n=1214). IgG-antibodies to H. pylori were found 
in 39% and increased gradually with age: from 25% in patients in the 40-50 years age 
group to 48% in patients aged 70-80 years (P<0.0001). No diff erence was observed be-
tween men and women, or between the three centres. In our population of rheumatic 
patients treated with NSAIDs the seroprevalence of H. pylori is substantial (39%), but 
seems to be lower than in previous reports, which may be due to a cohort eff ect.
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Introduction
Patients with rheumatic diseases who are treated with non-steroidal anti-inﬂ ammatory 
drugs (NSAIDs) are at increased risk of developing upper gastrointestinal (GI) mucosal 
damage1. This GI-damage varies from gastritis and erosions to gastric and duodenal 
ulcers and their life-threatening complications (e.g. bleeding and perforation).
Much evidence has accumulated for a pathogenetic role of Helicobacter pylori in the 
development of upper GI damage: there is evidence that it causes chronic gastritis, it is 
considered as a carcinogen and has been accepted as one of the most important risk 
factors for the development of peptic ulceration 2.
It is generally accepted that eradication of H. pylori accelerates healing of ulcers and 
decreases ulcer recurrence rates in patients with peptic ulcers and H. pylori infection, 
who are not on NSAIDs3. However, there is no consensus about the beneﬁ t of eradica-
tion of H. pylori in the absence of an ulcer.
The situation is even more complex in H. pylori–positive patients taking NSAIDs. 
Data on the interaction between NSAIDs and H. pylori in causing GI-damage are con-
ﬂ icting: in some studies eradication of H. pylori was beneﬁ cial in NSAID-users4, while 
others found impaired ulcer healing aft er eradicatio n5, 6.
Since some studies suggested a decreasing seroprevalence of H. pylori in the west-
ern wor ld7, we investigated the prevalence of antibodies to H. pylori in patients with 
rheumatic diseases, treated with NSAIDs, in the Netherlands.
Patients and methods
Patients
Between September 1999 and April 2000, patients were tested for the presence of 
 seru mantibodies to H. pylori. Aft er informed consent, patients were recruited from the 
outpatient rheumatology clinics of Amsterdam (Jan van Breemen Institute and the de-
partments of rheumatology of the VU university medical centre and Slotervaart Hos-
pital), Utrecht (University Medical Centre) and Enschede (Medisch Spectrum Twente) in 
the context of a large, collaborative study to prevent NSAID-gastropathy. Included were 
patients aged 40-80 years, with a rheumatic disease (e.g. rheumatoid arthritis, psoriatic 
arthritis, ankylosing spondylitis and osteoarthritis). All patients were on chronic NSAID 
treatment (at least 3 times a week). Patients with severe (co-) morbidity were excluded.
Methods
Serum samples were collected and stored at -20°C. Serologic assays for H. pylori IgG-
antibodies were performed with a commercial enzyme-linked immunosorbent assay 
Pyloriset® new EIA-G (Orion Diagnostica, Espoo, Finland) according to the manufac-
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turer’s instructions. A serum sample was considered seropositive for IgG antibodies to 
H. pylori if the test result was ≥ 300 International Units. In earlier studies, this cut-off  
showed a sensitivity and speciﬁ city of 98% and 85%, respectively in detecting H. pylori 
infection8. The ethics committees of all participating institutes approved the study.
Statistics
The χ2-test for trend was used to examine relationships between the presence of anti-
bodies to H. pylori and age, gender and centre. A P value less than 0.05 was considered 
to be signiﬁ cant.
Results
A total number of 1214 serum samples were assayed for presence of H. pylori IgG- 
antibodies. A positive test result for IgG-antibodies was obtained in 39%. The preval-
ence rates for the age-categories 40-49, 50-59, 60-69 and 70-80 years are shown in 
[table 1]. The seroprevalence of H. pylori was 25% in patients in the 40-50 yr. age group. 
This prevalence increased signiﬁ cantly with age up to 48% in patients aged 70-80 years 
(P<0.0001). No diff erence in seroprevalence of H. pylori was observed neither between 
men and women (35% and 40%, respectively, P=0.08), nor between the three centres 
Amsterdam, Utrecht and Enschede (39%, 39% and 43%, respectively, P=0.60).
Discussion
The main conclusion of the present study is that we observed a prevalence rate of anti-
bodies to H. pylori of 39% in patients with rheumatic diseases and chronic NSAID treat-
ment. A second conclusion is that seroprevalence increased with age.
Although seroprevalence of 39% is substantial, it is lower than was reported in pop-
ulation-based studies performed in Europe and the United States in which prevalence 
rates between 52-68 % were observed in the ninet ies9 , 10. However, some authors found 
a lower prevalence of 32-40% in corresponding age-gr oups 11.
Unfortunately, it is diffi  cult to compare between studies without making allowance 
for the composition of the population, selection bias and diagnostic methods for detec-
tion of H. pylori infection. A worldwide decline in H. pylori seropositivity was reported 
in earlier reports from developed cou ntries7. Our recent data suggest that the H. pylori 
infection rate is lower than in a study of the Dutch population in 1990 in which a sero-
prevalence of 49% was r eported12. These data conﬁ rm the decline of seroprevalence of 
H. pylori.
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The relatively low overall prevalence and the increasing prevalence with age (as de-
scribed in most previous  studies10, 11 may be caused by a cohort eff ect or an age eff ect. 
Elderly patients could have a higher prevalence of infection because they were born at a 
time when the risk of infection in childhood was higher than in those born later (cohort-
eff ect) or because they have lived longer (age-eff ect). The latter possibility is less likely 
as the acquisition of H. pylori is known to occur mostly in childhood. H. pylori prevalence 
rates found in studies that investigated subsequent birth-cohorts suggest that H. pylori 
prevalence will decrease in the next decades in the Western p opulation7.
The risk of having antibodies to H. pylori might, at least theoretically, also be inﬂ u-
enced by socio-economic status9, ethnic origin and the use of drugs (NSAIDs, antibiotics, 
protonpumpinhibitors (PPI), and intramuscular gold). In our study, the socio-economic 
status and ethnic origin of the population were not investigated. In the literature, there 
are no convincing data on the eff ect of NSAIDs4, PPI13 or intramuscular go ld therapy14 on 
the seroprevalence of H. pylori.
As a consequence of the widespread use of NSAIDs and the prevalence of H. pylori 
infection (especially in the elderly), these risk factors oft en coexist in the same patients. 
The interaction of NSAIDs with H. pylori is controversial and some data suggest that 
mutual antagonism exists, leading to one of the pathogenic factors actually deriving 
some protection from the damaging potential of the oth er6, 15, 16.
It is diffi  cult to speculate on trends in GI-damage, because of the decreasing sero-
prevalence of H. pylori. H. pylori might have declining inﬂ uence on the occurrence of 
GI-damage. This may probably lead to relative more NSAID-induced GI-damage. On the 
other hand, the rapid development of selective COX-2 inhibitors (COXIBs) as safer alter-
natives to NSAIDs might as well have implications for the incidence of GI-damage17. In 
fact, H. pylori might become the major cause of peptic ulceration in COXIB-users. Thus, 
since the eff ect of both NSAIDs and H. pylori on GI-damage is decreasing, it is diffi  cult to 
predict changes in incidence of GI-damage over the coming years.
In summary, we found a substantial prevalence of antibodies to H. pylori of 39% 
in patients with rheumatic diseases treated with NSAIDs. The prevalence of H. pylori 
seems to be lower than in previous reports, which may be due to a cohort eff ect.
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Table 1 Prevalence of sera with antibodies (> 300 I.U.) to H. pylori in patients with rheumatic diseases 
treated with NSAIDs
Age group 40-49yrs 50-59yrs 60-69yrs 70-80yrs Total
Positive 56 (25%) 133 (39%) 152 (42%) 133 (48%) 474 (39%)
Negative 168 (75%) 211 (61%) 212 (58%) 146 (52%) 737 (61%)
Number per group 224 344 364 279 1211
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Abstract
objective Gastrointestinal toxicity of nonsteroidal anti-inﬂ ammatory drugs includes 
perforations and bleeds. Several preventive strategies are being tested for cost-eff ect-
iveness, but little is known about the costs of the complications they are trying to prevent.
We estimated the direct costs of hospital treatment of bleeding and perforated ulcers 
in a university hospital, from data in discharge letters and the hospital management 
information system.
methods Eligible patients had been treated in the VU University Medical Center be-
tween January 1997 and August 2000 for an ulcer bleed or perforation (International 
Classiﬁ cation of Diseases code 531-4). Resource use comprised hospitalization days and 
diagnostic and therapeutic interventions. Insurance claim prices determined the costs 
from the payers’ perspective. In a secondary analysis we excluded resource use that was 
clearly related to the treatment of comorbid illness.
results Fift y-three patients with a bleeding (n=35) or perforated ulcer (n=15), or both 
(n=3) were studied, including 14 with comorbidity; 22 complications occurred in the 
stomach, 29 in the duodenum, 1 in both stomach and duodenum and 1 aft er partial gas-
trectomy. A simultaneous bleed and perforation was most expensive (k€ 26) followed 
by perforation (k€ 19) and bleeding (k€ 12). A bleed in the duodenum was more expen-
sive than in the stomach (k€ 13 vs. k€ 10), while the opposite was seen for perforations 
(k€ 13 vs. k€ 21). Co-morbidity increased costs substantially: even aft er correction for 
procedures unrelated to the ulcer complication, comorbidity more than doubled the 
costs of treatment.
conclusion Treatment of complicated ulcers is expensive, especially in patients with 
comorbid conditions.
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Introduction
Peptic ulcers of the upper gastrointestinal tract are a frequent side eff ect of nonste-
roidal anti-inﬂ ammatory drugs (NSAIDs). Although most ulcers are asymptomatic and 
heal without therapy, a small proportion causes potentially life-threatening bleeding 
and perforation1. The annual incidence of gastropathy among chronic NSAID users var-
ies from 15-20 % for mild events2 and 1-2 % for serious events such as hemorrhage and 
perforation 3-5. Several factors such as age and a history of peptic ulcers can substantially 
increase this risk.
Treatment of ulcer complications is relatively standard, but little is known about 
their costs in the Netherlands. Bleeding ulcers are most frequently treated by endo-
scopic injection of adrenaline. To prevent early recurrences this is oft en followed by 
clipping of the blood vessel6. Perforated ulcers are treated operatively by suture repair 
or with ﬁ brin glue either by laparotomy or laparoscopically7.
Several strategies are being tested to prevent NSAID-induced gastropathy. These 
include medical co-therapy with high dose histamine2receptor blockers, proton pump 
inhibitors or misoprostol, or replacement of NSAIDs by COX-2 selective antagonists. 
When proven eff ective, implementation of any of these would have important eco-
nomic consequences. In September 1999 we started a randomized controlled trial on 
the eff ectiveness of Helicobacter pylori eradication in the prevention of NSAID induced 
gastropathy. A cost-eff ectiveness analysis is conducted alongside. Because of the low 
incidence of bleeding and perforations, it is not possible to reliable calculate the cost of 
treatment of these complications within this trial.
Thus, we conducted a retrospective study to estimate the direct hospital costs of 
treatment of upper gastrointestinal bleeding and perforation from the payer perspective.
Methods
With the eligibility criteria of the trial in mind, patients aged between 39-80 with a 
gastric or duodenal ulcer complicated by bleeding or perforation (ICD code 531, 532, 533 
and 534) treated in the VU University Medical Center (VUMC), Amsterdam, the Nether-
lands, between January 1997 and August 2000 were selected. Patients transferred to or 
from other hospitals in the course of their admission were excluded because the data 
of these patients would be incomplete. On the basis of the discharge letters 3 authors 
(HvD, MB and WL) independently selected the patients for inclusion in the study; con-
ﬂ icts were resolved by consensus. Only patients with ulcer bleeds and perforations that 
were conﬁ rmed by endoscopy, surgery or autopsy were included in this study.
The data of the management information system (COGNOS) of the VUMC yielded the 
following data per patient: (1) Demographic data (age, sex); (2) number of days hospital-
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ized (normal care, special care or intensive care); (3) diagnostic and therapeutic inter-
ventions (e.g. radiodiagnostic tests, blood products used, laboratory tests and surgical 
procedures).
Costs of hospitalization days were estimated using the charges claimed at the pa-
tients’ health insurance companies. Costs of medication are included in these charg-
es and were not estimated separately. The costs of radiodiagnostic tests summarized 
as ‘speciﬁ c’ and ‘general’ are charges computed by the medical administration of the 
VUMC. Speciﬁ c radiodiagnostic tests comprise computed tomography, magnetic reso-
nance imaging, and angiography. General radiodiagnostic tests include all other proce-
dures with or without contrast and ultrasound procedures. The costs paid to the sup-
plier of blood products listed in the management information system of the VUMC were 
used to estimate the costs of blood products. The costs of tests necessary before infu-
sion of blood products were not incorporated. The costs of laboratory tests per patient 
consist of a general charge for the test, personnel costs, costs of materials and costs 
of equipment. The costs of diagnostic and therapeutic interventions (e.g. endoscopies, 
endoscopic injection, laparotomy, laparoscopy) were also estimated using the insurance 
claim charges.
The total costs of treating bleeding and perforated ulcers were calculated by adding 
the costs of all components.
Pre-existing comorbidity likely results in prolonged hospitalization or extra treatment 
that may be unrelated to treatment of the bleeding or perforated ulcer. In a secondary 
Table 1 Patient characteristics by co-morbidity status
All patients
n=53
Patients without 
co-morbidity n=39
Patients with 
co-morbidity n=14
Male, % 66 67 64
Age, yrs, mean (SD) 63 (12) 62 (12) 66 (11)
Event
 Ulcus ventriculi
 Ulcus duodeni
Bleeding
10
23
Perfo-
ration
11
4
Both
1
2
Bleeding
8
16
Perfo-
ration
8
4
Both
1
2
Bleeding
2
7
Perfo-
ration
3
0
Both
0
0
Use of antisecretory 
agents (%)
37 (70) 30 (77) 7 (50)
Total hospitalization 
days mean (SD)
 Normal care days
 Special care days
 Intensive care days
8.7 (7.9)
7.5 (8.1)
0.2 (0.6)
1.2 (2.7)
8.7 (8.5)
8.1 (8.4)
0.1 (0.5)
0.5 (2.1)
8.9 (6.5)
5.7 (7.1)
0.4 (0.9)
2.9 (3.5)
Two patients could not be unequivocally classiﬁ ed: one had multiple bleeding and perforated ulcers in both stomach 
and duodenum, and the other had a bleeding ulcer on the anastomosis of a previous Billroth II gastrectomy. Both 
patients had co-morbidity.
32
analysis, distinction was therefore made between costs of patients without comorbid-
ity, patients with comorbidity and patients with comorbidity corrected for procedures 
and hospitalization days not related to the treatment of the bleeding or perforated ul-
cer. To determine the inﬂ uence of comorbidity on the costs of treatment, signiﬁ cant 
costs that could be directly linked to pre-existing co-morbidity, independent of the ul-
cer complication were extracted. Although of necessity an arbitrary procedure, MB and 
WL independently checked the cases with comorbidity and resolved discrepancies in 
consensus. The criteria to exclude procedures/costs were: (1) the procedure clearly an-
tedated the ulcer complication, or (2) it was completely evident that the procedure was 
unrelated to the ulcer complication, and (3) the procedure or package of procedures was 
inexpensive (< € 90).
To illustrate this procedure two examples are given:
1 A patient was admitted with melena aft er taking NSAIDs for severe back pain. The 
patient died in hospital aft er 10 days of intensive care due to septic shock. In recon-
struction, alcohol abuse had resulted in liver cirrhosis and a poor general condition. 
She developed Staphylococcal endocarditis and spondylodiscitis followed by sepsis. 
The discitis prompted the use of NSAIDs, which led to multiple gastric and duode-
nal ulcers from which she bled. Multiple organ failure developed despite optimal 
therapy. Costs of care included a variety of expensive diagnostic tests (e.g. multiple 
CT scans of brain and abdomen), hemodialysis, and autopsy. In this case we were 
unable to exclude any costs as ‘unrelated to the ulcer bleeding’.
2 Another patient was admitted to the department of surgery for arterial insuffi  ciency 
of the right leg. He died aft er 28 days. His history included complicated arteriosclero-
sis with an aneurysm of the aorta treated with a vascular prosthesis and dialysis-
dependent renal failure. Aft er angiography his condition worsened necessitating an 
Table 2 Tariff s of frequently used interventions and hospitalization days in Euro (€) *
Therapeutic interventions: Tariff s
Suture repair: perforation (stomach) 782
Suture of bleeding vessel (duodenum) 792
Suture repair: perforation (duodenum) 1,144
Endoscopic Sclerosis of bleeding vessel (stomach) 354
Hospitalization days
 Normal care
 Special care
 Intensive care
332
735
1139
* 1 Euro= US$1.14
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acute laparotomy. A total obstruction of the femoral artery could be reversed, but 
the leg had suff ered too much ischemic damage and had to be amputated. Four 
days aft er surgery an acute abdomen developed. A re-laparotomy revealed perfor-
ated ulcus ventriculi that was closed. The postoperative course was complicated by 
progressive heart failure, to which the patient succumbed. In this case we decided to 
exclude in the secondary analysis as ‘unrelated’ all costs related to the ﬁ rst surgical 
procedures, the vascular workup and the hemodialyses.
Unless, otherwise stated, all costs are expressed in Euros (1 Euro (€)=1.14 US$).
Results
In the selected period 164 patients were admitted to the VUMC with the speciﬁ ed se-
lected ICD-codes 531-534. Of these, 97 were between 39-80 years of age. Twenty-one 
patients were transferred to or from other hospitals and 23 patients were incorrectly 
classiﬁ ed, i.e. the admission did not concern bleeding or perforation of a peptic ulcer. 
Thus, 53 patients were ﬁ nally included. Fourteen of these patients had severe co-mor-
bidity, such as diabetes mellitus, cardiovascular diseases and neurological disorders. 
Mean age was 63 years with a slight male predominance [Table 1]. On admission, thirty-
seven patients were treated with antisecretory agents, usually proton pump inhibitors.
Events included 35 bleeds, 15 perforations and 3 occurrences of both complications. 
Twenty-two patients had complications in the stomach, 29 in the duodenum. Of the 
two remaining cases, one had multiple bleeding ulcers in both stomach and duodenum, 
and the other had a bleeding ulcer on the anastomosis of a previous Billroth II gastrec-
tomy [Table 1].
Routine diagnostic interventions (chest radiograph, blood hemoglobin levels) were 
by far the most frequent procedures. Suture repair of perforations and bleeding vessels 
were the most frequent therapeutic interventions. [Table 2] shows the costs of the fre-
quently used, complication-related interventions and hospitalization days.
Overall, treatment of a simultaneous bleeding and perforated ulcer costs € 26,000, 
treatment of a perforated ulcer € 19,200 and a bleeding ulcer € 11,900. For all types of 
complications the costs of hospitalization days were the greatest part of the total costs. 
In the subgroup of patients with co-morbidity costs of treatment was substantially high-
er: perforation € 38,000 and bleeding € 25,200, respectively. Correction for procedures 
unrelated to the treatment of the ulcer complication partially corrected this diff erence, 
mostly due to lower costs of interventions [Table 3]. In the stomach, ulcer bleeds were 
less costly than in the duodenum (€ 9,600 vs. € 13,000) but perforations were more 
costly (€ 21,500 vs. € 13,100; [Table 3]).
costs of peptic ulcer complications
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Discussion
We estimated the direct hospital costs of treatment of bleeding and perforated ulcers 
in our university hospital. Direct costs of treatment of ulcer complications were high 
especially in patients with co-morbidity. Even aft er correction for procedures unrelated 
to the ulcer complication, costs of treating patients with comorbidity remained more 
than twice that of patients without comorbidity.
Under- or overestimation of the costs of treatment of ulcer complications may have 
occurred for several reasons. To determine the costs of hospitalization days we used 
the tariff  claimed at the insurance company of the patients. We did not incorporate the 
costs of medication separately, because they are included in the tariff s of hospital care, 
and represent only a small part of the total costs of treatment. In addition, we did not 
estimate the costs of subsequent outpatient care. These factors point to underestima-
tion of total costs. On the other hand, the study setting was a university hospital. This 
setting usually attracts patients with more severe and complicated disease. Also, costs 
in a university hospital are higher than elsewhere. This may also have resulted in an 
overestimation of total costs.
In another Dutch study, Chevat et al.8 assessed the cost of treating serious gastro-
intestinal events requiring hospitalization associated with the use of NSAIDs in pa-
tients with osteoarthritis and rheumatoid arthritis. They concluded that from a payers’ 
perspective the total costs ranged between € 1,800 and € 6,900. Included costs were 
similar, with the addition of medication and outpatient costs. Information on the use of 
medication was gathered from national databases. However the use of resources was 
determined on interviews with physicians such as general practitioners, gastroenterolo-
gists, rheumatologists, surgeons and hospital specialists, which may not be a reliable 
source. As our study is based on individual patient data we believe that our estimation 
is more reliable and better reﬂ ects daily clinical practice. As such, the estimate will be 
useful in determining the cost-eff ectiveness of strategies aimed at reducing the risk of 
complicated peptic ulcers in long-term NSAID users.
Cost studies are not directly comparable across countries. For the purpose of com-
parison, the purchase power parities (PPPs) values published by the Organisation for 
Economic Cooperation and Development could be used. PPPs are the rates of currency 
conversion that eliminate the diff erences in price levels between countries. In addition, 
the unit costs of interventions and hospitalization days could be used to compare across 
countries [table 2]. Studies concerning NSAID-gastropathy and costs in the United States 
have provided an estimate of the costs of hospitalization for serious GI complication s9-11. 
The reported costs were US $10.000-$20.000. However, the authors did not report how 
costs were calculated and what cost prices or tariff s were used to estimate these costs. 
We used a bottom-up approach to estimate costs and our publication includes informa-
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tion on costs of serious GI complications per type of ulcus (ulcus ventriculi versus ulcus 
duodeni, and bleeding versus perforation), and separately for ulcers with or without 
 co-morbidity. Therefore, we believe that our cost estimate provides additional informa-
tion to the ARAMIS data. The fact that the results are comparable and support each 
other is important. Also, our results show that the wide range reported may depend 
upon diff erences between bleeding and perforation, the anatomic area of the complica-
tion or presence of comorbid illness. It is the type of information, which is important as 
one tries to understand the impact of these complications on the patient and the health 
care system. Future economic evaluation is needed to evaluate this impact.
In conclusion, the hospital treatment of ulcer complications is costly, especially in 
patients with co-morbid conditions. With appropriate caution, the results of utilization 
are generalizable to other settings with similar levels of care, allowing estimation of 
costs aft er price adjustment.
Table 3 Mean (SD) costs per type of complication and per type of ulcer in 1000 Euro*
Complication Major 
Costs**
Total 
costs
Total costs 
by ulcer type***
Costs 
hospital-
ization days
Costs 
of inter-
ventions
Ulcus 
ventriculi
Ulcus 
duodeni
All patients n=53
 Bleeding n=34
 Perforation n=15
 Bleeding and perforation n=4
9.2 (10.1)
13.7 (10.8)
20.1(16.3)
2.6 (4.4)
5.3 (3.5)
5.5 (3.4)
11.9 (13.7)
19.2 (13.7)
26.0 (19.6)
9.6 (14.8)
21.5 (15.4)
54.1
13.0 (13.8)
13.1 (4.4)
16.8 (9.7)
Without co-morbidity n=39
 Bleeding n=24
 Perforation n=12
 Bleeding and perforation n=3
5.1 (4.4)
10.2 (5.8)
22.6 (19.0)
1.3 (2.3)
4.2 (1.6)
6.4 (3.6)
6.4 (6.2)
14.6 (6.6)
29.2 (22.6)
4.9 (3.2) 
15.3 (7.7)
54.1 
7.1 (7.2) 
13.1 (4.4) 
16.8 (9.7) 
With co-morbidity uncorrected n=14
 Bleeding n=10
 Perforation n=3
 Bleeding and perforation n=1
19.1 (13.0)
27.7 (16.3)
12.7
6.0 (6.3)
10.1 (5.4)
2.9
25.2 (17.8)
38.0 (20.2)
16.1
28.6 (31.6)
38.0 (20.2)
N.A.
26.6 (16.1) 
N.A.
N.A.
With co-morbidity corrected n=14
 Bleeding n=10
 Perforation n=3
 Bleeding and perforation n=1
15.7 (11.1)
21.1 (20.2)
12.7
3.6 (2.7)
8.7 (3.9)
2.9
19.5 (13.0)
30.0 (22.4)
16.1
13.0 (9.6)
30.0 (22.4)
N.A.
22.8 (13.9)
N.A.
N.A.
*  1 Euro= US $1.14
**  Minor (untabulated) costs include costs of laboratory tests.
*** Two patients could not be unequivocally classiﬁ ed: one had multiple bleeding an perforated ulcers in both 
 stomach and duodenum, and the other had a bleeding ulcer on the anastomosis of a previous Billroth II 
 gastrectomy. Both patients had co-morbidity.
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Abstract
background Helicobacter pylori and nonsteroidal anti-inﬂ ammatory drugs (NSAIDs) 
are the major causes of gastroduodenal ulcers. Studies on the beneﬁ t of eradication of 
H. pylori in NSAID users yielded conﬂ icting results.
Objective To investigate whether H. pylori eradication in patients on long-term 
NSAIDs reduces the incidence of gastroduodenal ulcers.
methods Patients on long-term NSAID treatment, and H. pylori-positive on serological 
testing, were randomly assigned to either H. pylori eradication (omeprazole, amoxycil-
lin, and Clarithromycin) or placebo. Primary endpoint was the presence of endoscopic 
gastric or duodenal ulcers 3 months aft er randomization.
results Hundred sixty-ﬁ ve (48%) of a total of 347 patients were on gastroprotective 
medication. At endoscopy, gastroduodenal ulcers were diagnosed in 6 (4%) and 8 (5%) 
patients in the eradication and placebo group, respectively (P=.65). During follow-up 
of 12 months, no symptomatic ulcers or ulcer complications developed. No signiﬁ cant 
diff erences were found in the development of gastroduodenal erosions, dyspepsia, or 
in quality of life.
conclusion H. pylori eradication therapy in patients on long-term NSAID treatment 
had no beneﬁ cial eff ect on the occurrence of ulcers, erosions, or dyspepsia. Ulcer rates 
in both study arms are remarkably low, in both patients with and without gastroprotec-
tive therapy.
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Introduction
Non-steroidal anti-inﬂ ammatory drugs (NSAIDs) are widely prescribed for rheumatic 
diseases. Their use is however limited by the frequent occurrence of gastropathy, which 
is characterized by dyspepsia, and by superﬁ cial and deeper mucosal damage, leading 
to erosions, gastroduodenal ulcerations, and their life-threatening complications such 
as bleeding and perforation 1,2. In recent years, various strategies have been developed to 
prevent NSAID-induced gastropathy and some are widely implemented in clinical prac-
tice. These strategies include co-therapy with gastroprotective agents, such as prosta-
glandin analogues (misoprostol), proton pump inhibitors (PPI), and H2-receptorantago-
nists (H2RA), and development of the cyclooxygenase-2-speciﬁ c inhibitors (COXIBs )3-5.
The identiﬁ cation of H. pylori infection, a very important factor in the development 
of gastroduodenal ulcer disease6, has raised the question of a possible additive or syn-
ergistic interaction between H. pylori and NSAID use in the etiology of gastroduodenal 
ulcers. In a meta-analysis of 16 endoscopic studies of 1625 NSAID takers, uncomplicated 
peptic ulcer disease was twice as common in patients positive than in those negative for 
H. pylori7. Eradication of H. pylori substantially decreases the rate of recurrence of peptic 
ulcers in patients not taking NSAI Ds8, 9. Furthermore, screening for and eradication of 
H. pylori in patients who are about to start with NSAID-therapy signiﬁ cantly reduces the 
risk of ulcer development. However it is not fully elucidated whether eradication is also 
useful for patients who are already on long-term NSAID-treatm ent10, 11.
Therefore, we investigated, in a randomized, double blind, placebo-controlled study, 
whether Helicobacter pylori eradication reduces the incidence of gastroduodenal ulcers 
in patients receiving long-term treatment with NSAIDs.
Methods
Patients
Patients were recruited from 8 rheumatology outpatient departments in 6 cities in the 
Netherlands. Patients with a rheumatic disease were eligible for inclusion if they were 
between 40 and 80 years of age, required long-term NSAID treatment and were positive 
for H. pylori on serological testing. Long-term NSAID treatment was deﬁ ned as the use of 
any NSAID for at least 3 days a week for the last month and the need to continue NSAID 
treatment. Exclusion criteria were: previous eradication therapy for H. pylori, known 
 allergy for the study medication and presence of severe concomitant disease. Concurrent 
use of steroids, low dose aspirin, anticoagulants, and gastroprotective agents including 
proton pump inhibitors, H2-receptor antagonists, and misoprostol, was allowed.
Serologic assays for H. pylori IgG-antibodies were performed with a commercial en-
zyme-linked immunosorbent assay (Pyloriset® new EIA-G, Orion Diagnostica, Espoo, 
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Finland) according to the manufacturer’s instructions. A serum sample was considered 
positive for IgG antibodies to H. pylori if the test result was ≥ 250 International Units (IU).
All patients continued the NSAID that was prescribed by their treating rheumatolo-
gist. Any NSAID (including COXIBs) was permitted, as were changes in the type or dose 
of NSAIDs. A relative daily NSAID dose was calculated by dividing the daily dose by the 
full therapeutic dose of that NSAID. The mainly used NSAIDs and their full therapeutic 
daily doses were: diclofenac (full therapeutic daily dose 150 mg), ibuprofen (2400 mg), 
naproxen (1000 mg), indometacin (150mg), meloxicam (15 mg), nabumetone (2000 mg), 
and rofecoxib (25 mg).
The study protocol was approved by research and medical ethics committees of all 
participating centers and all patients gave written informed consent.
Interventions
Aft er stratiﬁ cation by concurrent use of gastroprotective agents (proton pump inhibi-
tors, H2 receptor antagonists or misoprostol, but not prokinetics, or antacids), patients 
were randomly assigned to receive either H. pylori eradication therapy with omeprazole 
20 mg, amoxycillin 1000mg, and clarithromycin 500 mg (OAC) twice daily for 7 days or 
placebo. Patients with an allergy for amoxicillin were randomized in a separate stratum 
to receive omeprazole 20 mg, metronidazole 500 mg and clarithromycin 250 mg (OMC) 
or placebo therapy twice daily for one week. Randomization to consecutive patient 
numbers was done in proportions of 1:1, in blocks of four from a computer-generated 
list. The study centers were provided with individually sealed packages containing the 
treatment for each patient. Each center received entire blocks to be used sequentially. 
Rheumatologists were not practicing in more than one center. The study medication 
was given in a double blind, double dummy manner. Active and placebo preparations 
were identical in appearance. The employees of the VU University Medical Center phar-
macy who packaged the medication only knew the assignment. It was disclosed to the 
treating physician only in case of emergency. All study personnel and participants were 
blinded to treatment assignment for the duration of the study.
Follow-up
Appointments with the study physician or research nurse were scheduled at baseline, 
2 weeks, 3 months and 12 months aft er study initiation. At baseline patients were inter-
viewed about their history of gastroduodenal ulcers, smoking habits, alcohol consump-
tion, type of rheumatic disease, disease duration, coexisting disease, concurrent drug 
treatment (with emphasis on steroids, anticoagulants, platelet aggregation inhibitors, 
disease modifying drugs), height and body weight. At the 2-week follow-up visit, unused 
study medication was returned and remaining tablets were counted in order to check 
compliance. Patients were considered to be noncompliant if < 6 days (85%) of study 
medication were used. Three months aft er baseline, patients underwent endoscopy of 
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the upper gastrointestinal tract. Endoscopists were blinded for treatment allocation. 
In each center all endoscopies for this study were preferentially performed by a single, 
experienced endoscopist. At every endoscopic examination, the number of erosions and 
ulcers was recorded separately for esophagus, stomach, and duodenum. An ulcer was 
deﬁ ned as a break of at least 5 mm diameter in the gastric or duodenal mucosa pene-
trating the muscularis mucosae. Smaller or superﬁ cial lesions were classiﬁ ed as ero-
sions. Esophagitis was scored according to the Savary-Miller classiﬁ cation12. Further, en-
doscopic signs of gastritis and duodenitis were recorded. A total of eight biopsies were 
taken during each endoscopy. Four samples, two from the antrum, and two from the 
corpus were used for histology and scored according to the updated Sydney classiﬁ ca-
tion by experienced pathologists13. The remaining biopsies were used for culture. A pa-
tient was considered H. pylori-negative when both histology and culture were negative.
At all visits, patients were questioned about dyspepsia. Dyspeptic symptoms were 
assessed with 3 items (abdominal pain, reﬂ ux, and indigestion) of the gastrointesti-
nal symptoms rating scale (GSRS)14. At baseline and at 12 months, functional ability 
and health related quality of life were assessed with Health Assessment Questionnaire 
(HAQ-DI)15. Utility was measured with the EuroQol16 and quality of life was assessed 
with Short Form-36 (SF-36) health su rvey17. Treatment of non-ulcer dyspepsia was de-
ﬁ ned as treatment of upper-abdominal pain, discomfort, nausea, or non-ulcer mucosal 
damage as observed at endoscopy resulting in start or dose escalation of anti-ulcer 
therapy (PPI, H2A, or misoprostol).
Unscheduled visits were encouraged when dyspeptic complaints or adverse events 
occurred and unscheduled endoscopy was performed when clinical indicated. Serious 
adverse events were deﬁ ned as any adverse experience that resulted in death, hospital-
ization, was life-threatening, or resulted in a persistent or signiﬁ cant disability/incapac-
ity and scored by two independent observers who were blinded for treatment allocation.
Outcomes
The primary endpoint of this study was the presence of an endoscopically proven gastric 
or duodenal ulcer at 3 months from baseline. Secondary endpoints were the number of 
patients with a symptomatic ulcer (deﬁ ned as gastroduodenal ulcer found aft er work-up 
for dyspepsia), ulcer complication such as bleeding and perforation, other endoscopic 
gastroduodenal mucosal damage, treatment of non-ulcer dyspepsia, adverse events, 
compliance, and quality of life.
Costs
We expected eradication of H. pylori to be more eff ective than placebo, but to be associ-
ated with higher costs. Therefore, we collected all relevant direct cost data18. The results 
of the planned economic evaluation and the costs of H. pylori eradication therapy will 
be presented elsewhere.
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Statistical methods
The sample size calculation for this study was based on the assumption that the in-
cidence of gastroduodenal ulcer in respectively in the non-gastroprotection–stratum 
and the gastroprotection-stratum would be 20% and 10% in the placebo group and 
8% and 4% in the eradication group. Based on 80% power to detect a signiﬁ cant dif-
ference (P=0.05, two sided), 180 patients were required for each study group (360 in 
total). In  reality the incidence of ulcers turned out to be surprisingly low, even in the 
placebo group. We present conﬁ dence intervals for diff erences of proportions so as to 
provide insight in the precision (power) that was aft er all attained. Primary analysis was 
done with coded group allocation aft er data collection and entry were complete. All 
analyses were based on intention to treat and included all patients who were random-
ized. All available data were used. In addition tot the analysis based on the complete 
data, we performed subgroup analyses on the subgroups of patients on gastroprotec-
tion (n=165) and not on gastroprotection (n=182), patients in the diff erent centers, and 
with and without amoxicillin allergy. As the results of these subgroup analyses were 
entirely comparable to those of the main analysis, we present only the results of the 
main analysis below. Measurements are expressed as mean and SD or as the median 
and inter quartile range (IQR). Diff erences between groups were analyzed by chi-square 
test, Mann-Whitney U test, Student’s unpaired T-test where appropriate. The level of 
signiﬁ cance was set at P<0.05, two sided. None of the analyses were post-hoc analyses.
Results
Between May 2000 and June 2002, 2761 potentially eligible patients with rheumatic 
diseases were screened for anti-H. pylori antibodies (ELISA), 1091 (40%) of them tested 
positive and were further assessed for eligibility by the investigators. A total of 744 pa-
tients were not included because they refused participation (55%), or because they met 
exclusion criteria (45%), in particular: understated long-term NSAID use (21%), age (3%), 
severe comorbidity (4%), previous eradication therapy (3%), participation in other trials 
(5%), and other reasons (9%). Finally, 347 patients met all criteria and were randomized 
to eradication therapy (172 patients) or placebo (175 patients) [Figure 1]. Three-hundred-
and-ﬁ ft een patients could be included in the intention to treat analysis for the endo-
scopic endpoints. A total number of 323 patients completed the follow-up of 12 months.
Baseline characteristics
The treatment groups were comparable in terms of demographics, rheumatic disease, 
drug use, and prognostic variables [Table 1]. Our eligibility criteria resulted in a study 
group of Dutch Caucasian ethnicity with mainly inﬂ ammatory rheumatic diseases. The 
most commonly used NSAIDs were diclofenac (29%), naproxen (18%), and ibuprofen 
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(13%), most at full therapeutic doses (median relative daily dose 1 (IQR 0.5-1). Forty-eight 
percent of the patients used a gastroprotective drug in combination with an NSAID; 9% 
of the patients used a coxib (including 4 % using a combination of a coxib and gastro-
protective drugs). Thus, 53% percent of the patients used a gastroprotective drug and/
or a coxib. Thirty-seven patients (11%) had an ulcer history.
We assessed the propensity for gastroduodenal complications in the study popula-
tion by counting the number of important risk factors (advanced age [>70 years], his-
tory of ulcer, concomitant use of corticosteroids, the use of more than one NSAID, 
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Figure 1 Design and follow-up of the study
2761 patients screened 
for H. pylori
1091 patients positive
347 patients randomised
175 assigned 
to placebo group
166 patients completed 
12-month follow-up
172 assigned 
to eradication group
157 patients completed 
12-month follow-up
155 underwent 
endoscopy at 3 months
6 refused 
endoscopy
9 refused 
endoscopy
160 underwent 
endoscopy at 3 months
6 withdrew consent
4 had severe concomitant 
disease
1 died
2 withdrew consent
1 had severe concomitant 
disease
1 lost to follow-up
6 withdrew consent
2 had severe concomitant 
disease
1 withdrew consent
1 had severe concomitant 
disease
1 lost to follow-up
1670 patients negative
744 patients refused 
or met exclusion criteria
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Table 1 Base-Line Characteristics of the Patients*
Characteristic Eradication
(n=172)
Placebo
(n=175)
Age — years 59±11 60±10
Women 108 (63) 104 (60)
Underlying disease 
 Rheumatoid Arthritis 
 Spondylarthropathy 
 Psoriatic Arthritis
 Osteoarthritis 
 Other 
107 (62)
13 (8)
14 (8)
15 (9)
23 (13)
106 (61)
15 (9)
11 (6)
15 (9)
28 (16)
Disease duration—yr † 7 (3 to 14) 8 (3 to 15)
Gastroprotective treatment
 H2 antagonist 
 Proton pump inhibitor 
 Prostaglandin analogues (misoprostol)
9 (5)
64 (37)
0
14 (8)
63 (36)
1 (1)
NSAID treatment 
 Conventional NSAID
 COX-2 preferential NSAID (meloxicam, nabumetone)
 COXIB (rofecoxib, celecoxib)
 Combination drug (diclofenac/misoprostol)
118 (69)
27 (16)
17 (10)
10 (6)
116 (66)
33 (19)
13 (7)
13 (7)
Relative daily dose of NSAID †§ 1 (0.5 to 1) 1 (0.5 to 1)
Risk factors for gastroduonenal ulcers 
 History of gastroduodenal ulcer 
 Current smoking 
 Current alcohol drinking 
19 (11)
47 (27)
88 (51)
18 (10)
40 (23)
85 (49)
Current co-medication
 Coumarine derivatives
 Low dose aspirin 
 Corticosteroids
5 (3)
13 (8)
17 (10)
5 (3)
22 (13)
16 (9)
Titer H. pylori serology† 1590 (692 to 3536) 1846 (799 to 4057)
BMI ‡ 27.7±4.5 26.9±4.6
Ethnic Dutch Caucasian 130 (87) 133 (87)
Known allergy for amoxycillin 10 (6) 12 (7)
* Plus-minus values are means±SD; other values are counts (%) unless noted. † Median (Inter Quartile Range). ‡The 
body-mass index is the weight in kilograms divided by the square of the height in meters. §The relative daily dose 
of the NSAIDs was calculated by dividing the daily dose of NSAID by the full therapeutic dose of that NSAID.
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concomit ant administration of anticoagulants). Sixty-one percent of patients had none, 
28% had one, 12% had two, and 0.3% had three risk factors. The distribution was similar 
in the two treatment groups (data not shown). Dutch guidelines suggest gastroprotec-
tion should be off ered to patients with at least history of ulcer or age over 70 years (19). 
In our study, these guidelines were moderately adhered to: 48% of patients with no risk 
factor were treated — perhaps inappropriately — with a gastroprotective agent or coxib, 
only 55% with one risk factor, and in only 70% with 2 or 3 risk factors were treated with 
a gastroprotective agent or coxib.
Compliance
Compliance with the assigned regimen was 89 % in patients in the eradication group and 
99% in the placebo group (P<.001). Sixteen (80%) of the 20 patients who discontinued 
use of the study medication stopped because of an adverse eff ect (15 in the eradication 
group and 1 in the placebo group).
Gastroduodenal ulcers
At 3 months, gastroduodenal ulcers were diagnosed in 6 (4%) patients in the eradication 
group (ﬁ ve gastric and 1 duodenal ulcer) and 8 (5%) patients in the placebo group (6 gas-
tric and 2 duodenal ulcers) (P=.645; [table 2]). No patient developed a symptomatic ul-
cer, gastrointestinal bleeding, or perforation during the total study period of 12 months. 
No signiﬁ cant diff erences between the eff ect of eradication in the stratiﬁ ed analysis 
according to the use of gastroprotective drugs were found. All ulcers were diagnosed in 
patients on conventional NSAID (data not shown). At endoscopy, 29% of patients had 
erosions in the stomach and duodenum, with no signiﬁ cant diff erences between the 
eradication group (27%) and the placebo group (32%). Both groups did also not diff er 
with respect to the number of patients with more than 10 erosions [Table 2].
Dyspeptic symptoms
Dyspeptic complaints did not diff er between the study groups (P=.90; [Table 3]). Dur-
ing the study, 94 patients (43 in the eradication group and 51 in the placebo group) 
developed non-ulcer dyspepsia requiring therapy (P=.385). No signiﬁ cant diff erences 
between the eff ect of eradication in the stratiﬁ ed analysis according to the use of gas-
troprotective drugs were found.
Safety /Adverse events
The proportion of patients reporting any adverse reaction probably related to the study 
medication was signiﬁ cantly higher in patients in the eradication group than in the pla-
cebo group: 35 of 172 (20%) and 4/175 (2%), respectively, (P<.001). The most common 
treatment related events were diarrhea, dyspepsia, and stomatitis (respectively 17%, 
5%, and 4% in the eradication group versus 1%, 2%, 0% in the placebo group). The pro-
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portion of patients experiencing a severe adverse event, as judged by the investigators 
was comparable in the eradication group and in the placebo group: 24 of 172 and 20 of 
175, respectively. One patient in the eradication group died of a cardiac arrest 5 weeks 
aft er inclusion. The incidence of serious adverse events related to non-gastroduodenal 
malignancies and cardiocerebrovascular events was similar in both groups (respectively 
5 and 3 patients in the eradication group versus 1 and 5 patients in the placebo group). 
None of the serious adverse events was considered to be related to the study medica-
tion or to gastroduodenal disease.
H. pylori status
Three months aft er randomization, 87% of the patients in the eradication group and 
21% of the patients in the placebo group were H. pylori-negative by histology and cul-
ture of biopsy specimen. Seven out of eight ulcer patients in the placebo group were 
H. pylori positive at endoscopy. In the eradication group 3 ulcer patients were H. pylori-
negative, 2 ulcer patients were H. pylori-positive, and in 1 patient no biopsies were taken 
because of treatment with anticoagulant therapy.
Table 2 Incidence of Endoscopic endpoints at 3 months
Eradication 
(n=155)
Placebo
(n=160)
95% CI
Patients with gastroduodenal ulcer 
 Total 
 Gastric ulcer 
 Duodenal ulcer
6 (4)
5 (3)
1 (1)
8 (5)
6 (4)
2 (1)
-6.1 to 3.9
-5.1 to 4.0
-3.8 to 2.5
Patients with gastroduodenal erosions 
 >1 erosion
 Erosions stomach 
 Erosions duodenum
41 (27)
38 (25)
7 (1)
51 (32)
46 (29)
8 (5)
-15 to 4.8
-14 to 5.5
-5.5 to 5.8
Patients with >10 erosions or ulcer 11 (7) 12 (8) -6.3 to 5.8
Gastritis 60 (39) 69 (43) -15 to 6.4
Duodenitis 13 (9) 19 (12) -10 to 3.5
Oesophagitis (Savary-Miller)
 Grade 1
 Grade II
 Grade III
 Grade IV
34 (23)
22 (14)
7 (5)
1 (1)
4 (3)
26 (16)
20 (12)
3 (2)
0
3 (2)
-2.4 to 15
Hernia diaphragmatica 63 (41) 49 (31) -0.5 to 20
All values are counts (%). 95% Conﬁ dence Intervals (CI) are for the diff erence between the group given eradication 
therapy and the group given placebo.
h. py lori  er adication in long-term nsaid users
48
Discussion
The most important ﬁ ndings of this study are: (1) H. pylori eradication therapy in patients 
with rheumatic disease on long-term NSAID treatment had no beneﬁ cial eff ect on the 
occurrence of ulcers, erosions, or dyspepsia, but frequently caused adverse eff ects; and 
(2) the ulcer rates in both study arms are extreme low, both in patients with and without 
gastroprotective therapy.
Several studies suggested that screening for and eradication of H. pylori at the start of 
NSAID therapy signiﬁ cantly reduces the incidence of ulcer di sease19-21. Nevertheless, the 
test and treat strategy of H. pylori-positive NSAID starters is hardly implemented in the 
international and national guidelines, nor in clinical pr actice21, 22. This can be explained 
by the practical consequences of this strategy, which requires postponing NSAID treat-
ment in patients with pain, bother them with invasive or non-invasive H. pylori tests, 
and if positive treat them with eradication therapy. Such therapy is oft en accompanied 
by side eff ects as in our population. Eradication of H. pylori infection in patients already 
on long-term NSAIDs has not yet been shown to reduce occurrence of gastroduodenal 
ulcers10, 11, 23. Both studies in NSAID starters and patients on long-term NSAIDs did not 
represent patients as seen in daily clinical practice in Western countries. Most studies 
on this issue came from Asia and the extent of the inﬂ ammatory reaction on H. pylori 
depends on strain virulence and host susceptibility, may vary by regions in the world, 
and might therefore partly explain the variability between H. pylori eradication studies. 
Many studies excluded high-risk patients with history of ulcer, as well as patients on 
gastroprotective agents or COXIBs. In contrast, the present study was speciﬁ cally de-
signed to mirror daily clinical practice. Therefore, patients were included irrespective of 
the use of gastroprotective agents, corticosteroids, anticoagulants, or low-dose aspirin, 
an irrespective of the NSAID used. For that reason, we also did not exclude patients with 
a history of ulcer disease or ulcer complications.
We did not perform endoscopy at baseline, because invasive screening tests for 
H. pylori are less feasible in everyday practice. Instead, we used IgG serology to assess 
H. pylori status with an assay has a sensitivity and speciﬁ city in the Netherlands of 98-
100% and 79-85%, even in patients on acid suppressive therapy24-26.
Our results provide evidence that H. pylori eradication is of no beneﬁ t in long-term 
NSAID users. This lack of beneﬁ t is in contrast with previous studies in naïve patients 
who were about to start NSAI D therapy19-21, 23, 27. A possible explanation for this contrast 
is that the start of NSAID treatment probably aggravates of precipitates ulcer disease in 
susceptible individuals with the inclination to discontinue NSAID use28. Consequently, 
studies on patients with long-term use of NSAIDs will result in a group that can toler ate 
long-term NSAIDs, irrespective of their H. pylori status and therefore H. pylori eradica-
tion may not make any diff erence. The internal validity of the present study is guar-
anteed by the design of this randomized, double-blind, placebo controlled trial. As in 
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almost all trials, there could however be an unaccounted problem of external validity 
and thus generalizability. The main reason for eligible patients to decline participation 
was unwillingness to undergo a diagnostic endoscopy. In theory, it could be that pa-
tients, who refused to participate, would have had more beneﬁ t of H. pylori eradication 
therapy than those who participated in the trial. In our opinion, that this is very unlikely. 
In addition, the participation rate cannot directly be compared with the rate observed in 
other studies, because the denominator in our study was the number of patients with a 
positive serology as ﬁ rst diagnostic step, whereas in other studies the denominator was 
the number of patients having undergone endoscopy, resulting in a seemingly higher 
particip ation rate10,11,19.
The three-month endoscopic ulcer rate was only 4 percent in the total population, re-
gardless of H. pylori eradication at baseline. This incidence is low in comparison with 
previous clinical trials, which reported an endoscopic ulcer incidence between 15 and 
40 percent in patients on conventional NSAIDs, which recently decreased to between 5 
and 15 percent in patients on gastroprotective co-therapy, and between 4 and 9 percent 
Table 3 Secondary endpoints: Dyspepsia, functional disability, quality of life
Baseline Change during 1 year Diff erence 
between group 
means (95% CI)
Eradication Placebo Eradication Placebo
Dyspepsia (short-GSRS)
 Number of patients
 Short- GSRS
172
11 (8 to 16)
175
11 (8 to 16)
157
-1.19 ± 4.14
166
-0.87 ± 4.43 -0.32 (-1.26 to 0.62)
Functional disability (HAQ)
 Number of patients 
 HAQ
170
0.88 (0.38 
to 1.38)
174
0.81 (0.38 
to 1.25)
155
0.03 ±0.48
165
0.04 ±0.41 -0.01 (-0.11 to 0.09)
Quality of Life (SF-36)
 Number of patients
 Physical component score
 Mental component score
153
35 ± 6.5
52 ± 10.8
160
35 ± 6.5
52 ± 10.6
153
0.47±9.9
-0.44±6.3
160
-0.65±7.9
-0.38±6.3
1.12 (-0.86 to 3.11)
-0.05 (-1.46 to 1.36)
HAQ denotes Health Assessment Questionnaire. A higher score indicates more severe disability with a total score 
ranging from 0-3. GSRS denotes Gastrointestinal Symptom Rating Scale. A higher score indicates more discomfort 
with a total score ranging from 7-49. SF-36 denotes Short Form-36 health survey. A higher score indicates better 
health with a total score ranging from 0-100.
Baseline HAQ values and GSRS values, are given as the median (interquartile range). All SF-36 values and HAQ change 
values are given as the mean ± SD. Diff erences between group means (95% conﬁ dence interval) are between the 
eradication group and the placebo group. For comparison of the GSRS values as measured at baseline, 2 weeks, 3 
months and 12 months, the mean change from baseline value as calculated from area under the curve (year) is pre-
sented as a summary measure.
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in patient s on COXIBs3, 29-32. The unforeseen discrepancy between the present ulcer rate 
and those of previous studies may be explained by the fact that rheumatologists are very 
aware of the risk of NSAID gastropathy as the last decennia, much attention was given 
to NSAID gastropathy and several international and national guidelines were published 
on preventing  NSAID ulcers22, 33-35. Consequently, more than half of the population in our 
study was on chronic gastroprotective drugs or COXIBs. These preventive approaches 
may have reduced the magnitude of the morbidity caused by NSAID-gastropathy and is 
completely in line with recent data from the  United States36, 37. However, as compliance 
to guidelines was certainly not perfect, and the fact that, in this randomized study, in 
both gastroprotection users and patients who are not on gastroprotective drugs ulcer 
rates are low, with no diff erences between eradication and placebo for ulcers or any 
other endpoint, this eff ect is probably limited.
All the same, this study showed that the ulcer rate in patients on long-term NSAIDs 
is so low that the potential for further improvement by H. pylori eradication is limited 
anyhow (as can also be judged from the conﬁ dence intervals presented in [table 2]. 
Therefore, it appears that a possible minimal impact of H. pylori eradication is not an 
important clinical issue anymore but at most a theoretical problem38.
In conclusion, eradication of H. pylori has no beneﬁ cial eff ect on the incidence of 
gastroduodenal ulcers and erosions, or the occurrence of dyspepsia, and is associated 
with more frequent side eff ects than already implemented strategies to prevent gas-
tropathy without additional eradication treatment. Thus, a strategy of H. pylori test and 
eradication in patients with long-term NSAID treatment is not warranted.
ch apter 4
51
References
1 Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinﬂ ammatory 
drugs. N Engl J Med 1999;340:1888-99.
2 Hawkey CJ. Nonsteroidal anti-inﬂ ammatory drug gastropathy. Gastroenterology 2000;119:521-35.
3 Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. The prevention of chronic NSAID 
induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized con-
trolled trials. J Rheumatol 2000;27:2203-14.
4 Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity 
with celecoxib vs nonsteroidal anti- inﬂ ammatory drugs for osteoarthritis and rheumatoid arthritis: 
the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 
2000;284:1247-55.
5 Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. Comparison of upper 
gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR 
Study Group. N Engl J Med 2000;343:1520-8, 2.
6 Marshall BJ, Warren JR. Unidentiﬁ ed curved bacilli in the stomach of patients with gastritis and 
peptic ulceration. Lancet 1984;1:1311-5.
7 Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti- inﬂ am-
matory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
8 Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced 
duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996;110:1244-52.
9 Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment 
Pharmacol Ther 1995;9 Suppl 2:59-69.
10 Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A et al. 
Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-
inﬂ ammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 
1998;352:1016-21.
11 Lai KC, Lau CS, Ip WY, Wong BC, Hui WM, Hu WH et al. Eff ect of treatment of Helicobacter pylori on 
the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, 
placebo-controlled trial. Aliment Pharmacol Ther 2003;17:799-805.
12 Savary M, Miller G. The oesophagus: handbook and atlas of endoscopy. Solothurn, Switzerland: 
Grassman, 1987.
13 Dixon MF, Genta RM, Yardley JH, Correa P. Classiﬁ cation and grading of gastritis. The updated 
 Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J 
Surg Pathol 1996;20:1161-81.
14 Svedlund J, Sjodin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in 
 patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33:129-34.
15 Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: Dimensions and Practical 
 Applications. Health Qual Life Outcomes 2003;1:20.
16 EuroQol — a new facility for the measurement of health-related quality of life. The EuroQol Group. 
Health Policy 1990;16:199-208.
17 Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R et al. Translation, valid-
ation, and norming of the Dutch language version of the SF-36 Health Survey in community and 
chronic disease populations. J Clin Epidemiol 1998;51:1055-68.
18 Goossens ME, Rutten-van Molken MP, Vlaeyen JW, van der Linden SM. The cost diary: a method to 
measure direct and indirect costs in cost-eff ectiveness research. J Clin Epidemiol 2000;53:688-95.
19 Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T et al. Eradication of Helicobacter pylori and risk of 
peptic ulcers in patients starting long-term treatment with non-steroidal anti- inﬂ ammatory drugs: 
a randomised trial. Lancet 2002;359:9-13.
h. py lori  er adication in long-term nsaid users
52
20 Labenz J, Blum AL, Bolten WW, Dragosics B, Rosch W, Stolte M et al. Primary prevention of diclof-
enac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive 
patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002;51:329-35.
21 Malfertheiner P, Megraud F, O’Morain C, Hungin AP, Jones R, Axon A et al. Current concepts in the 
management of Helicobacter pylori infection — the Maastricht 2-2000 Consensus Report. Aliment 
Pharmacol Ther 2002;16:167-80.
22 Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn NSAID-gebruik en preventie van maag-
schade. Alphen aan den Rijn, The Netherlands: Van Zuiden Communications B.V., 2003.
23 Bannwarth B, Dorval E, Caekaert A, Barthelemy P. Inﬂ uence of Helicobacter pylori eradication ther-
apy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal 
antiinﬂ ammatory drugs combined with omeprazole. J Rheumatol 2002;29:1975-80.
24 Lerang F, Moum B, Mowinckel P, Haug JB, Ragnhildstveit E, Berge T et al. Accuracy of seven diff erent 
tests for the diagnosis of Helicobacter pylori infection and the impact of H2-receptor antagonists on 
test results. Scand J Gastroenterol 1998;33:364-9.
25 Meijer BC, Thijs JC, Kleibeuker JH, van Zwet AA, Berrelkamp RJ. Evaluation of eight enzyme immuno-
assays for detection of immunoglobulin G against Helicobacter pylori. J Clin Microbiol 1997;35:292-4.
26 Van de Wouw BA, de Boer WA, Jansz AR, Roymans RT, Staals AP. Comparison of three commercially 
available enzyme-linked immunosorbent assays and biopsy-dependent diagnosis for detecting 
 Helicobacter pylori infection. J Clin Microbiol 1996;34:94-7.
27 Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK et al. Randomised trial of eradication of Heli-
cobacter pylori before non-steroidal anti-inﬂ ammatory drug therapy to prevent peptic ulcers. Lancet 
1997;350:975-9.
28 Moride Y, Abenhaim L. Evidence of the depletion of susceptibles eff ect in non-experimental phar-
macoepidemiologic research. J Clin Epidemiol 1994;47:731-7.
29 Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ et al. Reduced risk of up-
per gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 
2000;95:1681-90.
30 Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J. Incidence of gastroduodenal ulcers in pa-
tients with rheumatoid arthritis aft er 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, 
randomised, double blind study. Gut 2003;52:820-6.
31 Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H et al. A randomized trial comparing the 
eff ect of rofecoxib, a cyclooxygenase 2-speciﬁ c inhibitor, with that of ibuprofen on the gastro-
duodenal mucosa of patients with osteoarthritis.Rofecoxib Osteoarthritis Endoscopy Study Group. 
Gastroenterology 1999;117:776-83.
32 Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC et al. Anti-inﬂ ammatory and up-
per gastrointestinal eff ects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 
1999;282:1921-8.
33 Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D et al. Current concepts in 
the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007.
34 Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the 
Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J 
Gastroenterol 1998;93:2037-46.
35 Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46.
36 Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of non steroid al 
antiinﬂ ammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004;50:
2433-40.
37 Steen KS, Lems WF, Aertsen J, Bezemer D, Dijkmans BA. Incidence of clinically manifest ulcers and 
their complications in patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:443-7.
38 Graham DY. NSAIDs, Helicobacter pylori, and Pandora’s Box. N Engl J Med 2002;347:2162-4.
ch apter 4
53
1 Department of Rheumatology, VU university medical centre, Amsterdam
2 Department of Pathology, VU university medical centre, Amsterdam
3 Department of Clinical Epidemiology and Biostatistics, VU university medical centre, Amsterdam
4 Department of Rheumatology, Medisch Spectrum Twente Hospital and Twenteborgziekenhuis, Enschede 
and Almelo
5 Department of Rheumatology, University Medical Centre Utrecht, Utrecht
6 Department of Rheumatology, Ziekenhuis Rijnstate, Arnhem
7 Department of Rheumatology, Atrium medical centre, Heerlen
8 Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam
Helicobacter pylori eradication
in patients on long-term treatment with 
NSAIDs reduces the severity of gastritis
A randomized controlled trial
journal of clinic al ga stroenterology.  2009;43:140–146
Helena TJI de Leest1
Kirsti SS Steen1
Elisabeth Bloemena2
Willem F Lems1
Ernst J Kuipers8
Mart AFJ van de Laar4
Johannes WJ Bijlsma5
Matthijs Janssen6
Harry HML Houben7
Piet J Kostense3
Maarten Boers3
Ben AC Dijkmans 1
chapter  5

Abstract
background Maintenance use of NSAIDs is oft en complicated by gastropathy. In non-
NSAID users, eradication of H. pylori is associated with decreased mucosal inﬂ amma-
tion, and may halt the progression to atrophy and intestinal metaplasia, but the con-
tinuous use of NSAIDs may interfere with these processes.
goal To investigate the eff ect of H. pylori eradication on gastric mucosal histology 
 during long-term NSAID use, with and without gastroprotective therapy.
study Patients were eligible for inclusion if they were on long-term NSAIDs and were 
H. pylori-positive on serological testing. Patients were randomly assigned to either eradi-
cation or placebo. Gastritis was assessed according to the updated Sydney classiﬁ cation 
for activity, chronic inﬂ ammation, gastric glandular atrophy, intestinal metaplasia, and 
H. pylori density.
results Biopsy specimens were available for histology of 305 patients. Of these, 48% 
were on chronic gastroprotective medication. Signiﬁ cant less active gastritis, inﬂ amma-
tion and H. pylori density was found in the eradication group compared to the placebo 
group in both corpus and antrum (P<0.001). In the corpus, less atrophy was found in the 
eradication group compared to the placebo group.
conclusion H. pylori eradication in patients on long term NSAID therapy leads to heal-
ing of gastritis despite ongoing NSAID therapy.
55
5
56
ch apter 5
Introduction
Nonsteroidal antiinﬂ ammatory drugs (NSAIDs) are widely prescribed for rheumatic dis-
eases. Maintenance use of NSAIDs is however oft en complicated by NSAID-gastropa-
thy, which is characterized by dyspepsia, superﬁ cial mucosal damage, gastroduodenal 
 ulcers, and even life-threatening ulcer complications1. Many strategies have been evalu-
ated in recent years to prevent and treat gastroduodenal ulcers and their life threaten-
ing complications in NSAID users such as the addition of acid suppressive therapies, 
treatment with selective and speciﬁ c cyclooxygenase-2 inhibitors and eradication of 
Helicobacter pylori  2-7.
H. pylori causes continuous gastric inﬂ ammation in nearly all infected persons8. This 
chronic inﬂ ammation persists throughout life and may lead to mucosal gland loss or 
atrophic gastritis, which may precede the development of intestinal metaplasia, dys-
plasia and cance r9, 10. Although NSAID use and H. pylori are the most common causes of 
peptic ulcers and their complications, and are frequently present in the same patients, 
the mechanisms of interaction require further study11.
While many studies have shown that eradication of H. pylori causes resolution of 
active and chronic gastritis in non-NSAID-use rs12-14, the eff ect of H. pylori eradication 
on gastric histology in patients on long-term NSAIDs is unclear because of a paucity of 
data.
One of the most eff ective and safest strategies to prevent ulcers is co-therapy with 
proton pump inhibitors (PPI). However, profound acid suppressive therapy changes the 
extent of H. pylori gastritis into a corpus-predominant gastritis, which may accelerate 
the development of gastric gland l oss15-17. The International Maastricht guideline there-
fore advises to consider H. pylori eradication in long-term PPI users18. This is of relevance 
for a considerable proportion of patients on long-term NSAIDs who are co-treated with 
acid suppressive therapy for many years. It is however unknown what the eff ect is of 
H. pylori eradication under these conditions.
Therefore we investigated, by means of a randomized, double blind, placebo-con-
trolled study, whether Helicobacter pylori eradication changes gastric histology in pa-
tients receiving long-term treatment with NSAIDs, both in patients with and without 
gastroprotective co-treatment.
Materials and methods
Patients
Patients suff ering from a rheumatic disease who were between 40 and 80 years of 
age were eligible for the study if they were using NSAID on a long-term basis and were 
positive for H. pylori on serological testing with ELISA. Long-term NSAID treatment was 
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deﬁ ned as the use of any NSAID for at least 3 days a week during at least the previous 
month. Exclusion criteria were: previous eradication therapy for H. pylori, allergy for 
the study medication (except amoxicillin) and presence of severe co-morbidity. Concur-
rent use of steroids, low dose aspirin, anticoagulants, and gastroprotective drugs were 
 allowed. The presence of IgG-antibodies to H. pylori was determined with a commercial 
enzyme-linked immunosorbent assay Pyloriset® new EIA-G (Orion Diagnostica, Espoo, 
Finland) according to the manufacturer’s instructions. This assay has been assessed in 
the population under study and has proven a sensitivity and speciﬁ city in the Nether-
lands of 98-100% and 79-85%, even in patients on acid suppressive the rapy19-21. The 
study protocol was approved by research and medical ethics committees of all partici-
pating centers and all patients gave written informed consent.
Study design
Aft er stratiﬁ cation by concurrent use of gastroprotective agents (proton pump inhibi-
tors, H2 receptor antagonists or misoprostol, but not prokinetics, or antacids), patients 
were randomly assigned to receive either H. pylori eradication therapy with omeprazole 
20 mg, amoxicillin 1000mg, and clarithromycin 500 mg (OAC) twice daily for 7 days or 
placebo. Patients with an allergy for amoxicillin were randomized in a separate stratum 
to receive omeprazole 20 mg, metronidazole 500 mg and clarithromycin 250 mg (OMC) 
or placebo therapy twice daily for one week. Randomization to consecutive patient 
numbers was done in proportions of 1:1, in blocks of four from a computer-generated 
list. The study centers were provided with individually sealed packages containing the 
treatment for each patient. Each center received entire blocks to be used sequentially. 
Rheumatologists were not practicing in more than one center. The study medication 
was given in a double blind, double dummy manner. Active and placebo preparations 
were identical in appearance. The employees of the VU University Medical Center phar-
macy who packaged the medication only knew the assignment. It was disclosed to the 
treating physician only in case of emergency. All study personnel and participants were 
blinded to treatment assignment for the duration of the study.
Three months aft er study initiation patients underwent endoscopy of the upper gas-
trointestinal tract. Endoscopic ﬁ ndings were recorded systematically. The procedures 
were performed without sedation, or under conscious sedation using midazolam de-
pending on patient’s preference. The clinical results of the trial have been described 
elsewhere22.
Biopsies for histology and H. pylori culture were taken with standard biopsy for-
ceps form the antrum (x4) and the corpus (x4). In the case of speciﬁ c lesions additional 
samples were obtained but these were not part of this study.
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Histology
All biopsies were routinely strained with haematoxylin-eosin. The slides were scored 
independently by an experienced gastrointestinal pathologist (EB) and the investigator 
(HdL), blinded to treatment assignment and clinical data, according to the updated Syd-
ney classiﬁ cation23. Separate scores were given for H. pylori density, acute and chronic 
inﬂ ammatory component of gastritis, gastric glandular atrophy, and intestinal meta-
plasia. All items were scored from 0 (absent), to 1 (mild), 2 (moderate), or 3 (severe) as 
deﬁ ned in the Sydney classiﬁ cation system. In case of discrepant results, the specimen 
was discussed until agreement was reached.
Statistical analysis
The primary analysis was a comparison of treatment arms, irrespective of H. pylori  status 
of individual patients. Measurements are expressed as mean and SD or as the median 
and inter quartile range (IQR). Diff erences between groups were analyzed by chi-square 
test and chi-square test for linear trend (linear-by-linear association). Another analysis 
compared outcomes (the eff ect of H. pylori eradication) between stratum (the use of 
gastroprotective drugs or not) by computing the homogeneity of the common odds ra-
tio. The level of signiﬁ cance was set at P<0.05, two sided. SPSS soft ware (version 11.0.0) 
was used to perform all analyses.
Results
Patients
Three hundred and forty seven H. pylori seropositive patients were randomized in this 
study. A total of 172 received one week course of OAC whereas 175 received placebo. The 
treatment groups were similar in terms of demographic, rheumatic disease, drug use 
and prognostic variables [Table 1]. Our eligibility criteria resulted in a study group (61% 
women, mean age 59 ± 10 years) with mainly inﬂ ammatory rheumatic diseases, 48% of 
the patients used one or two gastroprotective agent (77% PPI, 14% H2RA, 15% misopro-
stol) in combination with their NSAID therapy. No diff erences were noted between the 
treatment arms in terms of protocol violations.
Histology
In twenty patients in the eradication group and 22 in the placebo group gastric biop-
sies were not available for the following reasons: 16 patients withdrew consent for par-
ticipation of the trial, 15 refused endoscopy, 7 used anticoagulants prohibiting biopsy 
sampling according the protocol, in 3 patients biopsy specimens could not be obtained 
because of discomfort requiring early completion of the procedure, and one patient died 
of cardiac arrest within three months aft er randomization. Histopathologic specimens 
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could be assessed from 305 patients: 152 patients in the eradication group and 153 in 
the placebo group [Figure 1].
Corpus
Corpus biopsy specimens were not available for 6 patients in the eradication group and 
8 in the placebo group. Complete data from 291 subjects were available (as is shown 
in detail in [Table 2] and [Figure 2]). Corpus gastritis activity was moderate to severe 
in 4% of patients in the eradication group and in 35% of the placebo group (P<0.001). 
Moderate to severe chronic inﬂ ammation was present in 28% in the corpus of patients 
in the eradication group. By comparison, moderate to severe chronic inﬂ ammation was 
observed in 65% of the placebo group (P<0.001). Overall, moderate to severe corpus 
glandular atrophy was present in 10% of the eradication group and 22% of the placebo 
group (P=0.006). Intestinal metaplasia of the corpus mucosa did not diff er between 
Table 1 Baseline characteristics of the two groups (Eradication or Placebo)
Characteristic Eradication
(n=172)
Placebo
(n=175)
Age — yr * 59±11 60±10
Women 108 (63) 104 (60)
Underlying disease 
 Rheumatoid Arthritis 
 Spondylarthropathy 
 Psoriatic Arthritis
 Osteoarthritis 
107 (62)
13 (8)
14 (8)
15 (9)
106 (61)
15 (9)
11 (6)
15 (9)
Other 23 (13) 28 (16)
Disease duration—yr † 7 (3 to 14) 8 (3 to 15)
Gastroprotective treatment
 H2 antagonist 
 Proton pump inhibitor 
 Prostaglandin analogues (misoprostol)
9 (5)
64 (37)
0
14 (8)
63 (36)
1 (1)
NSAID treatment 
 Conventional NSAID
 COX-2 preferential NSAID (meloxicam, nabumetone)
 COXIB (rofecoxib, celecoxib)
 Combination drug (diclofenac/misoprostol)
118 (69)
27 (16)
17 (10)
10 (6)
116 (66)
33 (19)
13 (7)
13 (7)
Titer H. pylori serology† 1590 (692 to 3536) 1846 (799 to 4057)
Ethnic Dutch white 130 (87) 133 (87)
Known allergy for amoxycillin 10 (6) 12 (7)
* Plus-minus values are means ± SD; other values are counts (%) unless noted.
† Median (Inter Quartile Range)
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groups and was present in 6% of patients. H. pylori colonization of the corpus mucosa 
was present in 11% of the eradication group and in 71% of the placebo group (P<0.001).
Antrum
Antrum biopsy specimens were unavailable for 4 patients in the eradication group and 
4 in the placebo group. Accordingly, data from 297 patients were available as shown in 
[Table 3] and [Figure 3]. Antrum gastritis activity was moderate to severe in 3% of the 
patients in the eradication group and in 27% of the placebo group (P<0.001). Moderate 
to severe chronic gastritis was present in 51% in patients in the eradication group in the 
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Figure 1 Trial proﬁ le and numbers of patients of whom specimens were available. 
Data are number of patients
2761 patients screened 
for H. pylori
1091 patients positive
347 patients randomised
175 assigned 
to placebo group
172 assigned 
to eradication group
148 antrum 149 antrum146 corpus 145 corpus
152 available for
histologic analysis
153 available for
histologic analysis
10 withdrew consent
6 refused endoscopy
2 used anticoagulants
1 endoscopy not completed
1 died
6 withdrew consent
9 refused endoscopy
5 used anticoagulants
2 endoscopy not completed
1670 patients negative
744 patients refused 
or met exclusion criteria
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antrum, and in 76% of the placebo group (P<0.001). Antral glandular atrophy was scored 
moderate to severe in 33% in the eradication group and 41% in the placebo group (no 
signiﬁ cant diff erence). The presence of intestinal metaplasia did not diff er between the 
groups in antrum and was present in 17% of all patients. H. pylori colonization of the 
antrum mucosa was present in 14% in the eradication group and 62% in the placebo 
group (P<0.001).
Analysis of the eff ect of eradication stratiﬁ ed according to 
the use of gastroprotective drugs
corpus There were no diff erences between strata (according to the use of gastropro-
tective drugs) for the eff ect of eradication on active gastritis in the corpus (P=0.27). A 
signiﬁ cant greater eff ect of eradication was found in patients on gastroprotective drugs 
for the presence of moderate to severe chronic inﬂ ammation in the corpus (22% and 
74% in the eradication and placebo group respectively) than in patients who did not 
take gastroprotective drugs (33% and 55% in the eradication and placebo group respec-
tively) (P=0.007). No signiﬁ cant diff erence of eff ect of eradication was found in patients 
Table 2 Histological characteristics of the corpus, for patients randomly assigned to 
eradication therapy or placebo
Variable Score Eradication 
(n=146)
Placebo
(n=145)
P-value
Activity None
Mild
Moderate
Severe
132
9
2
3
55
39
29
22
<0.001
Inﬂ ammation None
Mild
Moderate
Severe
7
98
30
11
3
48
60
34
<0.001
Atrophy None
Mild
Moderate
Severe
76
55
12
3
54
59
28
4
0.003
Intestinal metaplasia None
Mild
Moderate
Severe
136
6
3
1
139
4
2
0
0.257
H pylori density None
Mild
Moderate
Severe
130
6
6
4
41
28
36
40
<0.001
Data are number of patients.
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Figure 2 Gastritis scores for the corpus for eradication group and for the placebogroup
0
20
40
60
80
100
120
140
PlaceboEradication
Corpus activity
N
o 
of
 p
at
ie
n
ts
0
20
40
60
80
100
120
140
PlaceboEradication
Corpus atrophy
N
o 
of
 p
at
ie
n
ts
0
20
40
60
80
100
120
140
Severe
Moderate
Mild
None
PlaceboEradication
Corpus H. pylori
N
o 
of
 p
at
ie
n
ts
0
20
40
60
80
100
120
140
PlaceboEradication
Corpus inflammation
N
o 
of
 p
at
ie
n
ts
0
20
40
60
80
100
120
140
160
PlaceboEradication
Corpus intestinal metaplasia
N
o 
of
 p
at
ie
n
ts
63
for the presence of corpus atrophy between patients using gastroprotection (42% and 
68% in the eradication and placebo group respectively) compared to in patients who 
did not take gastroprotective drugs (53% and 58% in the eradication and placebo group 
respectively) (P=0.067). There were no diff erences between strata for corpus intestinal 
metaplasia (P=0.10). No diff erence was found for eff ect of eradication therapy between 
strata on the presence of H. pylori (P=0.79).
antrum In the antrum, the eff ect of eradication was not modiﬁ ed by gastroprotective 
drugs on active gastritis (P=0.81), chronic inﬂ ammation in the antrum (P=0.99), antrum 
atrophy (P=0.59) nor antral intestinal metaplasia (P=0.052). No diff erence was found for 
eff ect of eradication therapy between strata on the presence of H. pylori (P=0.29).
Table 3 Histological characteristics of the antrum, for patients randomly assigned to 
eradication therapy or placebo
Variable Score Eradication
(n=148)
Placebo
(n=149)
P-value
Activity None
Mild
Moderate
Severe
126
17
4
1
66
43
27
13
<0.001
Inﬂ ammation None
Mild
Moderate
Severe
6
66
60
16
4
32
56
57
<0.001
Atrophy None
Mild
Moderate
Severe
9
90
42
7
4
84
56
5
0.181
Intestinal metaplasia None
Mild
Moderate
Severe
124
13
8
3
124
18
5
3
0.890
H pylori None
Mild
Moderate
Severe
127
9
4
8
57
22
37
33
<0.001
Data are number of patients.
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Figure 3 Gastritis scores for the antrum for eradication group and for the placebogroup
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Discussion
The major ﬁ nding of this large randomized, placebo-controlled study in long-term NSAID-
users was that H. pylori eradication results in signiﬁ cantly lower acute and chronic gastri-
tis scores despite ongoing NSAID use. An additional remarkable ﬁ nding was that corpus 
atrophy scores were signiﬁ cantly lower in the H. pylori eradication group than in the pla-
cebo group.
Many studies have shown that eradication of H. pylori causes resolution of active and 
chronic gastritis in non-NSAID- users12-14. Various studies addressed the potential inter-
action between H. pylori and NSAIDs on gastroduodenal mucosal damage. However, 
only few studies with limited number of patients regarded the eff ect of H. pylori eradica-
tion on gastric histology in patients on NSAIDs. In a small study of 11 H. pylori infected 
healthy subjects, high dose of naproxen for only 4 days had no eff ect on polymorpho-
nuclear cells nor on H. pylori d ensity24. A similar ﬁ nding was reported in a study of 52 pa-
tients with rheumatoid arthritis who received NSAIDs for one month. No diff erence in se-
verity of gastritis was found between H. pylori-positive and H. pylori-negative pa tients25.
In addition, in 118 patients receiving chronic NSAID treatment, the presence of H. pylori 
did not appear to increase histological damage or ulcer prevalence26. In contrast, an-
other study found that the presence of neutrophils increased the risk of ulceration in 
long-term NSAID users. Most of the inﬂ ammatory cells were found in H. pylori-positive 
patients. These patients had more severe gastritis and were thus at higher risk for ulcer 
 disease27. Hence, these studies point out that there is no agreement on the eff ect of 
H. pylori on histological characteristics in NSAID users. The present study with a high 
number of patients shows that eradication of H. pylori leads to signiﬁ cant reduction of 
active and chronic inﬂ ammation of both corpus and antrum mucosa within 3 months 
despite ongoing NSAID therapy. These ﬁ ndings support the proposition that H. pylori 
eradication might contribute to the prevention of NSAID gastropathy in chronic NSAID 
users. However, this seems not to be in line with data which are published elsewhere22. 
In that paper is described that H. pylori eradication therapy in patients on long-term 
NSAID treatment had no beneﬁ cial eff ect on the occurrence of ulcers, ulcer complica-
tion, erosions, dyspepsia, or quality of life. Nevertheless, the present study shows that 
H. pylori eradication improves the degree of gastritis in patients who are long-term on 
NSAID treatment in the biopsy samples. Whether this eff ect has clinical consequences, 
such as the risk of development of ulcers or cancer on the long term has to be further 
investigated.
There is general agreement that acid suppressive therapy changes the usually antral 
predominant gastritis to one that is corpus pr edominant28, 29. In addition, from stud-
ies of patients with gastro-oesophageal reﬂ ux disease, there is growing evidence that 
H. pylori eradication in PPI users reduces mucosal inﬂ ammation and induces regression 
of corpus glandul ar atrophy15-17, 30-32. These phenomena are relevant because the pat-
h. py lori  er adication reduces gastritis
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tern of gastritis, with or without progression of gastric atrophy, is associated with an 
increased risk for the development of gast ric cancer9. In order to assess the potential 
beneﬁ ts of H. pylori eradication in this setting, most studies are designed to examine 
regression of precancerous changes, such as gland loss and intestinal metaplasia of the 
gastric mucosa as surrogate end points. A follow-up of many years would be necessary 
to conﬁ rm long-term clinical signiﬁ cance of H. pylori eradication for these premalignant 
parameters. Our data showed indeed, in both patients with and without treatment with 
gastroprotection, lower gastritis scores, and lower prevalence of atrophic gastritis of 
the corpus mucosa 3 months aft er H. pylori eradication and a signiﬁ cant greater eff ect 
of eradication on corpus inﬂ ammation in the gastroprotection group than in those who 
were not receiving gastroprotection. In the absence of baseline biopsy samples, it is not 
completely certain whether the diff erence is due to a regression of atrophic gastritis 
but the probability that the diff erences between groups was already present by chance 
at baseline is very small, as the randomized groups are large. A previous study showed 
a regression of atrophic gastritis aft er H. pylori eradication in patients with reﬂ ux oe-
sophagitis taking omeprazole mainten ance therapy16. The ﬁ rst follow-up in the latter 
study however took place 12 months aft er eradication therapy. Probably, the same ef-
fect at an earlier stage is found in this study. As a large number of patients on long-term 
NSAIDs are treated with acid suppressive therapy for many years, eradication of H. pylori 
in these patients may be advisable to heal gastritis, in particular under the assumption 
that active gastritis increases the risk for NSAID gastropathy. Eradication may further 
prevent progression of atrophic gastritis as its eff ect would be expected to persist.
Whereas the histopathology of H. pylori gastritis is associated with well-deﬁ ned his-
tological features23, the spectrum and incidence of microscopic gastric lesions caused 
by chronic ingestion of NSAIDs is unspeciﬁ c and still a matter of debate. Some investiga-
tors used Dixons’s system for chemical gastritis but no correlation was found between 
the scoring system and endoscopic gastrodu odenal damage26, 33. Others concluded that 
there is no single histological feature that can be used to characterize the diagnose 
chemical gastritis and simultaneous infection by H. pylori and thus makes the histo-
logical diagnosis of chemical gastritis extremely diffi  cult34. In this study, interpretation 
of the gastric biopsies was made as uniform and objective as possible by the use of 
predeﬁ ned criteria of the updated Sydney System23 and by blinded assessment of all 
biopsies by the same histopathologists.
We did not perform endoscopy at baseline, because invasive screening tests for 
H. pylori are less feasible in everyday practice. Instead, we used an assay for the pres-
ence of IgG-antibodies to H. pylori. This assay has been assessed in the population un-
der study and has proven a sensitivity and speciﬁ city in the Netherlands of 98-100% and 
79-85%, even in patients on acid suppr essive therapy19-21. We analyzed the data accord-
ing to treatment arm (intention to treat analysis). In practice one might retreat patients 
in case patients remain H. pylori-positive despite eradication therapy with antibiotics.
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In conclusion, our study showed that H. pylori eradication in patients on long term 
NSAID therapy leads to healing of gastritis despite ongoing NSAID therapy. These data 
support the proposition that H. pylori eradication may reduce the severity of gastropa-
thy in chronic NSAID users.
h. py lori  er adication reduces gastritis
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Abstract
objective To investigate the upper gastrointestinal safety of COX-2 selective NSAIDs 
in Helicobacter pylori-positive patients.
methods We performed a post hoc analysis of a clinical trial in H. pylori-positive pa-
tients with current NSAID use for rheumatic diseases. Patients were randomized for 
H. pylori eradication or placebo. Endoscopy was performed at 13 weeks. Patients with 
gastroduodenal ulcers were compared to those without ulcers for their use of COX-2 
selective NSAIDs versus non-selective NSAIDs, as well as for possible confounders.
results A total of 301 patients underwent endoscopy; 221 (73%) used non-selective 
NSAIDs and 80 (27%) used COX-2 selective NSAIDs. Ulcers were diagnosed in 6 (4%) pa-
tients in the eradication group and 8 (5%) patients in the placebo group (P=0.65). None 
of the patients with ulcers used COX-2 selective NSAIDs; 0 (0%) in the ulcer group vs. 
80 (28%) in the non-ulcer group (P=0.02). Patients with ulcers signiﬁ cantly more oft en 
used concomitant low dose aspirin; 4 (29%) in the ulcer group vs. 27 (9%) in the non-
ulcer group (P=0.02).
conclusion In H. pylori-positive patients, use of COX-2 selective NSAIDs is associated 
with a signiﬁ cantly reduced risk for endoscopic upper gastrointestinal ulcers.
73
6
74
ch apter 6
Introduction
Non-steroidal anti-inﬂ ammatory drugs (NSAIDs) are frequently prescribed drugs, espec-
ially for arthritis and osteoarthritis. Treatment with NSAIDs is frequently complicated 
by serious gastrointestinal toxicity, such as bleeding and perforated ulcers1. The an-
nual incidence of serious NSAID ulcer complications is 1 to 2%, and despite improved 
intervention strategies, the associated mortality rate remains 10% to 15% 2-6. Therefore, 
risk assessment and adequate preventive strategies remain of paramount importance. 
Several strategies have been developed to prevent NSAID ulcer complication s7. These 
include concomitant use of proton-pump inhibitors (PPIs), high dose histamine-2 recep-
tor antagonists (H2RAs), high dose prostaglandin analogues, and the use of cyclooxy-
genase (COX)-2 selective NSAIDs.
The relative gastrointestinal safety of COX-2 selective NSAIDs was demonstrated 
in several large randomized clinical tria ls2, 3. However, some issues remain unresolved. 
Firstly, it is unclear whether COX-2 selective NSAIDs retain their gastrointestinal safety 
during long-term use. In an analysis of data from the gastrointestinal toxicity with cele-
coxib versus NSAIDs for osteoarthritis and rheumatoid arthritis (CLASS) study, celecoxib 
was associated with a lower incidence of ulcers compared to non-selective NSAIDs at 
6 months, but not at 12 or 16 months of treatm ent3, 8. Secondly, the role of Helicobac-
ter pylori infection in the gastrointestinal safety of COX-2 selective NSAIDs is unclear. 
H. pylori plays an important role in gastroduodenal ulcer disease and a possible additive 
interaction between H. pylori infection and NSAID use in the development of gastro-
duodenal ulcers might e xist8-11. Current understanding of the gastrointestinal safety of 
COX-2 selective NSAIDs in H. pylori-positive patients is still limited12. In an analysis of 
gastrointestinal risk factors from the Vioxx gastrointestinal outcomes research (VIGOR) 
study, rofecoxib compared to naproxen did not reduce the risk for duodenal ulcers in 
H. pylori-positive pat ients12, 13. Furthermore, in the rofecoxib group, patients with a his-
tory of gastrointestinal events who were H. pylori-positive were 3.5 times as likely to 
have a recurrent event as those who were H. pylori ne gative12, 13. In a study comparing 
celecoxib to naproxen, among those receiving celecoxib the incidence of endoscopic 
ulcers was 12.9% in H. pylori-positive patients versus 2.9% in H. pylori-negative patients 
(P=0.023). Conversely, H. pylori status did not inﬂ uence the ulcer risk in those receiving 
n aproxen14. These results suggest that a concurrent H. pylori infection may (partially) 
negate the gastrointestinal safety of COX-2 selective NSAIDs.
In a recently conducted randomized, double blind, placebo controlled clinical trial 
we found that eradication of H. pylori did not reduce the incidence of endoscopic gas-
troduodenal ulcers in H. pylori-positive patients with current NSAID use for rheumatic 
 diseases15. We subsequently performed a pre-planned post hoc analysis of the data, to 
determine whether in these patients the use of COX-2 selective NSAIDs was associated 
with a reduced risk of endoscopic ulcers compared to use of non-selective NSAIDs, in 
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order to determine whether H. pylori infection inﬂ uences the gastrointestinal safety of 
COX-2 selective NSAIDs, and to determine the role of possible confounders.
Methods
Patients
The methods of the primary randomized, double blind, placebo controlled clinical trial 
have been previously described [15]. Brieﬂ y; between May 2000 and June 2002, patients 
were recruited at eight rheumatology outpatient departments throughout the Nether-
lands. Eligible for inclusion where patients between 40 and 80 years of age with a rheu-
matic disease requiring current NSAID treatment, deﬁ ned as the use of any COX-2 selec-
tive or non-selective NSAID for at least 3 days a week over the last month. Patients were 
included in the study if they tested positive for H. pylori on serological testing using a 
commercial enzyme-linked immunosorbent assay for H. pylori IgG-antibodies (Pylori-
set® new EIA-G, Orion Diagnostica, Espoo, Finland). No change in NSAID therapy was 
permitted during the study, but there was no restraint on other concurrent medication. 
The study protocol was approved by the institutional ethical review boards of all partici-
pating centers and all patients gave written informed consent.
Study design
Aft er stratiﬁ cation on concurrent use of gastroprotective agents, patients were random-
ly assigned to either H. pylori eradication therapy with omeprazole 20 mg, amoxicillin 
1000mg, and clarithromycin 500 mg twice daily for 7 days, or to placebo. Patients with 
an allergy for amoxicillin were assigned to omeprazole 20 mg, metronidazol 500 mg 
and clarithromycin 250 mg twice daily for 7 days, or placebo. The study medication was 
given in a double blind, double dummy manner. Follow-up visits took place at 2, 13 and 
52 weeks. At baseline all patients were interviewed on their socio-demographic char-
acteristics, intoxications, current medication, co-morbidities, and medical history. At 13 
weeks all patients underwent gastroduodenal endoscopy, blinded for treatment alloca-
tion. The number of ulcers and erosions were recorded for the stomach and duodenum. 
An ulcer was deﬁ ned as a break in the mucosa of ≥ 5 mm in diameter, penetrating the 
muscularis mucosae. Smaller or superﬁ cial lesions were classiﬁ ed as erosions. Aft er en-
doscopy, observations continued through week 52.
Statistical methods
The primary endpoint of the study was the proportion of patients with endoscopically 
proven gastroduodenal ulcers at week 13. Secondary endpoints were the proportions of 
patients with symptomatic ulcers (deﬁ ned as gastroduodenal ulcers found aft er work-
up for dyspepsia) or ulcer complication such as bleeding and perforation, occurring at 
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any time during the study and follow-up. In this post hoc analysis we ﬁ rst compared 
ulcer rates in patients on COX-2 selective NSAIDs with those on non-selective NSAIDs. 
Secondly, we analyzed the eff ect of H. pylori eradication in patients on COX-2 selective 
NSAIDs. Thirdly, we analyzed possible confounders, such as concurrent use of low dose 
aspirin. All patients who underwent a complete gastroduodenal endoscopy at 3 months 
were included in the post hoc analysis. To search for possible bias or channeling of risk 
factors, a sub-analysis was performed comparing risk factors for NSAID-gastropathy 
in patients using COX-2 selective NSAIDs with those in patients using non-selective 
NSAIDs.
Continuous variables with a normal distribution were expressed as mean and stan-
dard deviation (SD), and continuous variables with a non-normal distribution as median 
and interquartile range (IQR). Diff erences between groups were analyzed using Students 
t-test, Mann-Whitney U test and Pearson’s Chi-square test or Fisher’s Exact test in case 
of low expected values. For all analyses P<0.05, two sided, was considered signiﬁ cant. 
All analyses were performed with SPSS for Windows, version 12.0.1 (SPSS, Chicago, IL, 
USA).
Results
The results of the primary study have been published [15]. Between May 2000 and June 
2002, 2761 patients with rheumatic diseases requiring current NSAID treatment were 
tested for H. pylori, of whom 1091 (40%) tested positive. Of these, 744 patients refused 
participation (55%), or met exclusion criteria. The remaining 347 patients were random-
ized to eradication therapy (172 patients) or placebo (175 patients).
Together, 301 patients underwent full gastroduodenal endoscopy at 13 weeks; 149 in 
the eradication group and 152 in the placebo group. In a further 14 patients endoscopic 
evaluation was incomplete, either because of technical problems or because the patient 
would not allow the procedure to be completed.
Baseline characteristics
The treatment groups were comparable in terms of socio-demographic variables, rheu-
matic diseases and use of medication [15]. The study population consisted mainly of 
patients of Dutch Caucasian ethnicity (87%) with predominantly rheumatoid arthritis 
(61%). Most patients (74%) used non-selective NSAIDs; diclofenac by 100 (29%) patients, 
naproxen by 63 (18%), ibuprofen by 44 (13%) and indometacine by 21 (6%). COX-2 selec-
tive NSAIDs were used by 90 (26%) patients; meloxicam by 38 (11%) patients, rofecoxib 
by 25 (7%), nabumetone by 22 (6%), and celecoxib by 5 (1%). At baseline there were no 
signiﬁ cant diff erences in NSAID use between the treatment groups.
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Table 1 Characteristics of patients with and without endoscopic ulcers at 13 weeks
Characteristics Ulcer – (n=287) Ulcer + (n=14) P-value
Age - years; mean ± SD 59 ± 10 61 ± 10 0.45
Female sex - no. (%) 174 (61) 6 (43) 0.19
Rheumatic disease requiring NSAIDs - no. (%)
 rheumatoid arthritis
 Spondylarthropathy
 psoriatic arthritis
 Osteoarthritis
 Other
176 (61)
22 (8)
23 (8)
25 (9)
41 (14)
9 (64)
2 (14)
0 (0)
1 (7)
2 (14)
0.82
0.37
0.27
0.84
1.00
Disease duration - years; median (IQR) 7 (3 to 14) 7 (2 to 14) 0.81
Co-morbidity - no. (%) 193 (67) 6 (43) 0.06
NSAID - no. (%)
Non-selective NSAIDs
 Diclofenac
 Naproxen
 Ibuprofen
 Indometacine
187 (65)
61 (21)
52 (18)
36 (13)
17 (6)
12 (86)
4 (29)
2 (14)
1 (7)
1 (7)
0.11
0.52
0.72
0.55
0.85
Selective NSAIDs
 COX-2 preferential NSAIDs
  Meloxicam
  Nabumetone
 Selective COX-2 inhibitors
  Rofecoxib
  Celecoxib
80 (28)
52 (18)
33 (12)
19 (7)
28 (10)
23 (8)
5 (2)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0.02
0.08
0.18
0.32
0.22
0.27
0.62
Combination drug 20 (7) 2 (14) 0.30
Gastroprotection - no. (%)
 proton pump inhibitor
 histamine-2 receptor antagonist
 prostaglandin analogues
139 (48)
109 (38)
17 (6)
1 (0.3)
7 (50)
4 (29)
2 (14)
0 (0)
0.91
0.48
0.21
0.83
Relative daily dose of NSAID; median (IQR) 1 (0.5 to 1) 1 (0.6 to 1) 0.15
Use of more than one NSAID - no. (%) 4 (1%) 0 (0) 0.66
History of gastroduodenal ulcer - no. (%) 31 (11) 1 (7) 0.67
Current corticosteroid use - no. (%) 27 (9) 0 (0) 0.23
Concurrent use of low dose aspirin - no. (%) 27 (9) 4 (29) 0.02
Concurrent use of coumarin - no. (%) 10 (4) 1 (7) 0.48
Current smoking - no. (%) 71 (32) 3 (30) 0.89
Current alcohol drinking - no. (%) 147 (51) 9 (64) 0.34
Eradication of Helicobacter pylori - no. (%) 144 (50) 8 (57) 0.61
SD: standard deviation; NSAIDs: non-steroidal anti-inﬂ ammatory drugs; COX: cyclo-oxygenase; COX-2 preferential 
NSAIDs: meloxicam, nabumetone; COX-2 selective inhibitors: rofecoxib, celecoxib; Selective NSAIDs: COX-2 preferen-
tial NSAIDs or COX-2 selective inhibitors; Combination drug: diclofenac-misoprostol. The relative daily dose of NSAID 
was calculated by dividing the daily dose by the full therapeutic dose.
cox-2 selective nsaids in h. py lori-positive patients
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Gastroduodenal ulcers
At endoscopy, gastroduodenal ulcers were diagnosed in 6 (4%) patients in the eradica-
tion group (5 gastric and 1 duodenal ulcer) and 8 (5%) patients in the placebo group (6 
gastric and 2 duodenal ulcers) (P=0.65) [15]. No patients developed symptomatic ulcers, 
gastrointestinal bleeding or perforation during the total study period of 52 weeks.
Post hoc analysis
At 13 weeks a full gastroduodenal endoscopy was performed in 301 patients; 14 had 
gastroduodenal ulcers while 287 did not. Demographic variables, rheumatic diseases, 
co-morbidity and medication use in those with ulcers vs. those without are shown in 
[table 1]. None of the patients using COX-2 selective NSAIDs had gastroduodenal ulcers 
at endoscopy, or developed symptomatic ulcers, gastrointestinal bleeding or gastro-
intestinal perforation during the total 52 week study period. The use of COX-2 selective 
NSAIDs was therefore signiﬁ cantly less common among ulcer patients than non-ulcer 
patients; 0 (0%) patients in the ulcer group vs. 80 (28%) patients in the non-ulcer group 
used COX-2 selective NSAIDs (P=0.02).
Through randomization patients using COX-2 selective NSAIDs had been evenly dis-
tributed over both treatment groups; 37 (46%) in the eradication group and 43 (54%) in 
the placebo group. As none of these patients developed gastroduodenal ulcers, H. pylori 
eradication did not inﬂ uence ulcer rates in patients on current COX-2 selective NSAIDs.
Another signiﬁ cant diff erence between the ulcer- and non-ulcer groups was con-
current use of low dose aspirin; 4 (29%) in the ulcer group vs. 27 (9%) in the non-ulcer 
group (P=0.02). Borderline signiﬁ cant was co-morbidity; 6 (43%) in the ulcer group vs. 
193 (67%) in the non-ulcer group (P=0.06). Concomitant use of gastroprotective drugs, 
corticosteroids or coumarins did not diff er signiﬁ cantly between the groups and neither 
did past history of gastroduodenal ulcers or eradication of H. pylori.
In 14 patients, endoscopic evaluation was incomplete, either because of technical 
problems during endoscopy or because the patient would not allow the procedure to 
be completed. In all these patients, the stomach could be evaluated and none of these 
patients had gastric ulcers. Adding these patients to those with a full endoscopic evalu-
ation did not change the results.
In a further sub-analysis, no signiﬁ cant diff erences were found in known risk factors 
for NSAID-gastropathy in patients using COX-2 selective NSAIDs compared to patients 
using non-selective NSAIDs [table 2].
Discussion
This study suggests that in Helicobacter pylori-positive patients on current NSAID treat-
ment for rheumatic diseases, use of COX-2 selective NSAIDs is associated with a signiﬁ -
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cantly reduced risk for endoscopic gastroduodenal ulcers. Helicobacter pylori eradication 
therapy does not appear to further ameliorate this risk. Furthermore, concomitant use 
of low dose aspirin is associated with a signiﬁ cantly increased risk for endoscopic gas-
troduodenal ulcers in patients on current NSAID treatment.
Several randomized controlled trials have previously demonstrated a 50% reduction 
in the risk for gastroduodenal ulcers during short-term use of COX-2 selective NSAIDs, 
as compared to non-selecti ve NSAIDs2, 3. However, it is unclear whether this eff ect re-
mains during longer use8. In the present study in current NSAID users, the reduction in 
risk for gastroduodenal ulcers might be even larger than 50%, as none of the 80 patients 
using COX-2 selective NSAIDs developed endoscopic gastroduodenal ulcers. However, 
due to the zero cases no exact value for the risk reduction could be calculated. A large 
risk reduction in the present study might be due to several reasons. Firstly, 36% of the 
patients using COX-2 selective NSAIDs concomitantly used proton pump inhibitors and 
5% used histamine-2 receptor antagonists. Although these percentages were slightly 
lower than in the group of patients using non-selective NSAIDs, a cumulative gastropro-
tective eff ect might be expected. Secondly, in previous randomized controlled trials rig-
orous selection criteria were maintained, and those at high risk for NSAID-gastropathy 
were usuall y excluded2, 3. In contrast with these studies, ours was speciﬁ cally designed 
to mirror daily clinical practice. We therefore also included current NSAID users with 
high risk proﬁ les for the development of NSAID-gastropathy, allowing concomitant use 
of corticosteroids, anticoagulants, low-dose aspirin, and patients with a past history of 
gastroduodenal ulcers. Furthermore, all patients were H. pylori positive on serological 
testing. However, unexpectedly at endoscopy the overall incidence of gastroduodenal 
Table 2 Sub-analysis of risk-factors for NSAID-gastropathy in patients using selective NSAIDs and pa-
tients using non-selective NSAIDs
Characteristics s-NSAIDs (n=80) ns-NSAID (n=221) P-value
Age - years; mean ± SD 58 ± 11 59 ± 10 0.41
History of gastroduodenal ulcers - no. (%) 11 (14) 21 (10) 0.29
Co-morbidity - no. (%) 56 (70) 143 (65) 0.39
Concomitant use of drugs
 proton pump inhibitors - no. (%)
 histamine-2 receptor antagonist - no. (%)
 low dose aspirin - no. (%)
 coumarins - no. (%)
 corticosteroids - no. (%)
29 (36)
4 (5)
6 (8)
3 (4)
7 (9)
84 (38)
15 (7)
25 (11)
8 (4)
20 (9)
0.78
0.57
0.34
1.00
0.94
Eradication of H. pylori - no. (%) 37 (46) 112 (51) 0.50
s-NSAIDs: selective NSAIDs; ns-NSAIDs: non-selective NSAIDs
cox-2 selective nsaids in h. py lori-positive patients
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ulcers was only 4.7%. It is possible that inadvertently patients were naturally pre-select-
ed by time for good NSAID tolerability, leading to very low
endoscopic gastroduodenal ulcer rates in those on current COX-2 selective NSAIDs. 
Previous studies in H. pylori-positive patients suggest that H. pylori infection may ne-
gate the gastrointestinal safety of COX-2 selec tive NSAIDs12-14. Conversely in the pres-
ent study, H. pylori eradication therapy did not inﬂ uence the ulcer risk in those current 
COX-2 selective NSAIDs. However, it is possible that a type II error might have occurred 
due to the overall low incidence of endoscopic ulcers and the relatively small number of 
patients on current COX-2 selective NSAIDs.
In a sub-analysis of risk factors for NSAID-gastropathy, we found no diff erences be-
tween COX-2 selective NSAID users and non-selective NSAID users. Whether or not 
the relative gastrointestinal safety of COX-2 selective NSAIDs is maintained during con-
comitant use of low dose aspirin remains unclear. In our study, current NSAID users who 
developed endoscopic ulcers signiﬁ cantly more oft en used low dose aspirin than those 
who did not develop ulcers. However, only 8% of the patients in the COX-2 selective 
NSAID group used low dose aspirin, and none of these patients developed endoscopic 
ulcers.
In summary, our ﬁ ndings suggest that in H. pylori-positive patients on current NSAID 
treatment for rheumatic diseases, the use of COX-2 selective NSAIDs is associated with 
a signiﬁ cantly reduced risk for endoscopic gastroduodenal ulcers. H. pylori eradication 
therapy does not appear to further ameliorate this risk. In patients on current NSAID 
treatment, concomitant use of low dose aspirin is associated with a signiﬁ cantly in-
creased risk for endoscopic gastroduodenal ulcers.
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Abstract
background In this post-hoc analysis of a randomized, double blind, placebo con-
trolled trial, we measured the sensitivity and speciﬁ city of Helicobacter pylori IgG-an-
tibody titer changes, hematoxylin and eosin (H&E) stains, immunohistochemical (IHC) 
stains and culture results in NSAID using patients, following H. pylori eradication ther-
apy or placebo.
methods 347 NSAID using patients who were H. pylori positive on serological testing 
for H. pylori IgG-antibodies were randomized for H. pylori eradication therapy or placebo. 
Three months aft er randomization, gastric mucosal biopsies were taken for H. pylori 
culture and histological examination. At 3 and 12 months, blood samples were taken 
for repeated serological testing. The gold standard for H. pylori infection was based on 
a positive culture or both a positive histological examination and a positive serological 
test. Sensitivity, speciﬁ city and receiver operating curves (ROC) were calculated.
results H. pylori eradication therapy was successful in 91% of patients. Culture pro-
vided an overall sensitivity of 82%, and 73% aft er eradication, with a speciﬁ city of 100%. 
Histological examination with either H&E or IHC stains provided sensitivities and speci-
ﬁ cities between 93% and 100%. Adding IHC to H&E stains did not improve these results. 
The ROC curve for percent change in H. pylori IgG-antibody titers had good diagnostic 
power in identifying H. pylori negative patients, with an area under the ROC curve of 0.70 
(95% CI 0.59 to 0.79, P=0.085) at 3 months and 0.83 (95% CI 0.76 to 0.89, P<0.0001) at 
12 months. A cut-off  point of at least 21% decrease in H. pylori IgG-antibody titers at 3 
months and 58% at 12 months provided a sensitivity of 64% and 87% and a speciﬁ city 
of 81% and 74% respectively, for successful eradication of H. pylori.
conclusions In NSAID using patients, following H. pylori eradication therapy or place-
bo, histological examination of gastric mucosal tissue biopsies provided good sensitivity 
and speciﬁ city ratios for evaluating success of H. pylori eradication therapy. A percentual 
H. pylori IgG-antibody titer change has better sensitivity and speciﬁ city than an absolute 
titer change or a predeﬁ ned H. pylori IgG-antibody titer cut-off  point for evaluating suc-
cess of H. pylori eradication therapy.
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Background
Helicobacter pylori (H. pylori) infection has been shown to be related to the develop-
ment of peptic ulcer disease, chronic gastritis, MALT lymphoma and gastric cancer 1-4. 
Accurate diagnosis of H. pylori infection has clinical consequences as H. pylori eradica-
tion improves outcome and recurrence of peptic ulcer disease. H. pylori infection can 
be detected using non-invasive tests such as serological tests, 13C-urea breath test and 
stool tests, and invasive tests requiring endoscopically obtained gastric mucosal tissue 
biopsies, such as tissue culture, examination of histological stains and the rapid urease 
test. Serological tests based on the detection of antibodies to H. pylori have been shown 
to have high sensitivity and are therefore useful in screening for H. pylori infectio n5-7. 
However, because serological tests merely detect an immune response, they do not dis-
criminate between current or previous infection. H. pylori infection of the gastric mucosa 
causes a chronic local inﬂ ammatory cell inﬁ ltration, which in turn gives rise to a serologi-
cal response, in which H. pylori speciﬁ c antibodies are almost always detectab le8, 9. Aft er 
successful H. pylori eradication therapy, the level of H. pylori speciﬁ c antibodies decreases 
progressively over a period of several months, possibly parallel to the slowly healing in-
ﬂ ammation of the gastric muc osa10. As a result, evaluating success of H. pylori eradication 
therapy using repeated serological tests has only been shown to be useful if a period of 
several months is maintained between t ests11-13.
Culture of H. pylori in biopsy specimens has very high speciﬁ city and allows testing 
for antibiotic susceptibility but has relatively low sensitivity and is labour-inte nsive14. 
Histological identiﬁ cation of H. pylori in biopsy specimens has long been considered 
to be the clinical standard for the diagnosis of H. pylori infection. A high density of 
H. pylori is readily apparent on routine hematoxylin and eosin (H&E) stains but detec-
tion of a lower density of bacteria may require additional staining tech niques15. H. pylori 
is more easily visualised with immunohistochemical H. pylori antibody stains than with 
the standard H&E staining. However, the use of immunohistochemical (IHC) stains adds 
time and expense to the diagnostic evaluation for H. pylori and is therefore not routinely 
performed.
The interaction between H. pylori infection and the use of non-steroidal anti-inﬂ am-
matory drugs (NSAIDs) in the development of gastroduodenal ulcers remains unclear. 
In a meta-analysis of 16 endoscopic studies in NSAID users from various countries, un-
complicated gastric ulcer disease was twice as common in H. pylori positive patients as 
in H. pylori negative patients16. However, the rate of H. pylori infection in patients with 
NSAID associated gastric ulcers is signiﬁ cantly lower than in those with non-NSAID as-
sociated gastric ulcers17. Furthermore, while eradication of H. pylori infection in NSAID-
naïve patients prior to NSAID therapy reduces the risk of ulcer development, it does 
not do so in current NSA ID users18-20. This was also conﬁ rmed in a recent randomized, 
double blind, placebo controlled clinical trial, in which we found that eradication of 
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H. pylori infection did not reduce the incidence of endoscopic gastroduodenal ulcers in 
H. pylori seropositive patients currently taking NSAIDs for rheumatic diseases21.
H. pylori infection has been shown to induce cyclooxygenase (COX)-2 expression in 
the gastric mucosa, which persists during active H. pylori infection22-25. It has been sug-
gested that COX-2 plays an immunosuppressive role in H. pylor i gastritis26. Conversely, in 
H. pylori infected mice, NSAID treatment has been shown to signiﬁ cantly decrease the 
degree of gastric  inﬂ ammation27. It is therefore possible that in patients with H. pylori in-
fection, concurrent NSAID treatment may aff ect levels of gastric inﬂ ammation and may 
consequently aff ect the serological response. While several studies have investigated 
the time course of H. pylori antibody titers aft er H. pylori eradication therapy, none have 
been conducted i n NSAID users9, 11-13, 28.
This study presents a post-hoc investigation into H. pylori IgG-antibody titer chang-
es following H. pylori eradication therapy in NSAID users. In patients participating in 
the before mentioned H. pylori eradication in NSAID users trial, we measured H. pylori 
IgG-antibody titers and titer changes in order to diagnose successful H. pylo ri eradica-
tion21. We further compared H. pylori IgG-antibody titers, H&E stains, IHC stains and 
H. pylori culture results in follow-up biopsies from H. pylori-positive NSAID-users ran-
domized to eradication treatment or placebo, to determine the sensitivity and speciﬁ c-
ity of these diff erent methods in NSAID users. Furthermore, we determined whether 
adding IHC stains to H&E stains improves the histological identiﬁ cation of H. pylori in 
these patients.
Methods
Study design
The methods of the primary randomized, double blind, placebo controlled clinical trial 
have been previously described in more detail21. Between May 2000 and June 2002, 
patients between the ages of 40 and 80 years with a rheumatic disease requiring NSAID 
treatment, were recruited and included in the study if tested positive for H. pylori on 
serological testing. During the study, no change in NSAID-therapy was permitted, but 
there was no restraint on other medication. Exclusion criteria were previous H. pylori 
eradication therapy and severe concomitant disease.
Aft er stratiﬁ cation by concurrent use of gastroprotective agents (proton pump inhib-
itors, H2 receptor antagonists or misoprostol, but not prokinetics, or antacids), patients 
were randomly assigned to receive either H. pylori eradication therapy with omeprazole 
20 mg, amoxycillin 1000mg, and clarithromycin 500 mg (OAC) twice daily for 7 days or 
placebo. Patients with an allergy for amoxycillin were randomized in a separate stratum 
to receive omeprazole 20 mg, metronidazol 500 mg and clarithromycin 250 mg (OMC) 
or placebo therapy twice daily for one week. Randomization to consecutive patient 
88
numbers was done in proportions of 1:1, in blocks of four from a computer-generated 
list. The study centers were provided with individually sealed packages containing the 
treatment for each patient. Each centre received entire blocks to be used sequentially. 
Rheumatologists were not practicing in more than one center. The study medication 
was given in a double blind, double dummy manner. Active and placebo preparations 
were identical in appearance. The employees of the VU University Medical Center phar-
macy who packaged the medication only knew the assignment. It was disclosed to the 
treating physician only in case of emergency. All study personnel and participants were 
blinded to treatment assignment for the duration of the study.
Aft er 3 months patients underwent gastroduodenal endoscopy, during which 4 an-
trum biopsies and 4 corpus biopsies were taken for culture and histological examina-
tion. Aft er 3 and 12 months, blood samples were taken for repeated serological testing. 
Immunohistochemical staining was only available for a subset of patients recruited at 
the Medisch Spectrum Twente hospital in Enschede, the Netherlands. The study proto-
col was approved by the Institutional Ethical Review Board of all participating hospitals 
and all patients gave written informed consent.
Serology
Serological testing for H. pylori IgG-antibodies was performed using a commercially 
available enzyme-linked immunosorbent assay (ELISA) kit (Pyloriset® new EIA-G, Orion 
Diagnostica, Espoo, Finland). Results were considered positive if the antibody titers were 
≥250 International Units per mL (IU/mL), according to the manufacturer’s guidelines. 
This assay has been assessed, in a population similar to the population in the presented 
trial, and has proven a sensitivity and speciﬁ city in the Netherlands of 98-100% and 79-
85%, even in patients on acid suppr essive therapy29-31.
Culture
Biopsy specimens of corpus and antrum taken during endoscopy were inoculated onto 
Columbia agar (Becton Dickinson, Cockeysville, MD, USA) with 10% lysed horse blood 
(Bio Trading, Mijdrecht, The Netherlands), and onto Columbia agar with H. pylori selec-
tive supplement (Oxoid, Basingstoke, UK). Media were then incubated for 72 hours at 
37°C under microaerophilic conditions (5% O2, 10% CO2 and 85% N2). The isolated colo-
nies of H. pylori were identiﬁ ed by Gram stain showing spiral-shaped Gram-negative 
rods, producing urease rapidly, with positive catalase and oxidase tests.
Histology
Biopsy specimens were stained for Hematoxylin and Eosin (H&E) according to the stan-
dard procedure. For immunohistochemical (IHC) staining, the slides were heated in 
an autoclave (Kavoklave, Prestige Medical Ltd, UK) in a citric-acid solution (pH = 6 to 
121-126 °C during 30 minutes for antigen retrieval. The slides were then incubated in a 
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Shandon Sequenza Immunostaining Center (Thermo Electron Corporation, the Nether-
lands) with a polyclonal rabbit IgG anti-Helicobacter pylori antibody (DakoCytomation, 
Denmark, dilution 1:300), followed by biotinylated goat anti-polyvalent antibody (Lab-
Vision Corporation, USA), strepavidin peroxidase (LabVision Corporation, USA) and 
Liquid DAB + substrate chromogen system (DakoCytomation, Denmark), and counter-
stained with hematoxylin.
All stained biopsy specimens of corpus and antrum taken during endoscopy were 
examined by a single expert pathologist who was blinded for clinical data, treatment 
allocation and other test results.
Gold standard deﬁ nition
As the gold standard for H. pylori infection in this study, at 3 months a patient was 
deﬁ ned as being H. pylori positive on the basis of a positive culture for H. pylori or, in 
the case of a negative culture, a positive examination of either H&E or IHC stains in 
combination with H. pylori IgG-antibody titers persistently ≥ 250 IU/mL. At 12 months, 
a patient was deﬁ ned as being H. pylori positive on the basis of a positive culture for 
H. pylori or, in the case of a negative culture, a positive examination of either H&E or IHC 
stains in biopsy samples at 3 months in combination with H. pylori IgG-antibody titers 
persistently ≥ 250 IU/mL at 12 months.
Statistical analysis
Continuous variables with a normal distribution were expressed as mean with standard 
deviation (SD), and continuous variables with a non-normal distribution as median with 
interquartile range (IQR). Diff erences between groups were analysed using Students 
t-test, Mann-Whitney U test, Pearson’s Chi-square test or Fisher’s Exact test in case of 
low expected values. For all analyses P<0.05, two sided, was considered signiﬁ cant. All 
analyses were performed with SPSS for Windows, version 19.0 (SPSS, Chicago, IL, USA). 
Receiver Operating Characteristic (ROC) curves and likelihood ratios were analysed with 
MedCalc for windows, version 12.1.3.0. Diff erences in the proportions of patients were 
analyzed with 95% conﬁ dence interval using the Conﬁ dence Interval Analysis soft ware 
for Windows (version 2.2.0).
Results
A total of 347 patients were included in the present study. The treatment groups (172 
patients in the eradication group and 175 patients receiving placebo) were similar in 
terms of demographics, rheumatic disease, NSAIDs and other drug use. Our eligibility 
criteria resulted in a study group with mainly inﬂ ammatory rheumatic diseases (rheu-
matoid arthritis 61%, spondyloarthropathy 8%, psoriatic arthritis 7%, osteoarthritis 9%, 
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other 15%). The most commonly used NSAIDs were diclofenac (29%), naproxen (18%), 
and ibuprofen (13%). The mean age was 60 years (SD 10), 61% was female. Twenty-two 
patients had a known allergy for amoxicillin and received metronidazole instead (10 
patients) or placebo (12 patients). Forty-eight percent used a gastroprotective drug (7% 
H2 receptor antagonists (H2RA), 37% proton pump inhibitors (PPI), 7% misoprostol, 3% 
used a combination of these).
At baseline, Anti-H. pylori IgG antibodies were present in all 347 patients (median 
titre 1689 (IQR 700-3732). At three months, data on both culture and histology were 
available in 305 patients; 152 in the eradication group and 153 in the placebo group. In 
two cases only culture data were available and in 1 case only histology was available. 
All three cases met the criteria for H. pylori-positivity and were found in the placebo 
group. A total of 32 patients (with no signiﬁ cant diff erences between eradication and 
placebo groups) refused the 3-month endoscopy, withdrew informed consent, or could 
not undergo endoscopy because of adverse events. Seven patients used anticoagulant 
therapy, ruling out biopsy sampling in accordance with the study protocol, and in one 
patient no biopsy specimens could be obtained because of discomfort requiring early 
completion of the procedure.
The results of H. pylori detection by each of the diff erent tests are shown in [Table 1]. 
Out of the 152 patients who had been treated with H. pylori eradication therapy, 141 (93%) 
had a negative culture, and of the 153 patients who had been receiving placebo, 54 (35%) 
had a negative culture (P<0.001). Out of the 152 patients who had been treated with 
H. pylori eradication therapy, 133 (88%) had a negative H&E stain, compared to 41 (27%) 
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Table 1 Results of H. pylori detection by each test
Test Positives (%) Negatives (%)
T=3 months
Culture (n=305) Eradication 
Placebo 
11 (7)
99 (65)
141 (93)
54 (35)
H&E stains (n= 305) Eradication
Placebo
19 (12)
112 (73)
133 (88)
 41 (27)
IHC stains (n=68) Eradication
Placebo
29 (85)
7 (20)
5 (15)
27 (79)
Serology (n=203) Eradication
Placebo
92 (91)
94 (92)
9 (9)
8 (8)
T=12 months
Serology (n=304) Eradication
Placebo 
96 (64)
138 (90)
55 (36)
15 (10)
H&E: hematoxylin and eosin, IHC: immunohistochemistry. Positive serology was deﬁ ned as H. pylori IgG-antibody 
titers ≥ 250 IU/mL.
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of the 153 patients who had been receiving placebo (P<0.001). In the subgroup (with sta-
tistically similar baseline characteristics as the whole population, data not shown) of 68 
patients in which IHC stains were performed, 29 (85%) of the 34 patients who had been 
treated with H. pylori eradication therapy had a negative IHC stain, compared to 7 (21%) 
of the 34 patients in the placebo group (P<0.001). There were no diff erences between 
patients using gastroprotection compared to patients who did not take gastroprotective 
drugs for the presence of H. pylori by culture or histology (P=0.454).
According to the gold standard criteria, a patient could be either H. pylori positive or 
H. pylori negative. The sensitivity, speciﬁ city, positive predictive values (PPV) and negative 
predictive values (NPV) of each test were calculated for the whole group and also diff er-
entiated for preceding H. pylori eradication therapy or placebo, as is shown in [table 2]. 
For the combined analysis of H&E and IHC stains, results were positive if either test was 
positive or results were negative if both tests were negative. According to the gold stan-
dard criteria for H. pylori infection, H. pylori eradication was successful in 133 (89.9%) 
of the 148 patients who had been treated with H. pylori eradication therapy, while 120 
(78.9%) of the 152 patients who had been receiving placebo remained H. pylori positive. 
Gold standard criteria could not be calculated in 4 patients in the eradication group en 1 
Table 2 Results of the sensitivity, speciﬁ city, positive predictive value (PPV) and negative predictive value 
(NPV) of each test; for the total study group and diff erentiated for preceding H. pylori eradication 
therapy or placebo
Test Sensitivity (%) Speciﬁ city (%) PPV (%) NPV (%)
Culture
  Total
  Eradication
  Placebo
82
73
83
100
100
100
100
100
100
87
97
62
H&E stains
  Total
  Eradication
  Placebo
93
93
92
99
99
100
99
93
100
94
99
78
Subgroup of 68 patients
IHC stains
  Total
  Eradication
  Placebo
100
100
100
95
94
100
94
60
100
100
100
100
H&E + IHC
  Total
  Eradication
  Placebo
100
100
100
92
90
100
91
50
100
100
100
100
H&E: hematoxylin and eosin, IHC: immunohistochemistry.
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in the placebo group because of missing or negative culture results, or missing serology 
data in combination with available histology results.
Serology
At baseline, H. pylori IgG-antibody titers varied from 250 IU/mL to 19029 IU/mL with 
a median of 1689 IU/mL (interquartile range (IQR) 700 to 3732 IU/mL) with no signiﬁ -
cant diff erences in titers between the groups assigned to H. pylori eradication therapy 
or to placebo (P=0.39). At endoscopy at 3 months, H. pylori IgG-antibody titers varied 
from 126 IU/mL to 12800 IU/mL, with a median of 1190 IU/mL (IQR 500 to 2820 IU/mL). 
Patients who had been treated with H. pylori eradication therapy had lower H. pylori 
IgG-antibody titers than those treated with placebo; eradication group (n=101) median 
730 IU/mL (IQR 415 to 1461 IU/mL) and placebo group (n=102) median 2026 IU/mL (IQR 
700 to 3571 IU/mL) (median diff erence -907, 95% CI -1356 to -460, P<0.001 [Figure 1]. 
At serological testing at 12 months, patients who had been treated with H. pylori eradi-
cation therapy had lower H. pylori IgG-antibody titers than those treated with placebo; 
eradication group (n=151) median 370 IU/mL (IQR 200 to 672 IU/mL) and placebo group 
(n=153) median 1340 IU/mL (IQR 490 to 3272 IU/mL) (median diff erence -778, 95% 
CI -1128 to -466, P<0.001 [Figure 1]).
At 3 months, H. pylori IgG-antibody titers had dropped below the 250 IU/mL thres-
hold for positivity in 17/203 (8.4%) patients; 9/101 (9%) in the eradication group and 
8/102 (8%) in the placebo group (P=0.78). At 12 months, H. pylori IgG-antibody titers had 
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Figure 1 Median (black diamond) and interquartile range (grey line) of H. pylori IgG-antibody titers in IU/
ml for the eradication and placebo groups, at baseline, 3 months and 12 months aft er eradication 
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dropped below the 250 IU/mL threshold for positivity in 70/304 (23%) patients; 55/151 
(36%) in the eradication group and 15/153 (10%) in the placebo group (P<0.05), [table 1].
The absolute change in H. pylori IgG-antibody titers from baseline to 3 months (titer at 
baseline minus titer at 3 months) did diff er signiﬁ cantly between the groups; eradication 
group median change 980 IU/mL (IQR 190 to 2720 IU/mL) and placebo group median 
change -26 IU/mL (IQR -605 (elevation of titer) to 870 IU/mL) (median diff erence 1006, 
95% CI 654 to 1471, P<0.001). The change in H. pylori IgG-antibody titers from baseline 
to 12 months also diff ered signiﬁ cantly between the groups; eradication group median 
change 1010 IU/mL (IQR 363 to 2917 IU/mL) and placebo group median change 167 IU/
mL (IQR -337 (elevation of titer) to 1625 IU/mL) (median diff erence 913, 95% CI 547 to 
1362, P<0.001).
Compared to baseline, at 3 months H. pylori IgG-antibody titers were median 55% 
lower (IQR 24% to 72%) in the eradication group and median 0.9% lower (IQR -32% to 
40%) in the placebo group (median diff erence 46%, 95% CI 34% to 60%, P<0.001). Com-
pared to baseline, at 12 months H. pylori IgG-antibody titers were median 77% lower 
(IQR 48% to 88%) in the eradication group and median 22 % lower (IQR -34% to 56%) in 
the placebo group (median diff erence 46%, 95% CI 36 to 58, P<0.001).
Using the predeﬁ ned H. pylori IgG-antibody titer cut-off  point of ≥250 IU/mL, serological 
testing for H. pylori IgG-antibodies at endoscopy at 3 months was found to be highly 
sensitive (99%) but with very poor speciﬁ city (15%), especially following H. pylori eradi-
cation therapy (10%). Arguably, the absolute or percent change in H. pylori IgG-antibody 
titers from baseline represent better methods for evaluating success of H. pylori eradi-
cation. [Figure 2] presents the Receiver Operating Characteristic (ROC) curves for abso-
lute and percent change in H. pylori IgG-antibody titers aft er 3 and 12 months, associ-
ated with a negative result for the gold standard criteria for H. pylori infection. Percent 
change scores had better diagnostic power in identifying H. pylori negative patients at 
both 3 and 12 months, with area under the ROC curves (AUCs) of 0.62 (95% CI 0.52 to 
0.72, P=0.343) for absolute change and 0.70 (95% CI 0.59 to 0.79, P=0.085) for percent 
change at 3 months and 0.73 (95% CI 0.65 to 0.80, P=0.0016) for absolute change and 
0.83 (95% CI 0.76 to 0.89, P<0.0001) for percent change at 12 months. The optimal cut-
off  point at 3 months for percent change in H. pylori IgG-antibody titers was 21%, cor-
responding to a sensitivity of 64% (95% CI 31% to 89%) and speciﬁ city of 81% (95% CI 
71% to 89%), negative Likelihood ratio 0.45 (95% CI 0.2 to 1.1), positive Likelihood ratio 
3.3 (95% CI 2.1 to 5.2). The optimal cut-off  point at 12 months for percent change in 
H. pylori IgG-antibody titers was 58 %, corresponding to a sensitivity of 87% (95% CI 
60% to 98%) and speciﬁ city of 74% (95% CI 65% to 81%), negative Likelihood ratio 0.18 
(95% CI 0.05 to 0.7), positive Likelihood ratio 3.3 (95% CI 2.6 to 4.1).
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Discussion
Following H. pylori eradication therapy or placebo, histological examination of gastric 
mucosal tissue biopsies provided good sensitivity and speciﬁ city ratios for evaluating 
success of H. pylori eradication therapy. In the subgroup with both IHC and H&E stain-
ing, IHC was slightly superior to H&E. Following eradication therapy both staining meth-
ods provided 100% sensitivity and also very high speciﬁ city. A combined analysis of H&E 
and IHC stains, in which results were positive if either test was positive or results were 
negative if both tests were negative, did not improve sensitivity while the number of 
false positive test results increased. Culture of H. pylori in gastric biopsy specimens has 
very high speciﬁ city but relatively low sensitivity5, 32. In the present study, culture pro-
vided 100% speciﬁ city and 82% sensitivity. However, aft er H. pylori eradication therapy 
sensitivity dropped to 73% due to an increasing percentage of false negative cultures. 
Culture of H. pylori therefore does not appear to be very useful for evaluating success of 
H. pylori eradication therapy. In clinical practice, invasive tests for conﬁ rmation of eradi-
cation should only be used in cases where repeat endoscopy is indicated, for example in 
patients with gastric ulcer. In all other cases non-invasive test should be employed for 
follow-up aft er H. pylori erad ication treatment33.
The choice of a gold standard aff ects test results of all other tests. According to the 
guidelines for clinical trials in H. pylori infection, a reliable gold standard should consist 
of at least 2 methods based on diff erent principles for detecting H . pylori infection5,34. In 
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Figure 2 Comparison of ROC curves for absolute and percent change of H. pylori-IgG antibody titers 
at 3 and 12 months aft er eradication therapy
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the present study, a patient was also considered H. pylori positive if culture alone was 
positive, in view of its absolute speciﬁ city. The gold standard in the present study cor-
responds to acceptable criteria.
Other accurate and relatively inexpensive non-invasive tests that may also be consid-
ered for the evaluation of success of H. pylori eradication therapy are serology, 13C-urea 
breath tests and  stool antigen tests33. While the 13C-urea breath test may have better 
accuracy (>90%), the serology test used in this study was less expensive and readily 
available in all study centres35. At the time of the study, stool antigen tests were not 
yet widely available in the Netherlands. PPI usage (in this study 48% of the population) 
may result in false negative test results in both invasive and non-invasive tests, such 
as culture, histology and 13C-urea breath testing, and should therefore be stopped two 
weeks before testing36. This does not apply for serological testing. Besides, stopping PPI 
in a population of chronic NSAID users would be non-ethical in a trial setting.
This study shows that in NSAID users, percent change in H. pylori IgG-antibody titers 
has better diagnostic power in identifying H. pylori negative patients at both 3 and 12 
months than absolute change in H. pylori IgG-antibody titers. Repeated serological test-
ing using a cut-off  point of 21% decrease in H. pylori IgG-antibody titers aft er 3 months 
and 58% aft er 12 months has suffi  ciently high sensitivity and speciﬁ city to be useful for 
evaluating the success of H. pylori eradication therapy. Other groups have found high 
sensitivity and speciﬁ city ratios for percent decrease in H. pylori IgG-antibody titers  using 
cut-off  points of 25% at 6 months an d 40% at 3 to 6 months10, 11, 37. Using a predeﬁ ned 
H. pylori IgG-antibody titer cut-off  point of 250 IU/mL, repeated serological testing for 
H. pylori IgG-antibodies was found to have little diagnostic value.
Overall, NSAID use did not seem to inﬂ uence H. pylori eradication rates or serological 
testing for H. pylori IgG-antibodies, when compared to other studies with patients who 
do not take NSAIDs5, 32. Although studies on H. pylori IgG serology are not new, there 
is some data available in which has been shown that NSAID treatment signiﬁ cantly 
decreases the degree of gastric inﬂ ammation22-25. However in some studies aspirin and 
NSAID possibly suppresses the growth of H. pylori and may inﬂ uence diagnostic test-
ing and increase its susceptib ility to the antibiotics38-40. It is therefore possible that in 
patients with H. pylori infection, concurrent NSAID treatment may aff ect levels of gas-
tric inﬂ ammation and may consequently aff ect the serological response. While  several 
studies have investigated the time course of H. pylori antibody titers aft er H. pylori eradi-
cation therapy, none have been conducted in NSAID users yet. Theoretically, if NSAID 
treatment decreases the degree of gastric inﬂ ammation and subsequently aff ects the 
serological response, one would not expect to ﬁ nd many false positive test results. How-
ever, such an eff ect still cannot be ruled out because in the present study, a relatively 
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strong decline in H. pylori IgG-antibodies was noted 3 months aft er H. pylori eradication 
(median 55% decline at 3 months and median 77% decline at 12 months), compared to 
other studies. A previous longitudinal analysis of H. pylori IgG-antibody titers following 
successful H. pylori eradication demonstrated a mean decline of 26% at 3 months, 43% 
at 6 months, and 55% at nine months follow-up, aft er which titers appeared to plateau 
at approximately 50% compared to baseline28.
Conclusions
In the present study in NSAID taking patients, following H. pylori eradication therapy or 
placebo, histological examination of gastric mucosal tissue biopsies provided good sen-
sitivity and speciﬁ city ratios. The H&E and IHC staining methods provided comparable 
high sensitivity and speciﬁ city but combining IHC and H&E did not improve results. A 
percentual H. pylori IgG-antibody titer change has better sensitivity and speciﬁ city than 
an absolute titer change or a predeﬁ ned H. pylori IgG-antibody titer cut-off  point for 
evaluating success of H. pylori eradication therapy.
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Abstract
purpose The treatment of choice of H. pylori infections is a 7- day triple-therapy with a 
proton pump inhibitor (PPI) plus amoxicillin and either clarithromycin or metronidazole, 
depending on local antibiotic resistance rates. The data on effi  cacy of eradication ther-
apy in a group of rheumatology patients on long term NSAID therapy are reported here.
methods This study was part of a nationwide, multicenter RCT that took place in 2000 
to 2002 in the Netherlands. Patients who tested positive for H. pylori IgG antibodies were 
included and randomly assigned to either eradication PPI-triple therapy or placebo. Aft er 
completion, follow up at 3 months was done by endoscopy and biopsies were sent for 
culture and histology.
results and conclusions In the eradication group 13% (20/152, 95% CI 9-20%) and 
in the placebo group 79% (123/155, 95%CI 72-85%) of the patients were H. pylori posi-
tive by histology or culture. H. pylori was successfully eradicated in 91% of the patients 
who were fully compliant to therapy, compared to 50% of those who were not (diff er-
ence of 41%; 95% CI 18-63%). Resistance percentages found in isolates of the placebo 
group were, 4% to clarithromycin, 19% to metronidazole, 1 to amoxicillin and 2% to 
tetracycline.
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Introduction
H. pylori eradication is strongly recommended in all patients with atrophic gastritis and 
peptic ulcer disease, but may also beneﬁ t subgroups of patients with dyspepsia, and 
patients who start with NSAID therapy 1-6. H. pylori eradication therapy is an important 
component of guidelines concerning these patient s7, 8.
Currently, non-invasive management strategies and the widespread shortage in en-
doscopic capacity make that many patients with H. pylori are managed without upper 
gastrointestinal endoscopy. The American College of Gastroenterology recommends 
that when an endoscopy is not performed, a serological test, which is the least ex-
pensive means of evaluating for evidence of H. pylori infection, should be done9. When 
endoscopy is indicated, biopsy specimens can be taken for microscopic demonstration 
of the organism, culture, histology or urease testing. Nowadays, in the Netherlands, bi-
opsies are not routinely sent for culture and susceptibility testing of the infecting strain 
because of the high costs.
Apart from patient compliance, resistance of Helicobacter pylori to antibiotics can 
decrease the success of H. pylori eradication therapy. Regimens of choice for eradication 
of H. pylori should be guided by local antibiotic resistance rates. In the Netherlands, the 
overall prevalence of resistance to clarithromycin and metronidazole was lower than 
in some surrounding countries possibly due to restrictive use of antimicrobia ls10-12. The 
advised treatment in the Netherlands consists of a proton pump inhibitor (PPI)-triple 
therapy for 7 days without prior susceptibility testing. An increase of resistance rates 
to antimicrobial agents is however expected because increasing number of patients 
treated and increasing consumption of antibiotics, in particular macrolides, was ob-
served in recent years13.
The aim of the present study was ﬁ rstly, to determine the effi  cacy of 7-day PPI-triple 
therapy for H. pylori in a well-deﬁ ned group of patients with a rheumatic disease and 
serologic evidence of H. pylori infection who were on long term NSAID therapy and sec-
ondly, to get insight in the prevalence of antibiotic resistance of H. pylori in the studied 
population.
Methods
This study was part of a placebo-controlled randomized clinical trial of which the clinical 
results have been described elsewh ere14, wherein we described that H. pylori eradica-
tion has no beneﬁ cial eff ect on the incidence of gastroduodenal ulcers or occurrence 
of dyspepsia in patients on long term NSAIDs treatment. Between May 2000 and June 
2002, patients were recruited from 8 rheumatology outpatient departments in 6 cities 
in the Netherlands. Patients with a rheumatic disease were eligible for inclusion if they 
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were between 40 and 80 years of age, were positive for H. pylori on serological testing 
and were on long term NSAID treatment. Forty-eight percent used a gastroprotective 
drug (7% H2 receptor antagonists (H2RA), 37% proton pump inhibitors (PPI), 7% miso-
prostol, 3% used a combination of these). Exclusion criteria were: previous eradication 
therapy for H. pylori, known allergy for the study medication or presence of severe con-
comitant disease.
Serologic testing for H. pylori IgG-antibodies was performed with a commercial en-
zyme-linked immunosorbent assay (Pyloriset® new EIA-G, Orion Diagnostica, Espoo, 
Finland) according to the manufacturer’s instructions. A serum sample was considered 
positive for IgG antibodies to H. pylori if the test result was ≥ 250 International Units (IU). 
This assay has been assessed, in a population similar to the population in the presented 
trial, and has proven a sensitivity and speciﬁ city in the Netherlands of 98-100% and 79-
85%, even in patients on acid suppressive ther apy15-17. The study protocol was approved 
by research and medical ethics committees of all participating centers and all patients 
gave written informed consent.
Aft er stratiﬁ cation by concurrent use of gastroprotective agents (proton pump inhib-
itors, H2 receptor antagonists or misoprostol, but not prokinetics, or antacids), patients 
were randomly assigned to receive either H. pylori eradication therapy with omeprazole 
20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg (OAC) twice daily for 7 days or 
placebo. Patients with an allergy for amoxicillin were treated with omeprazole 20 mg, 
metronidazole 500 mg and clarithromycin 250 mg (OMC) or placebo therapy twice daily 
for one week in a distinct stratum. All study personnel and participants were blinded to 
treatment assignment for the duration of the study. The study protocol was approved 
by research and medical ethics committees of all participating centres and all patients 
gave written informed consent.
At the 2-week follow-up visit, unused study medication was returned and remain-
ing tablets were counted in order to check compliance. Patients were considered to 
be noncompliant if ≤ 6 days (85%) of study medication were used. Three months aft er 
baseline, and additionally if clinically indicated, patients underwent endoscopy of the 
upper gastrointestinal tract. A total of eight biopsies were taken during each endoscopy. 
Four samples, two from the antrum and two from the corpus were used for histology. 
All  biopsies were stained with haematoxylin-eosin. The slides were scored indepen-
dently by an experienced gastrointestinal pathologist and the investigator (HdL), blinded 
to treatment assignment and clinical data, according to the updated Sydney classiﬁ ca-
tion18. In case of discrepant results, the specimen was discussed until agreement was 
reached. The remaining four biopsies were sent to a microbiological laboratory for cul-
ture and storage at –70°C. A patient was considered H. pylori-negative when histology 
as well as culture was negative. All isolated strains were assessed for susceptibility to 
clarithro mycin, metronidazole, tetracycline and amoxicillin at the central laboratory.
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Both biopsy specimens of corpus and antrum were streaked on Columbia agar (CA) 
(Becton Dickinson, Cockeysville, MD, USA) with 10% lysed horse blood (Bio Trading, 
 Mijdrecht, The Netherlands), referred to as Columbia agar plates, and on CA with H. pylo-
ri selective supplement (Oxoid, Basingstoke, UK). Plates were incubated for 72 h at 37°C 
in a micro-aerophilic atmosphere (5% O2, 10% CO2, 85% N2). Identiﬁ cation was carried 
out by Gram’s stain morphology, catalase, oxidase, and urea hydrolysis measurements.
Inocula were prepared from an H. pylori culture grown on CA plates. MICs of met-
ronidazole, clarithromycin, tetracycline and amoxicillin were determined by E-test (AB 
Biodisk, Solna, Sweden) on CA plates essentially as described by Glupczynski et al19. CA 
plates were inoculated with a bacterial suspension with a turbidity of a 3 McFarland 
standard (2 × 108 CFU/ml ). CLSI (tentative) breakpoints 2009 for susceptibility (S) and 
resistance (R ) were applied (metronidazole MIC <= 8 mg/l (S) and >= 16 mg/l (R ), 
amoxicillin MIC <= 0,5 mg/l (S) and >= 2 mg/l (R); tetracycline MIC <= 2 mg/l (S) and >= 
8 mg/l (R ), and clarithromycin MIC <= 0,25 mg/l.(S) and >=1 mg/l (R))20.
Measurements with a Gaussian distribution were expressed at baseline as mean and 
SD, and measures with a non-Gaussian distribution were expressed as the median and 
interquartile range (IQR; expressed as the net result of 75th percentile –25th percentile). 
An additional analysis compared outcomes (presence of H. pylori aft er H. pylori eradica-
tion therapy or placebo) between stratum (patients on gastroprotective drugs (n=165) 
and not on gastroprotective drugs (n=182) by computing the homogeneity of the com-
mon odds ratio. SPSS soft ware (version 17.0.0) was used to perform these analyses. 
Diff erences in the proportions of patients with susceptible and resistant H. pylori strains 
and for compliant and non-compliant patients were analyzed with 95% conﬁ dence in-
terval using the Conﬁ dence Interval Analysis soft ware for Windows (version 2.2.0). The 
level of signiﬁ cance was set at P<0.05, two sided.
Results
A total of 347 patients consented to be randomly assigned to eradication therapy (172 
patients) or placebo (175 patients). Anti-H. pylori IgG antibodies were present in all pa-
tients (median titre 1689 (IQR 700-3732).The treatment groups were similar in terms 
of demographic, rheumatic disease, NSAID and other drug use. Our eligibility criteria 
resulted in a study group with mainly inﬂ ammatory rheumatic diseases (rheumatoid 
arthritis 61%, spondylarthropathy 8%, psoriatic arthritis 7%, osteoarthritis 9%, other 
15%). The most commonly used NSAIDs were diclofenac (29%), naproxen (18%), and 
ibuprofen (13%), most at full therapeutic doses (median relative daily dose 1 (IQR 0.5-1).
The mean age was 60 years (SD 10), 61% was female. Twenty-two patients had a known 
allergy for amoxicillin and received metronidazole instead (10 patients) or placebo (12 
patients).
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Of these 347 patients, data on culture and histology of 304 patients were available 
[Table 1]. In two cases only culture data were available and in 1 case only histology re-
sult was available all three cases met the criteria for H. pylori-positivity and were found 
in the placebo group, but for clarity purposes were left  out of [Table 1]. A total of 32 pa-
tients (with no signiﬁ cant diff erences between eradication and placebo groups) refused 
the 3-month endoscopy, withdrew informed consent, or could not undergo endoscopy 
because of adverse events. Seven patients used anticoagulant therapy ruling out biopsy 
sampling according the protocol, and in one patient no biopsy specimens could be ob-
tained because of discomfort requiring early completion of the procedure.
At follow-up aft er 3 months, 79% (120 /152; 95% CI 72-85%) of the patients in the 
placebo group were H. pylori-positive by histology or culture of biopsy specimen. In the 
eradication group, this number was 13% (20/152; 95% CI 9-20%) [Table 1].
Patients in the placebo group who were H. pylori negative at 3 months as assessed 
by culture and histology had signiﬁ cant lower titers of H. pylori anti IgG antibodies at 
baseline than those who were H. pylori culture- and or histology-positive (mean diff er-
ence -1582, 95% CI -2637 to -527, P=0.004). There were no diff erences between strata 
according to the use of gastroprotective drugs for the presence of H. pylori by culture 
and or histology (P=0.454).
Compliance was 89 % in patients in the eradication group and 98% in the placebo 
group with the assigned regimen (P<0.001). In the eradication group, H. pylori could not 
be demonstrated in 91% in patients with full compliance (n=136). In patients who did 
not take all 7 days of eradication therapy (n=16) H. pylori was found in 50% (diff erence of 
41%; 95% CI 18-63%). No diff erences were found in the placebo group.
Antibiotic resistance rates
A total of 105 clinical isolates of H. pylori were available for susceptibility testing (one 
isolate per patient; 95 isolates from the placebo group, 10 from the eradication group) 
from the 6 participating laboratories in The Netherlands. The rates of resistance are 
summarized in [Table 2].
Table 1 Results of culture and histology on H. pylori
Culture Histology
Eradication group (n=152) Placebo group (n=152)
Total patients, n=304 H. pylori positive H. pylori negative H. pylori positive H. pylori negative
H. pylori positive 10 (6%) 1 (1%) 89 (57%) 9 (6%)
H. pylori negative 9 (6%) 132 (87%) 22 (15%) 32 (21%)
serology driven er adication of h. py lori
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In the placebo group (n=95), resistance was found in 4% (4/95) to clarithromycin (MIC 
>= 1 mg/l), in 1% (1/95) and 2% (2/95) intermediate susceptibility to amoxicillin (MIC: 
1 mg/l) and tetracycline (MIC: 4 mg/l), respectively, and in 19% (18/95) resistance to 
metronidazole.
Amongst these 95 isolates 2 were resistant to metronidazole in combination with 
intermediate susceptible to tetracycline and one strain was resistant to metronidazole 
and clarithromycin. The placebo group had an MIC90 for clarithromycin of 0,085 mg/l, 
for metronidazole >256 mg/l, for tetracycline 0,341 mg/l and for amoxicillin 0,16 mg/l. 
One H. pylori strain was resistant to clarithromycin and metronidazole, and interme-
diate susceptible to tetracycline and amoxicillin. No diff erence was found in H. pylori 
resistance rates between man and women (P=0.217) or between patients who used 
gastroprotective agents and who did not (P=0.25). In the eradication group, 2 strains 
were resistant to clarithromycin and 3 to metronidazole. No strains were resistant to 
tetracycline or amoxicillin.
Conclusion and discussion
We report the results of a study on the effi  cacy of a test and treat strategy for H. pylori 
in rheumatology patients of the Netherlands who were positive for anti-H. pylori IgG-
antibodies. The main ﬁ ndings in the studied patient population were: (1) a 7-day PPI-
triple eradication therapy either with clarithromycin or metronidazole was effi  cacious 
with eradication rates of 87% (95% CI 80-91%) without prior testing for susceptibility of 
the infecting strain; (2) in 21% of the patients in the placebo group, the positive H. pylori 
serology test could not be conﬁ rmed by positive culture or histology. (3) compliance was 
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Table 2 Antibiotic resistance of H. pylori isolates
Resistance rate
Placebo group (n=95) Eradication group (n=10) 
Clarithromycin 4% 20%
Metronidazole 19 % 30%
Tetracyclin* 2% 0
Amoxicillin* 1% 0
All patients in the eradication group who were still H. pylori positive were assigned OAC and not OMC
* Intermediate susceptible.
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an important factor for successful eradication of H. pylori; (4) prevalence of antibiotic 
resistance in H. pylori was low.
The main reason for not performing endoscopy at baseline was that this was not 
feasible in everyday rheumatology practice, therefore serology was done to test for 
H. pylori. The reliability of serological kits for H. pylori infection has been widely con-
ﬁ rmed21, contributing to the reputation of serology as a simple, minimally invasive and 
inexpensive diagnostic and screening test. The best available serology test at the time 
of the study was the Pyloriset® an EIA-G from Orion Diagnostica, Espoo, Finland, with 
a speciﬁ city of 79-91% as assessed in previous studies in the Netherlands, including 
patients on acid suppressive th erapy22-24.This speciﬁ city correlates well with our ﬁ nding 
that in the placebo group, H. pylori could not be conﬁ rmed by culture or histology in 21% 
of the IgG positive patients. PPI usage (in this study 37% of the population) can result 
in false negative invasive and non-invasive diagnostic tests, such as culture, histology 
and13-C urea breath, and should be stopped two weeks before t esting25. This does not 
apply for serology. 13-C urea breath test have better accuracy (>90%), but the serology 
test used in this study was less expensive and in all study centres easily av ailable26. On 
the other hand we must not overlook that conditions during transport of biopsies are 
critical for successful isolation of H. pylori. Possibly, the antibacterial eff ect of NSAIDs, 
as has been suggested in in vitro studies, might also partly explain a false positive rate 
of serology of 21%27-29. However, in a randomized clinical trial of 122 patients, aspirin in 
combination with a standard 7-days course OAC eradication was not signiﬁ cantly dif-
ferent compared to the standard therapy. Based on culture and histology ﬁ ndings we 
conclude that one ﬁ ft h of our patients was treated superﬂ uously, with possible risk of 
side-eff ects of the eradication medication. Fortunately, both regimens were generally 
well  tolerated14,30.
Resistance to antibiotics in H. pylori is of particular concern because it is one of the 
major determinants in the failure of eradication regimens. Resistance rates for metro-
n idazole and clarithromycin found in this study were similar as previously observed in 
other studies in the Netherlands in the yea rs 1997-9810 an d 1997-200211, 12, 31, 32. To our 
knowledge, there are no recent data available on H. pylori antibiotic primary resistance 
rates in the Netherlands33. In addition, in this study, compliance played a crucial role in 
success of eradication of H. pylori: Treatment failure was as high as 50% in the non com-
pliant group of patients. Possibly, the high number of tablets that has to be consumed 
during H. pylori eradication therapy is a contributing factor for non-compliance in this 
group of elderly patients who were also on other medications.
In conclusion, serology driven test and treat strategy eradication of H. pylori with a 
7-day PPI-triple therapy is successful in the majority of patients. Success of eradication is, 
also in this group of rheumatology patients, to a great extent determined by compliance.
serology driven er adication of h. py lori
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Summary and discussion
chapter  9

As well as the presence of Helicobacter pylori (H. pylori), the use of non-steroidal anti-
inﬂ ammatory drugs (NSAIDs) is one of the major causes for gastroduodenal damage 
such as erosions, gastric and duodenal ulcers, and their complications perforations and 
haemorrhages, also called NSAID-gastropathy 1-3. Notorious was the silent ulcer that can 
present itself without prior warning as a life-threatening complication4. NSAIDs belong 
to the category of most frequently prescribed medicin s5-7 and are oft en prescribed by 
rheumatologists in patients with inﬂ ammatory rheumatic diseases, such as rheumatoid 
arthritis, gout, Bechterew’s disease and osteoarthritis. General practitioners, dentists 
and other specialists also prescribe NSAIDs frequently for joint pains and pains caused 
otherwise. Furthermore, these drugs are also frequently sold over-the-count er8, 9.
Risk factors for the occurrence NSAID-gastropathy are advanced age (especially from 
the age of 70), an ulcer, perforation or gastroduodenal haemorrhage in the prior medical 
history, co-occurrence of co-morbidity such as heart failure, serious rheumatoid arthri-
tis and diabetes mellitus or simultaneous use of anti-coagulants, acetylsalicylic acid, 
selective serotonin reuptake inhibitors (SSRIs) or corticostero ids10-14.
Several strategies which can prevent NSAID-induced gastroduodenal damage have 
been investigated and developed. Co-medication with so-called gastroprotective agents 
such as highly dosed histamine-2 (H2) receptor antagon ists15-17, proton pump inhibitors 
 (PPI)18-21 or prostaglandin analogues such as misop rostol22-26 has proven to be eff ect-
ive with regard to the prevention of endoscopic ulcers. Another proven strategy is the 
replacement of conventional or non-selective NSAIDs (nsNSAIDs) with more cyclooxy-
genase (COX)-2 selective NSAIDs (COXIBs) which are less toxic for the  stomach27-30. The 
background of this development is that the eff ect of NSAIDs is based on the inhibition 
of at least two isoforms of the enzyme cyclooxygenase (COX-1 and COX-2)31. It appeared 
that for the anti-inﬂ ammatory and analgesic eff ect of NSAIDs inhibition of the COX-2 re-
ceptor is responsible, while the major adverse eff ects in the gastrointestinal tract  occur 
via inhibition of the COX-1 receptors.
An alternative strategy which has been investigated is eradication of H. pylori. This is 
a Gram-negative bacterium32 which is frequently found in the stomach and which is a 
major causal factor for the development of gastroduodenal ulcers33, erosions and in-
ﬂ ammation of the stomach and gastric cancer (gastric carcinoma but also MALT l ym-
phoma)34, 35. The eradication of H. pylori accelerates the healing of ulcers and reduces 
recurrence of gastric and duodenal ulcers in non-NS AID users36, 37 and protects against 
the occurrence of gastric carcinoma38.
During the planning and at the start of the research projects which are described in this 
thesis, during the period 1996-2000, there was no consensus as to whether there is a 
form of synergism existing between H. pylori and NSAIDs for the development of gastro-
duodenal ulcers. Neither was there consensus regarding the question whether eradica-
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tion of H. pylori is useful for the prevention of gastroduod enal damage39-42. Proton pump 
inhibitors and H2-receptor antagonists were well available and at that time elaborate 
attention was paid to the prevention of NSAID-gastropathy. The ﬁ rst national ‘Guideline 
NSAID use and prevention of gastric damage’ by the Dutch Institute for Healthcare 
Improvement CBO was published in 200311. The ﬁ rst COXIBs were introduced on the 
Dutch market in 2000. In those days NSAID related gastroduodenal damage was a ma-
jor problem in both the practice of rheumatologists as well as in the practice of general 
practitioners.
In this thesis a number of studies is described which are mainly focussed on prevalence, 
diagnostics and the eff ect of eradication of H. pylori in patients using NSAIDs for an 
inﬂ ammatory rheumatic disease.
[Chapter 1] includes a general introduction into NSAIDs, H. pylori, NSAID-gastropathy 
and the outline this thesis.
In [Chapter 2] the prevalence of H. pylori in patients with rheumatic diseases and long-
term NSAID use is described. H. pylori can be demonstrated with the presence of IgG-
antibodies of H. pylori in the blood. In this study 39% of the 1214 patients with rheumatic 
diseases and long-term NSAID use was H. pylori positive aft er serological testing. The 
prevalence of IgG-antibodies of H. pylori increased with age (40-49 years: 25%, 50-59 
years: 39%, 60-69 years: 42% and 70-80 years: 48%). This eff ect can probably be as-
cribed to the cohort-eff ect: older people have higher infection rates because they were 
born in a time in which the risk of infection at a young age was higher than for those 
who were born later.
It is diffi  cult to compare prevalence rates and the composition of the patient popula-
tion, selection bias and the diagnostic test used to determine the presence of H. pylori 
have to be taken into account. In 1990 a study of a Dutch population of adults of com-
parable age showed a seroprevalence of H. p ylori of 49%43. A decrease in prevalence of 
H. pylori infection of 10% in 10 years is found which corresponds with the worldwide 
decrease as is described  in literature44. The causes mentioned for this decline include 
amongst others; the improved hygienic circumstances, decreasing family size and fre-
quent use of antibiotics. According to a Dutch study from 2008 carried out among an 
urban population, the prevalence of H. pylori is considerably higher in adults of non-
Dutch origin (65-96%) than in adults of Dutc h origin (46%)45. The decrease in prevalence 
of H. pylori has logically also led to a decrease in the occurrence of gastroduodenal 
ulcers associated with H. pylori46-49. Meanwhile the prevalence rates of H. pylori in the 
Netherlands appear to stabilize during the previous decades, as appears from a study 
in sequential birth cohorts of children from 1978,1993 and 2005 (at approximately 9% 
with an average  age of 8 years)50. The fact that the prevalence does not decrease any 
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further can be explained with the stabilisation in determinants of infections such as 
family size, living conditions and hygienic conditions, or compensation due to increased 
use of childcare and relative increase of children with parents of non-Dutch origin. This 
implicates that colonization with H. pylori will probably not completely disappear from 
the Dutch population during the years to come.
As a cost-eff ectiveness analysis was also planned for the treatment groups described in 
[Chapter 4], it ﬁ rstly had to be investigated what costs are incurred due to ulcer com-
plications such as haemorrhages and perforations. In the retrospective study described 
in [Chapter 3] the direct hospital costs were estimated for this purpose for 53 patients 
which were hospitalized during the period 1997 to 2000 in the VU university medical 
center, based on the hospital system and the costs claimed by insurance companies 
(from the payer’s perspective). This study included 53 patients who were hospitalized 
because of an ulcer haemorrhage (n=35), ulcer perforation (n=15) or both (n=3). The 
direct costs of ulcer complications were high; a haemorrhage and perforation occurring 
simultaneously was most expensive (€ 26,000), followed by a perforation (€ 19,000) and 
haemorrhage (€ 12,000). A haemorrhage in the duodenum incurred more costs than 
in the stomach (€ 13,000 versus € 10,000), while the reverse was seen in case of per-
forations (€ 13,000 versus € 21,000). Remarkable in this respect was that presence of 
comorbidity increased the costs substantially: even aft er correction for procedures not 
related to ulcer complication the costs were more than double compared to patients 
without comorbidity.
The generizability of the results of the costs analyses is possibly limited by a number 
of factors. Costs are not directly comparable between diff erent countries with similar 
levels of care. We have only estimated the direct medical costs of treatment of the ulcer 
complication from a healthcare perspective. Other costs which were not taken into con-
sideration are medical costs incurred outside of the hospital (for instance a visit to the 
general practitioner), direct non-medical costs (such as transport to the hospital) and 
indirect non-medical costs (such as absence due to illness). The costs were calculated 
in an university hospital and these costs may be higher than those made in peripheral 
hospitals. Shortly aft er our study another study was published which was carried out in 
a peripheral hospital, by Vonkeman et al., in which the direct costs of NSAID related ul-
cer complications were estimated with ﬁ gures from the period 2001-2003. Mean direct 
costs in this study were € 8,375 in 104 patients51. Other previ ous Dutch studies52,53 are 
also diffi  cult to compare because of other deﬁ nitions and methods. The ﬁ gures of the 
direct costs of an ulcer complication can be useful for a cost eff ectiveness analysis of 
for instance diff erent strategies for the prevention of ulcers and their complications. As 
no eff ect of the intervention as described in [Chapter 4] was detected, a subsequent 
cost eff ectiveness analysis has not been carried out. However, in the Netherlands as 
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well as abroad, such studies were indeed carried out and demonstrated that the use of 
gastroprotective agents and/or COXIBs are cost eff ective for the prevention of gastro-
duodenal damage and their complications, at least in groups with an increased risk for 
NSAID-associated gas troduodenal ulcers54-56.
[Chapter 4] describes a large, placebo-controlled and randomized multicenter study, 
the so-called HERA study (H. pylori Eradication in Rheumatoid Diseases) into the eff ect 
of eradication of H. pylori on the incidence of gastroduodenal damage in patients using 
NSAIDs. H. pylori positive (demonstrated by the presence of IgG-antibodies of H. pylori 
in the blood) patients with rheumatic diseases and long-term NSAID use, coming from 
rheumatology clinics in Utrecht, Enschede, Arnhem, Heerlen and Amsterdam, were ran-
domized to either the H. pylori eradication group and the placebo group. Patients in the 
eradication group received a combination of two antibiotics, amoxicillin and clarithro-
mycin, and a proton pump inhibitor (omeprazol) during one week. The placebo group 
received identical looking tablets without the active agent. At the start of the study the 
characteristics of the patient, data on the disease and concurrent drug treatment were 
collected. Aft er three and twelve months the eff ect of the study medication was evalu-
ated. Three months aft er the study medication, the patients underwent an endoscopy of 
the upper part of the gastrointestinal tract in order to score the presence of erosions and 
ulcers of the oesophagus, stomach and duodenum, gastritis and to take biopsy samples 
in order to assess whether H. pylori were still present. A patient was considered H. pylori 
negative when H. pylori could not be detected in the culture nor during histological 
assessment. The primary objective of the study was the presence of gastroduodenal ul-
cers at 3 months. Secondary objectives were the number of clinical manifest gastroduo-
denal ulcers, complications of ulcers (bleedings and perforations), dyspepsia and side 
eff ects. From May 2000 to June 2002, 2761 potential candidates were screened for IgG-
antibodies. From this group 1091 patients (40%) were H. pylori positive and ﬁ nally 347 
patients appeared to meet all the inclusion criteria of the study. A total of 172 patients 
were randomized in the eradication group and 175 patients in the placebo group. Aft er 
three months 315 patients underwent an endoscopy and 323 patients fully completed 
the study period of 12 months follow-up. The two treatment groups were similar with 
respect to base-line characteristics. They mainly consisted of women (60%), patients 
with rheumatoid arthritis (61%) with an mean age of 60 years, and 37 patients (11%) ever 
had a gastroduodenal ulcer before. The most frequently used NSAIDs were diclofenac 
(29%), naproxen (18%) and ibuprofen (13%). 48% of the patients used a gastroprotective 
agent together with a NSAID and 9% of the patients used a COXIB. A total of 53 % of the 
patients had received preventive treatment for NSAID related gastroduodenal damage, 
consisting of a gastroprotective agent and/or a COXIB. Some patients used a COXIB as 
well as a gastroprotective agent. Three months aft er randomization, gastroduodenal ul-
cers were found in 6 patients (4%) in the eradication group and in 8 patients (5%) in the 
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placebo group (not signiﬁ cantly diff erent, P=0,645). No single patient developed a clini-
cal manifest gastroduodenal ulcer (established during endoscopy aft er complaints), or 
an ulcer complication during the follow-up of 12 months. The scores for upper abdomi-
nal discomfort did not diff er between both treatment groups (P=0,98). In the eradication 
group 35 of the 172 (20%) patients reported side eff ects of the study medication and 4 
of the 175 (2%) patients in the placebo group (P<0.001). The most important conclusions 
of this study were: (1) Eradication of H. pylori did not have an eff ect on the incidence 
of gastroduodenal damage in patients with rheumatic diseases and long-term use of 
NSAIDs, (2) The number of gastroduodenal ulcers and complications is remarkably low 
in patients with as well without gastroprotective agents.
The relation between H. pylori infection and NSAID use in gastroduodenal mucosal 
damage is complex. The mechanisms of the development of an ulcer are partly diff erent 
for H . pylori and NSAIDs57. H. pylori induced ulcers depend on abnormalities in the regu-
lation of gastric acid and on the inﬁ ltration of inﬂ ammatory cells in the gastric mucosa 
with the release of cytokines, leading to mucosal damage58. NSAIDs have a direct toxic 
eff ect on gastroduodenal mucosa and reduce mucosal blood ﬂ ow, which results in loss 
of protective mechanisms ag ainst mucosal damage57.
During the past years many clinical studies have been published in the literature, which 
have tried to elucidate the interaction between H. pylori and NSAIDs. In a meta-analysis 
with 25 studies H. pylori as well as NSAIDs independently and signiﬁ cantly increase the 
risk of a gastroduodenal ulcer and associated haemorrhage. The risk of an ulcer bleeding 
was 1,8 and 4,9 times higher, respectively, and the risk appeared to be 6,1 higher if both 
risk factors were present59.
In practice the clinician wants to know especially whether testing and treatment of 
H. pylori in patients who are taking or will be taking NSAID is useful for prevention of the 
risk of development of an ulcer and, even more important, its complications. The results 
of clinical trials with H. pylori eradication in NSAID users do not provide an unambiguous 
outcome.
In 2005 and 2012 two meta-analyses were carried out in wh ich respective ly ﬁ ve60-64 and 
seven60-66 eradication trials were analysed in which the eff ect of H. pylori eradication 
was investigated i n patients using NSAIDs67, 68. They both demonstrated that H. pylori 
eradication obviously reduces the risk of ulcers in the total group. Sub-analyses of these 
studies show a clear eff ect of H. pylori eradication in NSAID-naive patients but that does 
not apply to patients with long-term use of NSAIDs. H. pylori eradication in starters 
with NSAIDs is oft en not feasible in practice. In rheumatologic practice many patients 
have for instance already started using NSAIDs. Furthermore is it not practical and ethi-
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cal to wait for H. pylori diagnosis and eradication before starting NSAID when patients 
are in serious pain. Furthermore, in sub-analysis studies from the West less eff ect was 
seen than in studies of Asian populations. There are two studies which have compared 
H. pylori eradication directly with P PI maintenance therapy63, 69. A clear advantage appears 
to exist for PPI when compared to H. pylori eradication when the results of these studies are 
an alysed in a meta-analysis67. In the second meta-analysis the study described in this thesis 
was one of the studies with the largest numbers of patients. Our ﬁ ndings are in line with the 
ﬁ nd ings of the other studies 61, 64, 66 and the sub-ana lysis of both meta-analyses67, 68 with no 
beneﬁ t of eradication of H. pylori in long-term NSAID users.
A possible explanation for the fact that H. pylori eradication is indeed eff ective in NSAID-
naive patients and not in patients with long-term NSAID use is that the risk of ulcer 
complications is highest during the ﬁ rst year of NSAID use70 even though the risk re-
mains during the full term of use. Because of that, many patients with the highest risk 
may already have stopped using NSAID (aft er ulcer complications or complaints) and 
are therefore not included in studies with long-term NSAID use. The studies with long-
term NSAID users include patients with lower ulcer risks. The absolute risk reduction 
achieved with H. pylori eradication depends on the baseline risk and therefore it is dif-
ﬁ cult to demonstrate an eff ect in this population with low ulcer risk (for instance only 
with large sample size, type II error). Of course one may wonder whether there is any 
clinical relevance when very large sample sizes are required.
In case of secondary prevention of gastroduodenal ulcers (patients who already have 
a gastroduodenal ulcer) in long-term NSAID users, Hawkey et al. demonstrated that 
H. pylori eradication is not better than a PPI alone for the prevention of a recurrence 
aft er 6 months61. In a meta-analysis H. pylori eradication did however have a positive ef-
fect on the prevention of a r ecurrent gastroduodenal ulcer67. It is therefore not diffi  cult 
to understand that the current guidelines recommend to test and treat patients with an 
ulcer for H. pylori independently of NSAID use and give a maintenance treatment with 
PPI to pati ents with prolonged NSAIDs use38, 71, 72.
A limitation of all studies, including the studies described in this thesis, is the limited 
follow-up. Most studies only gave short-term data: varying from 1 to 6 months, with 
outliers to 1 year. (In the studies included in this thesis there is an endoscopic follow-up 
of 3 months and a clinical follow-up of 1 year.) Eradication of H. pylori is indeed a per-
manent intervention as the risk of re-infection is very small73 and it is expected that this 
eff ect persists, but the long-term eff ect (later development of gastroduodenal ulcers) is 
not known in patients with long-term NSAID use.
A remarkable ﬁ nding in [Chapter 4] was that in patients with as well without gastro-
protective agents the number of gastroduodenal ulcers and complications is remarkably 
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low (4%) compared to other clinical trials for prevention of NSAI D related gastroduode-
nal damage22, 74. A possible explanation for this is that the study population truly repre-
sents the daily practice of patients who had a higher (aspirin) or lower (gastroprotective 
agent or COXIB) risk of NSAID-gastropathy due to co-medication. This has resulted in a 
study population of which half of the patients used a gastroprotective agent and/or a 
COXIB. The extent of the morbidity of NSAID related gastroduodenal damage is smaller 
than before. This is in accordance with  data from both the Unite d States75 as from the 
Nederlands76, 77, which shows a decreasing incidence of NSAID-gastropathy in a popula-
tion of patients with rheumatic diseases. One of the explanations for this is that this 
population uses considerably less nsNSAIDs, partly due to replacement by COXIBs, but 
it is more likely that the use of NSAIDs was less needed because the rheumatic diseases 
are treated better and more intensively than in the past due to the use of so-called bio-
logicals and improved treatment strategies78.
The ulcer incidence was so low in this population of long-term NSAID users with 
rheumatic disease that further improvement with H. pylori eradication will be limited so 
that it no longer forms a major clinical relevant problem but a more theoretical problem 
instead.
In the study set out above, the eff ect of H. pylori eradication on the histology of the 
gastric mucosa was also studied and is described in [Chapter 5]. For this study all bi-
opsies taken in the context of the study described in [Chapter 4] were scored histologi-
cally in a hematoxylin eosin staining according to the updated Sydney classiﬁ cation for 
active and chronic inﬂ ammation, presence of glandular atrophy, intestinal metaplasia 
and H. pylori density. Biopsies from 305 patients were available for histological scoring. 
The group which had received H. pylori eradication showed signiﬁ cantly less active and 
chronic inﬂ ammation in the gastric corpus as well as in the gastric antrum even though 
the use of NSAIDs was continued. In the corpus and antrum a moderate to serious 
acute inﬂ ammation was noted in 4% and 3%, respectively, in de eradication group and 
35% and 27%, respectively, in the placebo group (P<0,001). Moderate to serious chronic 
inﬂ ammation was found in corpus and antrum in 28% and 51%, respectively, in the 
eradication group and 65% and 76%, respectively, in the placebo group. Furthermore 
the corpus showed considerably less moderate to serious atrophy in the eradication 
group (10%) when compared to the placebo group (22%, P=0,006). No diff erences were 
found with respect to intestinal metaplasia and atrophy.
It has been known for a long time that active and chronic inﬂ ammations in non-NSAID 
users improv e aft er eradication of H. pylori79-81. Now this is also described in a large 
group of NSAID users. These ﬁ ndings are remarkable because endoscopically no dif-
ferences were found between both groups [Chapter 4] with regard to the prevention 
of ulcers and erosions. A relation is described between the degree of inﬂ ammation in 
histological assessment and the risk of gastroduode nal ulcers in long term NSAID us-
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ers82. This could support the hypothesis that H. pylori eradication could (help) prevent 
NSAID-gastropathy.
As our population consisted of NSAIDs users only we could make no assertions con-
cerning the eff ect of NSAIDs on the extend of histological abnormalities. Furthermore, 
this study showed a greater eff ect of H. pylori eradication in patients using gastropro-
tective agents than in long-term NSAID users without gastroprotective agents as far as 
the prevention of the chronic inﬂ ammation in the corpus was concerned. It has been 
demonstrated that long term PPI use extends a H. pylori associated gastritis of espe-
cially the antrum to a corpus predominant gastritis. This is associated with accelerated 
progression into atrophic gastritis83, which is a premalignant change. There is no evi-
dence indicating that H. pylori eradication in this group prevents the development of 
gastric cancer but there are studies which show that gastric cancer is more frequently 
seen in patients with PPI84. Probably this involves ‘confounding by indication’ but a re-
cent European guideline (2012) recommends to consider H. pylori eradication for pa-
tients with long-term use of gastroprotective agents (> 1 year) in order to prevent gastric 
carcinoma38. As yet more research has to be carried out in order to support a test and 
treatment strategy of H. pylori for all patients with or without NSAIDs for the purpose of 
preventing gastric carcinoma.
In [Chapter 6] a post hoc analysis is described of the clinically randomised trial as de-
scribed in [Chapter 4]. In this post-hoc analysis patients with and without gastric ulcers 
were compared with the use of COX-2 selective and nsNSAIDs and with other possible 
confounders for the occurrence of ulcers. Of the 301 patients undergoing endoscopy, 
6 (4%) patients in the eradication group and 8 (5%) patients in the placebo group had 
an ulcer (P=0,65). None (0%) of the patients with a gastric or duodenal ulcer and 80 
(28%) patients without ulcer used selective NSAIDs (P=0,02). Patients with an ulcer sig-
niﬁ cantly more frequently used concomitant low dose aspirin than patients without 
gastroduodenal ulcer: 4 (29%) patients in the ulcer group versus 27 (9%) in patients 
without ulcer (P=0,02). No diff erences were found with regard to the use of PPI, H2 
receptor antagonists and prostaglandin analogues between patients with or without 
gastric or duodenal ulcer (P=0,48). As in many other studies, this study also involved use 
of COX-2 selective NSAIDs associated with a lower ulcer risk than the use of nsNSAIDs. 
Because of the small numbers of ulcers no assertions could be made on the diff erence 
in the eff ect of H. pylori eradication for nsNSAID and selective NSAID users, but H. pylori 
eradication does not seem to reduce the risk any further. At the time of the start of this 
study, the COXIBs, rofecoxib and celecoxib were just introduced in the Netherlands and 
were then relatively infrequently used in the study population (7% and 1%, respectively). 
In this study the more COX-2 speciﬁ c NSAIDs (with a less strong eff ect on the COX-2-re-
ceptor than COXIBs) such as nabumetone and meloxicam were more frequently used 
(11% and 6%) and categorized in the group of COX-2-selective NSAIDs.
ch apter 9
123
Chapters seven and eight describe the value of diagnostic tests aft er a H. pylori eradica-
tion such as serology, culture and histology and the effi  ciency of the followed test and 
treatment strategy. [Chapter 7] presents a post-hoc analysis of a randomized clinical 
study of H. pylori positive patients with long-term NSAID use because of rheumatic 
diseases, in which is investigated how a persisting H. pylori infection or successful eradi-
cation aft er therapy can best be determined. In this clinical study H. pylori was estab-
lished by means of serological testing for anti-H. pylori IgG-antibodies. H. pylori positive 
patients were randomized for eradication triple therapy or placebo with endoscopy and 
serology aft er 3 months and serology again aft er 12 months. In the post hoc analysis 
we compared repeated H. pylori antibody titres, hematoxylin and eosin (H&E) staining, 
immunohistochemical (IHC) staining of biopsies and culture of H. pylori in biopsies of 
all patients, in order to establish the sensitivity and speciﬁ city of these diff erent de-
tection methods. Furthermore, we determined whether the addition of IHC staining 
to H&E staining improves the histological detection of H. pylori in these patients. In 
accordance with the gold standard criteria, existing of either a positive culture or both 
a positive histological test as well as a positive serological test, H. pylori eradication 
therapy was successful in 90% of the patients. Cultures provided 100% sensitivity but 
speciﬁ city was 82% and 73% aft er eradication. Histological testing with H&E or IHC 
staining gave a sensitivity and speciﬁ city between 93% and 99%. Addition of IHC did 
not improve results. Furthermore, receiver operating characteristics (ROC) curves of the 
repeated serologic test results were calculated. The ROC curve for per cent change of 
H. pylori IgG antibody titers had a better diagnostic power for identiﬁ cation of H. pylori 
negative patients than the absolute changes in titres. The optimal cut-off  point in these 
ROC curves was 21% decrease aft er 3 months and 58% decrease aft er 12 months, cor-
responding with a sensitivity of 64% and 87%, respectively, and a speciﬁ city of 81% and 
74%, respectively. These ﬁ gures are not ideal and currently serology does no longer play 
a role in the conﬁ rmation of H. pylori eradication, and urea breath tests or stool antigen 
tes ts are better non-invasive alternatives38. However, in case of an indication for follow 
up endoscopy, then biopsy-based techniques such as culture and histological testing 
are go od methods for checking H. pylori status38. [Chapter 8] describes the effi  cacy of 
a serology driven ‘test and treatment strategy’ of H. pylori in patients with a rheumatic 
disease and long-term NSAID use. In the Netherlands the ﬁ rst choice of eradication 
treatment of H. pylori consists of a 7-day triple-therapy with a PPI, amoxicillin and clar-
ithromycin or metronidazole. This study, which was carried out from 2000 to 2002, was 
part of the national, multicenter randomized study described in [Chapter 4]. Patients 
were screened with serology for H. pylori IgG antibodies and, if they were found to be 
positive, they were included in the study and randomized for either eradication therapy 
or placebo. Aft er 3 months follow-up an endoscopy was carried out during which bi-
opsies were taken from the gastric antrum and corpus. On the hand of culture and 
histological testing these biopsies were tested for the presence of H. pylori. The main 
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conclusions of this study were: ﬁ rstly that a 7-day PPI-based triple eradication therapy 
was adequate in 87% of the patients without prior antibiotic susceptibility testing. Sec-
ondly, for 21% in the placebo group, the positive H. pylori serology could not be con-
ﬁ rmed by the presence of H. pylori in culture and histology and that implicates that pos-
sibly one ﬁ ft h has received unnecessary eradication therapy. Thirdly, compliance was a 
very important factor for successful eradication of H. pylori. H. pylori was successfully 
eradicated in 91% of the patients who were fully compliant with the study medication, 
compared to 50% of those who were not (diff erence of 41%; 95% CI 18-63%). Finally, the 
prevalence of antibiotic resistance in H. pylori was very low. The resistance percentages 
found in the isolated strains of the placebo group were, 4% for clarithromycin, 19% for 
metronidazole, 1% for amoxicillin and 2% for tetracycline. Resistance to antibiotics in 
H. pylori is of importance because resistance may play a major role in therapy failure. 
The antibiotic resistant percentages for metronidazole and clarithromycin in this popu-
lation are virtually just as low as in other studies carried out in t he Netherlands  during 
the years 1997-199885 and 1997-200286-90. As far as known, there are no more recent 
data of primary H. pylori  resistance to antibiotics in the Nederlands91, 92. Therefore it can 
be advocated to start with standard triple therapy (PPI-claritromycine and amoxicillin) 
without prior susceptibility testing.
The studies in [Chapter 7 and 8] have the limitation that no baseline endoscopy has 
been carried out but only 3 months aft er eradication. At that time, serology was chosen 
as baseline H. pylori test. The main reasons were that invasive endoscopy was not feasi-
ble in the daily rheumatologic practice for non-symptomatic patients, and that serology, 
as inexpensive and commonly available alternative, had pos itive results in several vali-
dation studies.93-96 The use of PPI (37% of the population in this study) can provide false 
negative results aft er invasive as well as non-invasive tests, such as culture, histology, 
urea breath test and also stool antigen test, and should therefore  be discontinued at 
least two weeks in advance97. Furthermore, in a population with long-term NSAID use, 
discontinuation of PPI for study purposes is unethical. At the time this study started 
H. pylori stool antigen tests were not available yet.
Conclusion
During the ﬁ rst half of the 20th century the incidence of gastroduodenal ulcers became 
epidemic98. Since then, new insights and medical innovations have led to enormous im-
provements in treatment of gastroduodenal ulcers and not only the morbidity has de-
creased considerably but the mortality has also decreased with 75% since the nineteen 
eighties98. This reduction can be explained by several factors, in the general population 
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as well as in the rheumatologic population: the discovery of H. pylori and its eradica-
tion, subsequently the gradual decline of the prevalence of H. pylori, introduction of 
acid inhibiting drugs such as H2-receptor antagonists and PPI (in the late seventies 
and eighties), the introduction of diagnostic and therapeutic endoscopy, development of 
guidelines for prevention of NSAID related gastroduodenal damage (in the Netherlands 
in 2003) and the introduction of COXIBs (early 2000), and speciﬁ cally for the rheumato-
logic practice: more intensive and better treatment of inﬂ ammatory rheumatic diseases 
due to which NSAIDs as analgesic is less needed.
During the past years, several studies were published in which H. pylori eradication in 
NSAID users was examined. Eradication of H. pylori seems to be useful when preceding 
NSAID use but in practice this is not or hardly feasible. Patients with many symptoms do 
not want to wait starting with NSAID in order to undergo H. pylori diagnostics and eradi-
cation ﬁ rst. In long-term NSAID users it is not useful to eradicate H. pylori in order to 
prevent gastroduodenal ulcers and its complications, as our study also demonstrated. 
An explanation for the diff erence in eff ect of H. pylori between NSAID naive patients and 
long-term NSAID users is that the risk of ulcers is so very low in patients who tolerate 
NSAIDs on a long term that H. pylori eradication cannot further reduce that risk. This 
was conﬁ rmed by our study: gastroduodenal ulcers were very rare in this population of 
long-term NSAID users with rheumatic disease. Therefore the presence of H. pylori in 
long-term NSAID users is no longer a major clinically relevant problem, but a theoretical 
problem instead. Our study provides little support for the active detection of a H. pylori 
infection in patients with rheumatic diseases and NSAID use. This balance is even less 
favourable when the prevalence of H. pylori is further declining.
Studies examining the eff ects on NSAID related gastroduodenal ulcers are oft en dif-
ﬁ cult to be carried out given the need for hard endpoints such as endoscopically con-
ﬁ rmed lesions. In order to demonstrate an eff ect of intervention or diff erence between 
comparative groups it is oft en necessary to include large numbers of patients in mul-
ticenter studies. However, there are several reasons why NSAID related complications 
still require attention. The adherenc e to the existing guidelines is far from ideal99. It is 
expected that, contrary to the rheumatologic practice in which NSAID use has been 
reduced due to better treatment of the inﬂ ammatory rheumatic diseases, the use of 
NSAID in the general population for musculoskeletal disorders will yet increase due 
to the ageing. In recent years it has become apparent that the guidelines itself are no 
longer completely up-to-date. For instance, there are side-eff ects of NSAIDs aff ecting 
the lower gastrointestinal tract, which may be inﬂ uenc ed by COXIBs but not by gastro-
protective agents30 and when choosing NSAID or COXIB and/or gastroprotective agent 
the cardiova scular risk proﬁ le should be taken into account100-102.
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helicobac ter p ylori  en non-steroidal anti-infl ammatory drugs 
bij  patiënten met reumatische a andoeningen
chapter  10

Naast de aanwezigheid van Helicobacter pylori (H. pylori), is het gebruik van non-steroidal 
anti-inﬂ ammatory drugs (NSAIDs) één van de belangrijkste oorzaken van gastro-duode-
nale schade in de vorm van maag- en darmulcera (zweren), erosies en hun complicaties 
zoals perforaties en bloedingen, ook wel NSAID-gastropathie genoemd 1-3. Berucht was 
het stille ulcus dat zich zonder waarschuwing kan presenteren als een levensbedrei-
gende complicatie4. NSAIDs behoren tot de meest voorgeschreven geneesmiddele n5-7 
en worden vaak voorgeschreven door reumatologen aan patiënten met inﬂ ammatoire 
reumatische aandoeningen, zoals chronisch gewrichtsreuma (reumatoïde artritis), jicht, 
de ziekte van Bechterew en artrose. Ook huisartsen, tandartsen en andere specialisten 
schrijven veelvuldig NSAIDs voor vanwege gewrichtspijnen en pijn door andere oorza-
ken. Daarnaast worden deze medicijnen veelvuldig over-the-counter verkoc ht8, 9.
Risicofactoren voor het optreden van gastro-intestinale complicaties van NSAID ge-
bruik zijn; een hogere leeft ijd (vooral vanaf 70 jaar), een ulcus, perforatie of gastro-intes-
tinale bloeding in de voorgeschiedenis, het tegelijkertijd voorkomen van co-morbiditeit 
zoals hartfalen, ernstige reumatoïde artritis en diabetes mellitus of gelijktijdig gebruik 
van anti-coagulantia, acetylsalicylzuur, selectieve serotonine opname remmers (SSRIs) 
of corticosteroi den10-14.
Meerdere strategieën zijn onderzocht en ontwikkeld die NSAID-gerelateerde maag- 
en darmschade kunnen voorkomen. Co-medicatie met zogeheten maagbeschermers 
zoals hoog gedoseerde histamine-2 (H2) receptorantagoni sten15-17, protonpomprem-
mers  (PPI)18-21 of prostaglandine analogen zoals misop rostol22-26 heeft  bewezen werk-
zaam te zijn ter preventie van endoscopische ulcera. Een andere bewezen strategie is 
het vervangen van klassieke of niet selectieve NSAIDs (nsNSAIDs) door meer cyclo-oxy-
genase- (COX)-2 selectieve NSAIDs (COXIBs) die minder toxisch voor de ma ag zijn27-30. 
De achtergrond van deze ontwikkeling is dat de werking van NSAIDs berust op remming 
van tenminste twee iso-vormen van het enzym cyclo-oxygenase (COX-1 en COX-2)31. Het 
is gebleken dat het ontstekingsremmende en analgetische eff ect van NSAIDs aangrijpt 
via de COX-2 receptor, terwijl de belangrijkste bijwerkingen in het maagdarmkanaal op-
treden via remming van de COX-1 receptoren.
Een alternatieve strategie die onderzocht is, is eradicatie van H. pylori die eventueel 
aanwezig is. Dit is een Gram-negatieve bacterie32 die vaak voorkomt in de maag en een 
belangrijke oorzakelijke factor is bij het ontstaan van maagzweren33, erosies en ontste-
king van de maag en maagkanker (maagcarcinoom maar ook MALT  lymfoom)34, 35. Het 
eradiceren van H. pylori versnelt het genezen van ulcera, vermindert recidiveren van 
maag- en darmulcera bij non-NSAID g ebruikers36, 37 en beschermt tegen het optreden 
van maa gcarcinoom38.
Tijdens het ontwerp en bij aanvang van de onderzoeksprojecten in de periode 1996-
2000, die beschreven staan in dit proefschrift  was er geen consensus of er synergisme 
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tussen H. pylori en NSAIDs bestaat voor het ontstaan van gastro-duodenale ulcera. Er 
was ook geen consensus over de vraag of eradicatie van H. pylori zin heeft  om gastro-
duodenale schade t e voorkomen39-42. Protonpompremmers en H2-receptorantagonis-
ten waren goed beschikbaar en in die tijd werd er ruim aandacht besteed aan preven-
tie van NSAID-gastropathie. De eerste landelijke ‘Richtlijn NSAID-gebruik en preventie 
van maagschade’ door Kwaliteitsinstituut voor de Gezondheidszorg CBO verscheen in 
200311. De eerste COXIBs zijn in 2000 op de Nederlandse markt geïntroduceerd. NSAID-
gerelateerde maag- en darmschade was in die tijd in zowel de reumatologische praktijk 
als in de huisartsenpraktijk een belangrijk probleem.
In dit proefschrift  wordt een aantal onderzoeken beschreven die zich vooral richten op 
prevalentie, diagnostiek en eff ect van eradicatie van H. pylori bij patiënten die NSAIDs 
gebruiken in verband met een inﬂ ammatoire reumatische aandoening.
In [Hoofdstuk 1] wordt een algemene inleiding gegeven over NSAIDs, H. pylori, NSAID-
gastropathie en de aanleiding voor het onderzoek dat verder in het proefschrift  is be-
schreven.
In [Hoofdstuk 2] wordt de prevalentie van H. pylori bij patiënten met reumatische aan-
doeningen en chronisch NSAID gebruik beschreven. H. pylori kan worden aangetoond 
door de aanwezigheid van IgG-antilichamen van H. pylori in het bloed. In dit onderzoek 
was 39% van de 1214 patiënten met reumatische aandoeningen en chronisch NSAID 
gebruik H. pylori positief bij serologisch onderzoek. De prevalentie van IgG-antilichamen 
van H. pylori nam toe met de leeft ijd (40-49 jaar: 25%, 50-59 jaar: 39%, 60-69 jaar: 42% 
en 70-80 jaar: 48%). Dit eff ect is meest waarschijnlijk toe te schrijven aan het cohort-
eff ect: ouderen hebben een hogere infectieprevalentie omdat ze geboren zijn in een tijd 
waarin de infectiekans op jeugdige leeft ijd hoger is dan bij diegenen die later geboren 
zijn.
Het is lastig prevalentiecijfers te vergelijken en om H. pylori vast te stellen moet 
er rekening gehouden worden met de samenstelling van de patiëntenpopulatie, selec-
tie bias, en de gebruikte diagnostiek. Een studie in 1990 in een Nederlandse populatie 
van volwassenen van vergelijkbare leeft ijd met die van onze studiepopulatie liet een 
seroprevalentie van H. pylori  zien van 49%43. Er wordt een daling van prevalentie van 
H. pylori infectie van 10% in 10 jaar gevonden die overeenkomt met de wereldwijde 
daling zoals vermeld wordt in  de literatuur44. Genoemde oorzaken hiervoor zijn onder 
andere de verbeterde hygiënische omstandigheden, dalende gezinsgrootte en veelvul-
dig gebruik van antibioticakuren. In een Nederlands onderzoek uit 2008 onder stedelijke 
bevolking ligt de prevalentie van H. pylori duidelijk hoger onder volwassenen van niet-
Nederlandse origine (65-96%) dan onder volwassenen van Nederlandse origine (46%)45. 
De afnemende prevalentie van H. pylori heeft  logischerwijs ook geleid tot het afnemen 
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van het voorkomen van H. pylori geassocieerde gastro-d uodenale ulcera46-49. Inmiddels 
lijken de prevalentiecijfers van H. pylori de laatste 10 jaar in Nederland te stabiliseren 
rond de 9%, blijkend uit een onderzoek van sequentiële geboortecohorten bij kinderen 
(met een gemiddelde leeft ijd van 8 jaar) uit 1 978,1993 en 200550 Het niet verder dalen 
van de prevalentie kan verklaard worden door stabilisatie in determinanten van infectie 
zoals gezinsgrootte, leefomstandigheden en hygiënische condities, dan wel compensa-
tie door toename van kinderopvang en relatieve toename van het aantal kinderen van 
ouders van niet-Nederlands origine. Dit impliceert dat kolonisatie met H. pylori de ko-
mende jaren waarschijnlijk niet helemaal uit de Nederlandse populatie zal verdwijnen.
Omdat er bij het in [Hoofdstuk 4] beschreven onderzoek ook een kosteneff ectiviteits-
analyse voor de verschillende behandelarmen was gepland, moest eerst onderzocht 
worden wat de kosten zijn van de ulcuscomplicaties zoals bloedingen en perforaties. 
Hiervoor werden, in het in [Hoofdstuk 3] beschreven retrospectieve onderzoek, de di-
recte ziekenhuiskosten geschat bij 53 patiënten die opgenomen waren in de periode 
1997 tot 2000 in het VU medisch centrum aan de hand van het ziekenhuissysteem en 
de door de verzekering geclaimde kosten (vanuit het perspectief van de betaler). In deze 
studie werden 53 patiënten geïncludeerd die opgenomen waren vanwege een ulcus-
bloeding (n=35), ulcusperforatie (n=15) of beide (n=3). De kosten van ulcuscomplicaties 
waren hoog; een simultane bloeding en perforatie was het meest kostbaar (€ 26.000), 
gevolgd door perforatie (€ 19.000) en bloeding (€ 12,000). Een bloeding het duodenum 
was duurder dan in de maag (€ 13.000 versus € 10.000), terwijl het omgekeerde te zien 
was voor perforaties (€ 13.000 versus € 21.000). Opvallend daarbij was de aanwezigheid 
van comorbiditeit die de kosten substantieel deed stijgen: zelfs na correctie voor proce-
dures die niet gerelateerd waren aan een ulcuscomplicatie waren de kosten meer dan 
het dubbele van de kosten bij patiënten zonder comorbiditeit.
De generaliseerbaarheid van de resultaten van kostenanalyses wordt mogelijk beperkt 
door een aantal factoren. Kosten zijn niet direct vergelijkbaar tussen verschillende lan-
den. Wij hebben alleen de directe medische kosten van behandeling van ulcuscomplica-
tie geschat vanuit een gezondheidszorgperspectief. Andere kosten die buiten beschou-
wing zijn gelaten zijn extramurale directe medische kosten (zoals bezoek huisarts), 
directe niet-medische kosten (zoals vervoer naar ziekenhuis) en indirecte niet-medische 
kosten (zoals ziekteverzuim). De kosten werden berekend in een universitair ziekenhuis 
en mogelijk zijn deze hoger dan de kosten die gemaakt worden in perifere ziekenhuizen. 
Kort na onze studie is er nog een studie verschenen verricht in een perifeer ziekenhuis 
door Vonkeman et al., waarin de directe kosten van NSAID-gerelateerde ulcuscompli-
caties werd geschat met getallen uit periode 2001-2003. Gemiddelde directe kosten in 
deze studie waren € 8.375 bij 104 patiënten51. Andere eerdere Ne derlandse studies52, 53 
zijn ook lastig te vergelijken door hantering van andere deﬁ nities en methoden. De getal-
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len van directe kosten van een ulcus complicatie zijn van nut bij een kosteneff ectivi-
teitsanalyse van bijvoorbeeld verschillende strategieën om ulcera en hun complicaties 
te voorkomen. Aangezien er geen eff ect van de interventie zoals beschreven in [Hoofd-
stuk 4] werd gezien is er niet aansluitend een kosteneff ectiviteitsanalyse verricht. Wel 
zijn er zowel in Nederland als in het buitenland dergelijke onderzoeken verricht waaruit 
blijkt dat het gebruik van maagbeschermers en/of COXIBs om gastro-duodenale schade 
en complicaties te voorkomen kosteneff ectief zijn, tenminste in groepen met verhoogd 
risico op NSAID-geassocieerde gastr o-duodenale ulcera54-56.
[Hoofdstuk 4] beschrijft  een grote, placebo gecontroleerde en gerandomiseerde mul-
ticenter studie, de zogenoemde HERA studie (H. pylori Eradicatie bij Reumatisch Aan-
doeningen) naar het eff ect van eradicatie van H. pylori op de incidentie van maag- en 
darmschade bij patiënten die NSAIDs gebruiken. H. pylori positieve (aangetoond door 
de aanwezigheid van IgG-antilichamen van H. pylori in het bloed) patiënten met reu-
matische aandoeningen en chronisch NSAID gebruik, afk omstig uit reumatologie poli-
klinieken in Utrecht, Enschede, Arnhem, Heerlen en Amsterdam, werden ingedeeld in 
twee groepen, de H. pylori eradicatiegroep en de placebogroep. Patiënten in de eradi-
catiegroep kregen een combinatie van twee antibiotica, amoxicilline en claritromycine, 
en een maagbeschermer (omeprazol) gedurende één week. De placebogroep ontving 
identiek uitziende tabletten, echter zonder het werkzame middel. Bij het begin van de 
studie werden de karakteristieken van de patiënt en de ziekte, en de medicatie verza-
meld. Na drie en twaalf maanden werd het eff ect van de studiemedicatie geëvalueerd. 
Drie maanden na de start van de studiemedicatie ondergingen de patiënten een maag-
onderzoek (gastroscopie) om het aantal beschadigingen (ontstekingen en erosies) en 
ulcera van de slokdarm (oesophagus), maag en twaalfvingerige darm (duodenum) te 
scoren en te beoordelen of er nog H. pylori aanwezig was. Een patiënt werd beschouwd 
als H. pylori negatief wanneer zowel in de kweek alsook bij histologische beoordeling 
H. pylori niet aantoonbaar was. De belangrijkste uitkomstmaat van de studie was de 
aanwezigheid van gastro-intestinale ulcera op 3 maanden. Secundaire uitkomstmaten 
waren het aantal klinisch manifeste gastro-intestinale ulcera, complicaties van ulcera 
(bloedingen en perforaties), dyspepsie en bijwerkingen. Tussen mei 2000 en juni 2002 
werden 2761 potentiële kandidaten gescreend op IgG-antilichamen. Hiervan waren 1091 
patiënten (40%) H. pylori positief en uiteindelijk bleken 347 patiënten te voldoen aan 
alle inclusiecriteria van de studie. In totaal werden 172 patiënten gerandomiseerd in 
de eradicatiegroep en 175 patiënten in de placebogroep. Na 3 maanden ondergingen 
315 patiënten een gastroscopie en 323 patiënten hebben de studietijd van 12 maanden 
follow-up volledig doorlopen. De patiënten in de twee groepen kwamen qua karakte-
ristieken overeen. Het betrof vooral vrouwen (60%), patiënten met reumatoïde arthritis 
(61%) met een gemiddelde leeft ijd van 60 jaar, en 37 patiënten (11%) hadden ooit eer-
der een gastro-intestinaal ulcus gehad. De meest gebruikte NSAIDs waren diclofenac 
hoofdstuk 10
139
(29%), naproxen (18%) en ibuprofen (13%). Door 48% van de patiënten werd een maag-
beschermer in combinatie met een NSAID gebruikt en 9% van de patiënten gebruik-
te een COXIB. In totaal had 53 % van de patiënten een preventieve behandeling voor 
NSAID- gerelateerde gastro-intestinale schade namelijk een maagbeschermer en/of 
een COXIB. Sommige patiënten gebruikten zowel een COXIB als een maagbeschermer. 
Drie maanden na randomisatie werden gastro-intestinale ulcera in 6 patiënten (4%) in 
de eradicatie groep en in 8 patiënten (5%) in de placebo groep vastgesteld (niet signi-
ﬁ cant verschillend, P=0.645). Geen enkele patiënt ontwikkelde een klinisch manifest 
gastro-intestinaal ulcus (vastgesteld bij een scopie na klachten), of een ulcuscomplicatie 
tijdens de duur van de studie. De scores voor bovenbuikklachten verschilden niet tus-
sen beide studie groepen (P=0.98). In de eradicatie groep rapporteerden 35 van de 172 
(20%) patiënten bijwerkingen van de studiemedicatie en 4 van de 175 (2%) patiënten in 
de placebo groep (P<0.001). De belangrijkste conclusies van deze studie waren: (1) Era-
dicatie van H. pylori had geen eff ect op de incidentie van gastro-duodenale schade bij 
patiënten met reumatische ziekten en chronisch NSAID gebruik, (2) Zowel bij patiënten 
met als zonder maagbeschermer is het aantal gastro-intestinale ulcera en complicaties 
opmerkelijk laag.
De relatie tussen H. pylori infectie en NSAID gebruik in gastro-duodenale pathologie is 
complex. De mechanismen bij het ontstaan van een ulcus zijn deels verschillend voor 
 H. pylori en NSAIDs57. H. pylori geïnduceerde ulcera zijn afh ankelijk van afwijkingen in de 
maagzuurregulatie en de inﬁ ltratie van inﬂ ammatiecellen in de maagmucosa met het 
vrijkomen van cytokines, leidend tot mucosale schade58. NSAIDs hebben direct toxisch 
eff ect op gastro-duodenale mucosa en reduceren mucosale doorbloeding, wat resul-
teert in verlies van beschermende mechanismen  voor mucosale schade57.
Er zijn de laatste jaren veel klinische studies verschenen in de literatuur die de interactie 
tussen H. pylori en NSAIDs hebben proberen op te helderen. In een grote meta-analyse 
met 25 studies verhogen zowel H. pylori als NSAIDs onafh ankelijk en signiﬁ cant het 
risico op een gastro-duodenale ulcus en geassocieerd bloeding. Het risico op een ulcus-
bloeding was respectievelijk 1.8- en 4.9-keer zo groot en het risico bleek 6.1 keer zo groot 
te zijn als beide factoren aanwezig waren59.
In de praktijk wil de clinicus met name weten of het testen en behandelen van H. pylori 
in patiënten die NSAID nemen of gaan nemen zinvol is om daarmee het risico op het 
ontwikkelen van een ulcus en, belangrijker nog, complicaties te voorkomen. De resul-
taten van klinische trials met H. pylori eradicatie in NSAID gebruikers geven geen een-
duidige uitkomst.
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In 2005 en 2012 zijn twee meta-analyses verricht waarin respectievel ijk vijf60-64 en 
 zeven60-66 eradicatie t rials zijn geanalyseerd67, 68 waarin het eff ect van H. pylori eradi-
catie werd onderzocht bij patiënten die NSAIDs gebruiken. Deze lieten beiden zien dat 
H. pylori eradicatie het risico op ulcera evident reduceert in de totale groep. Bij sub-
analyses van deze studies wordt een duidelijk eff ect van H. pylori eradicatie gezien in 
NSAID-naïeve patiënten maar dat geldt niet voor patiënten die chronisch NSAIDs ge-
bruiken. H. pylori eradicatie bij starters van NSAIDs is in de praktijk vaak niet haalbaar. 
In de reumatologische praktijk zijn bijvoorbeeld veel patiënten al gestart met NSAIDs. 
Bovendien is het niet praktisch en ethisch om te wachten op H. pylori diagnostiek en 
evt. eradicatie voordat er met een NSAID gestart kan worden als patiënten veel pijn 
hebben. Verder was opvallend dat bij subanalyse van de studies uit het Westen minder 
eff ect werd gezien dan bij de studies in Aziatische populaties. Er zijn twee studies die 
H. pylori eradicatie direct met PPI onderhoudsth erapie hebben vergeleken63, 69. Er lijkt 
een duidelijk voordeel te zijn voor PPI ten opzichte van H. pylori eradicatie als de resul-
taten van deze studies in een meta-an alyse worden geanalyseerd67. Het in dit proef-
schrift  beschreven onderzoek was in de tweede meta-analyse een van de studies met 
de grootste patiënten aantallen. Onze bevindingen stroken met de bevindingen van de 
andere studies met  chronisch NSAID gebruikers61, 64, 66 en de subanal yse van beide meta-
analyses67,68 waarin ook geen voordeel van H. pylori eradicatie wordt gezien.
Een mogelijke verklaring voor het feit dat H. pylori eradicatie wel eff ect heeft  in NSAID-
naïeve patiënten en niet in patiënten die chronisch NSAIDs gebruiken is dat het risico op 
ulcuscomplicaties het grootst is in het eerste jaar van NSAID gebruik70 alhoewel er een 
risico blijft  bestaan gedurende de hele periode van het gebruik. Daardoor zouden veel 
van de patiënten met het hoogste risico al gestopt kunnen zijn met NSAID gebruik (door 
ulcus complicaties of klachten) en worden dus niet in studies met langdurige NSAID–
gebruik geïncludeerd. De studies met langdurig NSAID gebruikers includeren patiënten 
met lagere ulcusrisico’s. De absolute risicoreductie verkregen door H. pylori eradicatie 
hangt af van het baseline risico en daardoor is het in deze populatie met laag ulcusrisico 
moeilijk om een eff ect aan te tonen (bijvoorbeeld alleen door grote sample size, type II 
error). Natuurlijk kan men zich afvragen of er sprake is van een klinische relevantie als er 
erg grote sample sizes nodig zijn.
In geval van secundaire preventie van gastro-duodenale ulcera (patiënten hebben al een 
gastro-duodenale ulcus) bij chronisch NSAID gebruikers toonde Hawkey et al. aan dat 
H. pylori eradicatie niet beter is dan alleen een PPI om recidief ulc us te voorkomen na 
6 maanden61. In een meta-analyse had H. pylori eradicatie wel gunstig eff ect op het 
voorkomen van een re cidief gastro-duodenaal ulcus67. Het is dan ook goed voor te stel-
len dat de huidige richtlijnen aanbevelen om bij iedereen met een ulcus H. pylori te 
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testen en te behandelen onafh ankelijk of er NSAID gebruikt is maar patiënten met lang-
durig gebruik van NSAIDs een onderhou dsbehandeling met PPI te geven38, 71, 72.
Een beperking van alle studies inclusief de studies die in dit proefschrift  beschreven zijn 
is de beperkte follow-up. De meeste studies gaven alleen korte termijn data: variërend 
van 1 tot 6 maanden, met uitschieters naar 1 jaar (in de studies in dit proefschrift  en-
doscopische follow-up van 3 maanden en klinische follow-up van 1 jaar). Eradicatie van 
H. pylori is weliswaar een permanente interventie aangezien de kans op re-infectie erg 
klein is73 en men verwacht dat dit eff ect blijft  bestaan, maar het eff ect op lange termijn 
(het later ontstaan van gastro-duodenale ulcera) is niet bekend bij patiënten met lang-
durig NSAID-gebruik.
Een opvallende bevinding in [Hoofdstuk 4] is dat bij patiënten zowel met als zonder 
maagbeschermer het aantal gastro-intestinale ulcera en complicaties opmerkelijk laag 
(4%) was ten opzichte van andere klinische trials ter preventie van NSAID gerel ateerde 
gastro-duodenale schade22, 74. Een mogelijke verklaring hiervoor is dat de studiepopulatie 
echt de dagelijkse praktijk representeert van patiënten die door co-medicatie een hoger 
(aspirine) of lager (maagbeschermer of COXIB) risico op NSAID gastropathie hadden. Dit 
heeft  geresulteerd in een studiepopulatie waarvan de helft  van de patiënten langdurig 
een maagbeschermer en/of een COXIB gebruikte. De omvang van de morbiditeit van 
NSAID gerelateerde gastro-duodenale schade is kleiner dan voorheen. Dit komt overeen 
met onderzo ek zowel uit de Ve renigde Staten75 als in Nederland76, 77 waar een dalende 
incidentie van NSAID-gastropathie wordt waargenomen in een populatie van patiën-
ten met reumatische ziekten. Een van de verklaringen hiervoor is dat er veel minder 
nsNSAIDs worden gebruikt in deze populatie, deels door het vervangen door COXIBs, 
maar waarschijnlijker is dat het gebruik van NSAIDs minder nodig is aangezien reuma-
tische ziekten beter en intensiever behandeld worden dan vroeger door het gebruik van 
de zogeheten biologicals en betere behandelstrategieën78.
De incidentie van ulcera was dusdanig laag in deze populatie van langdurig NSAID 
gebruikers met reumatische ziekte dat verdere verbetering door H. pylori eradicatie be-
perkt zal zijn en het dus geen belangrijk klinisch relevant probleem meer is maar eerder 
een theoretisch probleem.
In bovenstaande studie is het ook eff ect van H. pylori eradicatie op de histologie van de 
maagmucosa onderzocht en is beschreven in [Hoofdstuk 5]. Voor dit onderzoek zijn 
alle biopten die zijn genomen in het kader van het in [Hoofdstuk 4] beschreven onder-
zoek in een hematoxyline-eosine kleuring histologisch gescoord volgens de updated 
 Sydney classiﬁ catie voor actieve en chronische ontsteking, aanwezigheid van glandu-
laire atroﬁ e, intestinale metaplasie en H. pylori densiteit. Er waren van 305 patiënten 
biopten aanwezig voor histologische scoring. In de groep die H. pylori eradicatie had 
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ontvangen was signiﬁ cant minder acute en chronische ontsteking te zien in zowel het 
corpus als in het antrum van de maag ondanks dat NSAID gebruik voortgezet werd. Zo 
werd in het corpus en het antrum matig tot ernstige acute ontsteking gezien in respec-
tievelijk 4% en 3% in de eradicatiegroep en respectievelijk 35% en 27% in de placebo 
groep (P<0.001). Matig tot ernstige chronische inﬂ ammatie werd in corpus en antrum 
gevonden in respectievelijk 28% en 51% in de eradicatiegroep en in respectievelijk 65% 
en 76% in de placebogroep. Verder werd in het corpus duidelijk minder matig tot ern-
stige atroﬁ e gevonden in de eradicatiegroep (10%) in vergelijking met de placebogroep 
(22%, P=0.006). Er werden geen verschillen gevonden voor intestinale metaplasie en 
atroﬁ e. Het is al lange tijd bekend dat in niet-NSAID gebruikers actieve en chronische 
ontsteking verb etert na eradicatie van H. pylori79-81. Nu is dat ook beschreven in een gro-
te groep NSAID gebruikers. Deze bevindingen zijn opvallend omdat endoscopisch geen 
verschil voor de beide groepen werd gevonden [Hoofdstuk 4] voor het de ontwikkeling 
van ulcera en erosies. Er is een relatie beschreven tussen de mate van ontsteking in 
histologische beoordeling en het risico op gastro-duodenale u lcera in langdurig NSAID-
gebruikers82. Dit zou de gedachte kunnen ondersteunen dat H. pylori eradicatie NSAID 
gastropathie zou kunnen (helpen) voorkomen.
Aangezien onze populatie alleen uit NSAIDs gebruikers bestond, konden we geen 
uitspraken doen over eff ect van NSAIDs op de mate van de histologische afwijkingen. 
Verder werd in deze studie een groter eff ect van H. pylori eradicatie gezien bij patiën ten 
die maagbeschermers gebruiken dan bij chronisch NSAID gebruikers zonder maagbe-
schermers voor het voorkomen van chronische ontsteking in het corpus. Er is aange-
toond dat gedurende langdurig PPI gebruik een H. pylori geassocieerde gastritis van met 
name het antrum uitbreidt naar een corpus predominante gastritis. Dit wordt geas-
socieerd met versnelde  progressie naar atroﬁ sche gastritis83, wat een premaligne af-
wijking is. Er is geen bewijs dat door H. pylori eradicatie in deze groep de ontwikkeling 
van maagcarcinoom wordt voorkomen maar er zijn studies waarin bij patiënten  met 
PPI vaker maagkanker wordt gezien84. Waarschijnlijk is daar sprake van ‘confounding by 
indication’ maar wel wordt er in een recente Europese richtlijn (2012) geadviseerd om 
H. pylori eradicatie te overwegen bij patiënten die chronisch (> 1 jaar) maagbescher-
mers gebruiken om daarmee maagcarcinoom te voorkomen38. Vooralsnog zal er eerst 
meer onderzoek moeten volgen alvorens een test- en behandelstrategie van H. pylori 
verdedigd kan worden voor alle patiënten met of zonder NSAIDs met het doel maagcar-
cinoom te voorkomen.
In [Hoofdstuk 6] wordt een vooraf geplande post hoc analysis beschreven van de kli-
nische gerandomiseerde trial zoals is beschreven in [Hoofdstuk 4]. In deze post-hoc 
analyse werden patiënten met en zonder maagzweren vergeleken naar het gebruik van 
COX-2 selectieve en niet-selectieve NSAIDs en voor mogelijke andere confounders voor 
het optreden van ulcera. Van de 301 patiënten die een endoscopie ondergingen, hadden 
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6 (4%) patiënten in de eradicatiegroep een ulcus en 8 (5%) patiënten in de placebogroep 
(P=0.65). Geen (0%) van de patiënten met een maag of duodenum ulcus en 80 (28%) 
patiënten zonder ulcus gebruikten selectieve NSAIDs (P=0.02). Patiënten met een ulcus 
gebruikten signiﬁ cant vaker een concomitante lage dosis aspirine dan patiënten zonder 
gastro-duodenaal ulcus: 4 (29%) patiënten in de ulcusgroep versus 27 (9%) in patiënten 
zonder ulcus (P=0.02). Er werd geen verschil gevonden voor het gebruik van PPI, H2-
receptorantagonisten en prostaglandine analogen tussen patiënten met of zonder ulcus 
in maag of duodenum (P=0.48). Zoals in vele andere studies, is ook in dit onderzoek 
gebruik van COX-2 selectieve NSAIDs geassocieerd met een lager ulcusrisico dan het 
gebruik van nsNSAIDs. Gezien de lage ulcusaantallen kon geen uitspraak gedaan wor-
den over verschil in het eff ect van H. pylori eradicatie voor nsNSAID en selectieve NSAID 
gebruikers, maar H. pylori eradicatie lijkt het risico niet verder te verminderen. Ten tijde 
van de start van deze studie werden de selectieve COX-2 NSAIDS, rofecoxib en celecoxib 
net geïntroduceerd in Nederland en deze werden dan ook relatief weinig frequent ge-
bruikt in de studiepopulatie (resp. 7% en 1%). In dit onderzoek werden de meer COX-2 
speciﬁ eke NSAIDs (met minder sterke werking op de COX-2-receptor dan COXIBs) zoals 
nabumetone en meloxicam vaker gebruikt (11% en 6%) en bij deze analyse in de groep 
selectieve NSAIDs ingedeeld.
Hoofstukken zeven en acht beschrijven de waarde van diagnostische testen ter controle 
van een H. pylori eradicatie zoals serologie, kweek en histologie en de effi  ciency van de 
gevolgde test-en-behandel strategie. [Hoofdstuk 7] presenteert een post-hoc analyse 
van een gerandomiseerde klinische studie van H. pylori positieve patiënten met lang-
durig NSAID gebruik vanwege reumatische ziekten, waarin wordt onderzocht wat de 
beste manier is om een persisterende H. pylori infectie dan wel succesvolle eradicatie na 
therapie te kunnen vaststellen. In deze klinische studie werd H. pylori vastgesteld door 
middel van serologisch onderzoek naar anti-H. pylori IgG-antilichamen. H. pylori posi-
tieve patiënten werden gerandomiseerd voor eradicatie triple therapie of placebo met 
controle endoscopie na 3 maanden en nogmaals serologie na 12 maanden. In de post 
hoc analyse vergeleken we herhaalde H. pylori antilichaam titers, hematoxyline en eo-
sine (H&E) kleuringen, immunohistochemische (IHC) kleuringen van biopten en kweek 
van H. pylori in de biopten van alle patiënten, om de sensitiviteit en speciﬁ citeit van deze 
verschillende detectie methoden vast te stellen. Verder bepaalden we of toevoeging 
van IHC kleuringen aan H&E kleuringen de histologische detectie van H. pylori in deze 
patiënten verbetert. Overeenstemmend met de gouden standaard criteria bestaande 
uit óf een positieve kweek óf zowel een positief histologisch onderzoek als een positieve 
serologische test, was H. pylori eradicatie therapie in 90% van de patiënten succesvol. 
Kweken leverden 100% sensitiviteit maar de speciﬁ citeit was 82% en 73% na eradicatie. 
Histologisch onderzoek met H&E of IHC kleuringen leverde een sensitiviteit en speciﬁ -
citeit tussen 93% en 99%. De toevoeging van IHC verbeterde de resultaten niet. Verder 
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werden receiver operating characteristics (ROC) curves van de herhaalde serologische 
testresultaten berekend. De ROC curve voor percentuele verandering van H. pylori IgG 
antilichaam titers had een betere diagnostisch power voor het identiﬁ ceren van H. py-
lori negatieve patiënten dan de absolute verandering van de titers. Het optimale afk ap-
punt in deze ROC curves was 21% daling na 3 maanden en 58% daling na 12 maanden, 
corresponderend met een sensitiviteit van respectievelijk 64% en 87% en speciﬁ citeit 
van respectievelijk 81% en 74%. Deze getallen zijn niet ideaal en tegenwoordig is voor 
follow-up van H. pylori eradicatie geen rol meer voor serologie en zijn ureum adem 
testen of feces antigen tes ten betere niet-invasieve alternatieven38. Indien er toch een 
indicatie is voor controle endoscopie zijn de biopsie-gebaseerde technieken zoals kweek 
en histologisch onderzoek goede method es om de H. pylori status te controleren38. In 
[Hoofdstuk 8] wordt doelmatigheid van een serologische ‘test en behandel strategie’ 
van H. pylori bij patiënten met een reumatologische ziekte en langdurig NSAID gebruik 
beschreven. In Nederland bestaat de behandeling van eerste keuze voor eradicatie van 
H. pylori uit een 7-daagse triple-therapie met een PPI, amoxicilline en clarithromycin 
of metronidazole. Dit onderzoek dat plaats vond van 2000 tot 2002 was deel van het 
nationale, multicenter gerandomiseerde onderzoek dat is beschreven in [Hoofdstuk 4]. 
Patiënten werden gescreend met serologie voor H. pylori IgG antilichamen en indien 
ze positief waren, werden ze geïncludeerd in de studie en gerandomiseerd voor of era-
dicatietherapie óf placebo. Na 3 maanden follow-up werd er en gastroscopie verricht 
waarbij biopten werden genomen van antrum en corpus van de maag. Deze biopten 
werden door middel van kweek en histologisch onderzoek onderzocht op aanwezigheid 
van H. pylori. De belangrijkste conclusies van dit onderzoek waren: ten eerste dat een 
7-daagse PPI-gebaseerde triple eradicatie therapie adequaat was in 87% van de patiën-
ten zonder vooraf testen op gevoeligheid voor antibiotica. Ten tweede kon in 21% van 
de patiënten in de placebogroep de positieve H. pylori serologie niet bevestigd worden 
door aanwezigheid van H. pylori in kweek en histologie, en dit impliceert dat mogelijk 
een vijfde onnodig eradicatietherapie ontvangen heeft . Ten derde, therapietrouw was 
een erg belangrijke factor voor succesvolle eradicatie van H. pylori. H. pylori was suc-
cesvol geëradiceerd in 91% van de patiënten die volledig trouw zijn geweest bij het in-
nemen van de medicatie, vergeleken met 50% bij diegenen die dat niet waren geweest 
(verschil van 41%; 95% CI 18-63%). Als laatste valt op te merken dat de prevalentie van 
de antibiotische resistentie in H. pylori erg laag was. De gevonden resistentie percen-
tages in de geïsoleerde stammen van de placebogroep waren, 4% voor clarithromycin, 
19% voor metronidazole, 1% voor amoxicilline en 2% voor tetracycline. Resistentie voor 
antibiotica in H. pylori is van belang aangezien resistentie een belangrijke rol speelt bij 
het falen van de therapie. De antibiotica resistentiepercentages voor metronidazole en 
clarithromycin in deze populatie zijn vrijwel even laag als in andere studies  in Nederland 
i n afgelopen jaren 1997-199885 en 1997-200286-90. Zover bekend, zijn er geen nieuwere 
data van primaire H. pylori resistentie tegen antibiotica in Nederland91, 92. Derhalve is het 
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goed te verdedigen om te starten met standaard triple therapie (PPI-claritromycine en 
amoxicilline) zonder vooraf gevoeligheid te bepalen.
De onderzoeken in [Hoofdstuk 7 en 8] hebben de beperking dat er niet op baseline 
een endoscopie is verricht maar alleen 3 maanden na eradicatie. Destijds is gekozen 
voor serologie als baseline H. pylori diagnostiek. De belangrijkste redenen waren dat in-
vasieve endoscopie niet haalbaar was in de dagelijkse reumatologische praktijk in niet-
symptomatische patiënten, en dat serologie, als goedkoop en overal beschikbaar alter-
natief, goed uit  verschillende validatie studies was gekomen93-96. Het gebruik van PPI (in 
dit onderzoek 37% van de populatie) kan fout-negatieve uitkomst van zowel invasieve 
als niet invasieve testen, zoals kweek, histologie, ureum adem test en ook feces antigen 
test, opleveren en moet daar om minimaal twee weken tevoren gestopt worden97. In 
een populatie met chronisch NSAID gebruik is het stoppen van PPI in studieverband 
bovendien niet ethisch. Ten tijde van de start van dit onderzoek waren H. pylori fecale 
antigen testen niet beschikbaar.
Conclusie
De incidentie van maag- en duodenale ulcera nam tijdens de eerste helft  van de 20e 
eeuw epidemische vormen aan98. Sindsdien hebben nieuwe inzichten en medische 
innovaties geleid tot enorme verbeteringen bij de behandeling van gastro-duodenale 
 ulcera en is niet alleen de morbiditeit sterk afgenomen maar ook de sterft e door gastro-
duodenale ulcera is met 75% gedaald sinds de jaren ’8098. Deze afname kan verklaard 
worden door verschillende factoren zowel in de algemene als in de reumatologische 
populatie: de ontdekking van H. pylori en eradicatie daarvan, later de geleidelijke da-
ling van de prevalentie van H. pylori, introductie van zuurremmende medicijnen zoals 
H2-receptorantagonisten en PPI (in de late jaren 1970 en 1980), de introductie van di-
agnostische en therapeutische endoscopie, ontwikkeling van richtlijnen ter preventie 
van NSAID gerelateerde gastro-duodenale schade (in Nederland in 2003) en de komst 
van de COXIBs (begin jaren 2000), en speciﬁ ek voor de reumatologische praktijk: inten-
sievere en betere behandeling van inﬂ ammatoire reumatische aandoeningen waardoor 
NSAIDs als pijnstiller minder nodig is.
Er zijn gedurende de afgelopen jaren meerdere studies verschenen waarin H. pylori era-
dicatie bij NSAID gebruikers is onderzocht. Voorafgaand aan NSAID gebruik lijkt eradica-
tie van H. pylori wel zin te hebben maar dit is in de praktijk niet of nauwelijks haalbaar. 
Immers patiënten met veel klachten zullen niet willen wachten met NSAID gebruik om 
eerst H. pylori diagnostiek en eradicatie te ondergaan. Bij chronisch NSAID gebruikers 
is het niet zinvol om H. pylori te eradiceren om gastro-duodenale ulcera en de compli-
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caties hiervan te voorkomen, zoals ook bleek uit ons onderzoek. Een verklaring voor 
het verschil in eff ect van H. pylori tussen NSAID naïeve patiënten en langdurig NSAID 
gebruikers is dat het risico op ulcera zodanig laag is in patiënten die langdurig NSAIDs 
verdragen dat H. pylori eradicatie dat risico niet verder kan beperken. Dat bleek ook uit 
onze studie: gastro-duodenale ulcera kwamen erg weinig voor in deze populatie van 
langdurig NSAID gebruikers met reumatische ziekte. Dat maakt de aanwezigheid van 
H. pylori in chronisch NSAID gebruikers dus geen belangrijk klinisch relevant probleem 
meer, maar eerder een theoretisch probleem. Ons onderzoek geeft  weinig steun voor 
het actief opsporen van een H. pylori infectie bij patiënten met reumatische aandoe-
ningen en NSAID gebruik. Deze balans wordt nog minder gunstig als de prevalentie van 
H. pylori nog verder daalt. De relatie van H. pylori met maagkanker zou wel een goede 
reden kunnen zijn om H. pylori te eradiceren met name in patiënten met langd urig PPI 
gebruik (als co-medicatie bij NSAIDs)83 maar voorafgaand zal er eerst meer onderzoek 
moeten volgen om een test-en-behandel-strategie van H. pylori te verdedigen in de 
Nederlandse populatie.
Studies die eff ecten op NSAID gerelateerde ulcera bestuderen zijn vaak moeilijk uit te 
voeren gezien de behoeft e aan harde eindpunten zoals endoscopisch bevestigde af-
wijkingen. Om een eff ect van interventie of verschil tussen vergelijkende armen aan te 
tonen is het vaak nodig grote aantallen patiënten te includeren in multicenter studies. 
Toch moet er om verschillende redenen nog aandacht blijven voor NSAID gerelateerde 
complicaties. De adherentie a an de bestaande richtlijnen is verre van ideaal99. De ver-
wachting is dat in tegenstelling tot de reumatologische praktijk waarin NSAID gebruik is 
afgenomen door betere behandeling van de inﬂ ammatoire reumatische aandoeningen, 
het NSAID gebruik onder de algemene bevolking voor aandoeningen aan het bewe-
gingsapparaat juist zal toenemen door vergrijzing. Afgelopen jaren is ook gebleken dat 
de richtlijnen niet meer helemaal up-to-date zijn. Zo zijn er ook bijwerkingen van NSAIDs 
op de lagere tractus digestivus die mogelijk wel beïnvloed w orden door COXIBs maar 
niet door maagbeschermers30 en kan er bij de keuze van NSAID of COXIB en/of maagbe-
schermer rekening gehou den worden met het cardiovasculaire risicoproﬁ el100-102.
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Zonder samenwerking met vele anderen zou dit proefschrift  niet tot stand gekomen 
zijn. Bij deze wil ik iedereen bedanken die hieraan heeft  bijgedragen. Graag wil ik, naast 
de patiënten die hebben geparticipeerd aan het onderzoek, een aantal mensen in het 
bijzonder bedanken voor hun betrokkenheid bij mijn promotieonderzoek.
Promotoren
Jaren geleden begon ik als onderzoeker bij de HERA-studie (H.pylori Eradicatie bij 
patiënten met Reumatische Aandoeningen). Na een keuze-co schap reumatologie in 
het Slotervaartziekenhuis, ben ik als onderzoeker gestart in het VUmc. Ik dacht voor een 
jaar, uiteindelijk zijn dat er meer geworden. Op het moment dat ik begon, liep de inclusie 
van patiënten in de HERA-studie helemaal niet goed. ben dijkmans en willem lems, ge-
lukkig is het met jullie positieve benadering gelukt om het project weer goed op de rails 
te krijgen en mij te motiveren om het onderzoek af te ronden. Hartelijk dank voor de 
jarenlange steun, het vertrouwen en de continue aanmoediging en vasthoudendheid. 
Mijn overstap van reumatologie naar MDL was voor sommigen geen verassing maar 
voor anderen kwam het onverhoopt. Ik ben erg blij dat we het zo goed hebben kunnen 
afronden. Veel dank daarvoor.
maarten boers, je scherpe maar ook relativerende kijk op het onderzoek tijdens de 
wekelijkse HERA-vergaderingen, maar ook je adviezen en ideeën bij het schrijven van de 
manuscripten waren voor mij van grote waarde. Veel dank voor de prettige samenwerking.
Leescommissie
Graag wil ik prof. dr. e.j. kuipers, prof. dr. c.j. mulder, prof. dr. j.w.j. bijlsma, mw. prof. 
dr. c.m.j.e. vandenbroucke-grauls, prof. dr. g.a. meijer, dr. m.t. nurmohamed en mw. 
dr. v.m.h. coupé bedanken voor de kritische beoordeling van mijn proefschrift .
Het HERA-team
Ik bedank alle betrokkenen (reumatologen, arts-assistenten, arts-onderzoekers, trial-
nurses, poli-assistenten, secretaresses, MDL-artsen, laboranten en analisten, microbi-
ologen, pathologen) van het HERA-team voor de hulp bij het mogelijk maken van de 
HERA-studie in Amsterdam, Utrecht, Twente, Arnhem en Heerlen.
 Speciaal wil ik hierbij noemen: In Utrecht hans bijlsma en margriet huisman; in 
Twente mart van der laar, harald vonkeman, annette en anita; in Heerlen: harry 
houben en hermine; in Arnhem: matthijs janssen, sylvana kadir en tonnie.
En natuurlijk in Amsterdam, naast mijn promotoren: alle reumatologen en reuma-
tologen-i.o. van het VUmc, Slotervaartziekenhuis en toenmalig Jan van Breemen Insti-
tuut (JBI, thans Reade). Voor (jonge) onderzoekers is in de Amsterdamse regio een erg 
goed en gedegen onderzoeksklimaat.
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De endoscopieafdelingen van het VUmc en het Slotervaartziekenhuis: waarschijnlijk is 
bij jullie mijn interesse voor de MDL gewekt.
De medewerkers van alle laboratoria: m.n. margret de koning en rob van de stadt 
in het JBI.
Het kostenteam: hiske van dieten, maurits van tulder en ingeborg korthals-de 
bos: jammer dat er uiteindelijk geen kosten-eff ectiviteitsanalyse gedaan kon worden 
binnen de HERA-studie.
Pathologie: elisabeth bloemena, zonder de uren samen achter de microscoop en je 
adviezen bij het schrijven van het manuscript was dit proefschrift  niet geworden wat het 
nu is. Hartelijk dank daarvoor.
Imunnogenetica: servaas morre, bart crusius, irene van de horst en jolein: On-
danks interessante hypotheses en veel werk bleken de data helaas niet bruikbaar voor 
zinvolle analyse. Dank voor jullie moeite en tijd.
Microbiologie: yvette debets-ossenkop en christina vandenbroucke-grauls: dank 
voor jullie kritische en zeer waardevolle aandeel bij de H. pylori diagnostische studies.
Epidemiologie en biostatistiek: piet kostense, jij hebt me op je eigen enthousiaste 
wijze geduldig geholpen bij bepaalde analyses en lastige vragen van referenten op 
statistisch gebied. Hartelijk dank daarvoor. dick bezemer dank voor je hulp in de begin-
fase van de HERA-studie.
ernst kuipers: jij was al vertrokken naar Rotterdam toen ik begon met dit onder-
zoek. Toch bleef je betrokken bij de studie en ik heb je commentaren en adviezen vanuit 
het MDL-gezichtspunt bij het schrijven van de manuscripten zeer waardevol gevonden.
Mijn voorganger op het NSAID-gastropathie onderzoek: kirsti steen. Een groot deel 
van dit proefschrift  is het resultaat van gezamenlijke inspanning waarvoor hartelijk dank.
De verzameling en verwerking van de gegevens van de studie waren voor een groot 
deel in handen van cathy de laat en later joke van wegen. Hartelijk dank voor jullie 
bijdrage.
Collega’s
In de onderzoeksjaren heb ik veel geleerd op het gebied van wetenschap en heb ik veel 
plezier gehad met de collega’s van de onderzoekerskamer van de reumatologie in het 
VUmc. mariette, marijn, vokko, mark, gerrit, joost, esmeralda, irene, conny, ruud, 
mirjam, arno, philomien, hartelijk dank voor deze leuke jaren. Veel succes met jullie 
verdere carrières. Secretaresses marjo sluiter, ida gaspersz en noortje vesters jullie 
waren en zijn de spil van de afdeling reumatologie. Hartelijk dank voor alle ondersteun-
ing en luisterend oor.
Afdelingen MDL Haarlem en Amsterdam
Natuurlijk wil ik ook de afdelingen MDL en Interne Geneeskunde van het Kennemer 
Gasthuis te Haarlem niet vergeten. Met name wil ik bedanken: rené van der hulst, 
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johan kuijvenhoven, dr. ferweda en jolande keulemans, jullie hebben mede aan de 
basis gestaan van mijn keuze om MDL-arts te worden. En later met amabel vehmeijer-
scherpenzeel, brechje van eijck-stigter, willem marsman en ellert van soest: met 
jullie heb ik heel gezellig gewerkt en veel van jullie geleerd.
Afdeling MDL in het VUmc: chris mulder, ad van bodegraven, elly klinkenberg, 
richelle felt, carin van nieuwkerk, maarten jacobs, stijn van weijenberg, gerd bouma, 
alle MDL-artsen-i.o. en onderzoekers, verpleegkundigen, secretaresses en assistenten. 
Hartelijk dank voor de goede tijd en voor jullie interesse. De vraag: Hoe is het met je 
proefschr…? werd me soms vaker dan me lief was gesteld maar uiteindelijk is het er toch 
van gekomen…
Afdeling MDL Rijnstate
Mijn bijzondere dank gaat uit naar mijn collega MDL-artsen uit het Rijnstate: peter 
wahab, jan maarten vrolijk, bert den hartog, david hirsch, jan sindram, marcel 
groenen, marcel spanier en rob robijn. Dank voor het vertrouwen dat ik van jullie 
heb gekregen bij de afronding van dit proefschrift . Ik ben erg blij om in het Rijnstate te 
mogen werken, we hebben met alle medewerkers van de afdeling endoscopie en MDL 
een geweldig team. Verder veel dank voor ons secretariaat in het Rijnstate (mariette, 
christa, julia, karin) voor de ondersteuning bij de allerlaatste fase van dit boekje.
Paranimfen
irma en dorien, mijn paranimfen. Ik vind het bijzonder om jullie aan mijn zijde te heb-
ben tijdens de promotie.
Familie en vrienden: mijn basis
Hoewel werk leuk is, maar er meer is dan werk wil ik juist de personen die mij het meest 
na staan niet overslaan in dit dankwoord. Jullie onvoorwaardelijke steun is geweldig 
geweest door de jaren heen: mam, pa & simonne, dorien & axel, sjaak, mijn schoonfa-
milie: johan & henny, carin & wim. Zoals jullie er altijd zijn bij belangrijke momenten. 
Dank voor jullie steun en interesse. Pa, jij zei altijd: gewoon volhouden dan komt het 
vanzelf af…
 Al mijn vrienden wil ik bedanken voor jullie belangstelling, steun en gezelligheid 
na(ast) het werk. gina, ruth, marion, irma, karo, gerco, nienke, djamilla: de laatste 
jaren hebben we regelmatig over dit proefschrift  en over jullie werk gesproken maar 
de gesprekken gingen ook over andere belangrijke en leuke zaken van het leven. Onze 
nieuwe vrienden, mijn ﬁ etsvriendinnen en buren uit Arnhem, door jullie voelen we ons 
hier helemaal thuis.
Zonder thea en piet, jannie en frans, willeke en andré zou ons gezin niet kunnen 
functioneren en zou er al helemaal niet rustig achter een computer gewerkt kunnen 
worden, dank voor jullie ﬂ exibiliteit en zorg voor onze kinderen.
Mijn allergrootste dank gaat naar ramon. Dank je wel voor alles, maar met name voor je 
geduld en de ruimte die je hebt gegeven om dit proefschrift  te kunnen schrijven. hugo 
en nora, ik ben apetrots op jullie.
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marleen de leest is op 27 augustus 1973 geboren te Eersel. In 1991 behaalde ze het 
V.W.O.-diploma aan het Rythoviuscollege te Eersel. Na twee jaar geneeskunde gestu-
deerd te hebben aan de Rijksuniversiteit Gent, België, vervolgde zij de studie genees-
kunde aan de Vrije Universiteit te Amsterdam waar ze in 2000 haar basisartsdiploma 
haalde. Aansluitend werkte ze tot 2004 als arts-onderzoeker, onder leiding van prof. dr. 
b.a.c dijkmans, prof. dr.w.f. lems en prof. dr. m. boers, aan de afdelingen reumatologie 
van het VU medisch centrum, het Slotervaartziekenhuis en het Jan van Breemeninsti-
tuut (thans Reade) te Amsterdam. Hier hield ze zich met name bezig met onderzoek 
waarvan de resultaten terug te vinden zijn in dit proefschrift . In deze tijd deed ze ook 
 poliklinische werkzaamheden in het Slotervaartziekenhuis. In 2004 begon ze met de 
vooropleiding Interne geneeskunde in het Kennemer Gasthuis te Haarlem (opleider 
prof. dr. r.w. ten kate). In 2006 is ze gestart met de opleiding MDL-ziekten in het Ken-
nemer Gasthuis, Haarlem (opleider dr. r.w.m. van der hulst). Van 2007 tot 2010 ver-
volgt ze de opleiding tot MDL-arts aan het VU medisch centrum (opleider prof.dr. 
c.j.j. mulder). Het laatste half jaar van haar opleiding tot MDL-arts keerde ze terug in het 
Kennemer Gasthuis te Haarlem (opleider dr. r.w.m. van der hulst). Sinds januari 2011 is 
ze werkzaam als MDL-arts in het Rijnstate te Arnhem. Marleen deelt haar leven met 
ramon kranendonk en samen hebben ze twee kinderen hugo en nora.

